

SUCCESS LIFE AFTER CURE LIMITED

England & Wales · Charity number 1188298

Details

Other names	SUCCESS LIFE AFTER CURE CHARITY
Status	Registered
Legal form	Charitable company
Company number	11785842
Registered	2020-03-03
Register	View on the Charity Commission register

Contact

Address	Success Life After Cure Ltd C/O Baker McKenzie 280 Bishopsgate London EC2M 4AG
Phone	0300 302 0515
Email	INFO@SUCCESSCHARITY.ORG.UK
Website	https://successcharity.org.uk

Activities

Objects: FOR THE PUBLIC BENEFIT, TO PROMOTE AND PROTECT THE PHYSICAL AND MENTAL HEALTH, AND RELIEVE THE NEEDS OF CHILDHOOD BRAIN TUMOUR SURVIVORS ("SURVIVORS") TREATED IN THE UNITED KINGDOM BY PROVIDING EQUIPMENT, FACILITIES AND SERVICES NOT NORMALLY PROVIDED BY THE STATUTORY AUTHORITIES AND IN PARTICULAR:(I) PROVIDING INFORMATION, RESOURCES, ADVOCACY SUPPORT AND EDUCATION SUPPORT TO THE SURVIVORS, THEIR FAMILIES AND THEIR EDUCATION PROFESSIONALS;(II) PROVIDING MULTI-DISCIPLINARY CLINICIAN LED REHABILITATION TREATMENT ANCILLARY TO THAT PROVIDED BY THE STATUTORY AUTHORITIES;(III) UNDERTAKING RESEARCH INTO THE TREATMENT AND OUTCOMES OF SURVIVORS TO IDENTIFY REHABILITATION NEEDS AND CHALLENGES AND PUBLISHING THE USEFUL RESULTS;(IV) PROVIDING MENTORING AND NETWORK GROUPS FOR SURVIVORS AND THEIR FAMILIES; AND(V) PROVIDING GRANTS TO SURVIVORS TO ACCESS MEDICAL SUPPORT.

Activities: Success Charity is committed to enabling brighter futures for survivors of childhood brain tumours. Success provides dedicated rehabilitative support, access to information, resources and key

assessments, connects survivors via peer support and networking events and conducts research to better understand the consequences of brain injury after treatment, and to improve advocacy for survivors.

Classification

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives, Disability, Other Charitable Purposes
- **Who:** Children/young People, People With Disabilities

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£114,975	£141,832	-	-
2023-12-31	£117,355	£128,655	-	-
2022-12-31	£85,312	£73,964	-	-
2021-12-31	£79,559	£78,436	-	-
2020-12-31	£203,377	£74,615	-	-

Trustees

Name	Role	Appointed
Dr HELEN ALEXANDRA SPOUDEAS	Chair	2019-01-24
David Pickup		2025-10-10
Fatima Patel		2025-10-10
Hugh Stewart		2022-09-15
JANE ELISABETH HOBSON		2019-01-24
JENNIFER ALISON LIMOND		2019-01-24
Kathryn Harley		2025-03-31
Laura Jane Albery		2025-04-04
Murray James David		2025-10-10
Sinead Mary Bryan		2025-04-04

SUCCESS LIFE AFTER CURE LIMITED

England & Wales - Charity number 1188298

Accounts

Charity registration number 1188298 (England and Wales)

Company registration number 11785842

SUCCESS LIFE AFTER CURE LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

SUCCESS LIFE AFTER CURE LIMITED

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Philip Austin Jane Hobson Hugh Stewart Jennifer Limond Marco Previero Dr Helen Spoudeas Dr Jane Williams Richard Crowther	(Retired by rotation, 9 th February 2024)
Charity number (England and Wales)	1188298	
Company number	11785842	
Registered office	280 Bishopsgate London EC2M 4RB	
Independent examiner	Tom Wilcox Counterculture Partnership LLP Bank Chambers Main Street Hawes North Yorkshire DL8 3QL	

SUCCESS LIFE AFTER CURE LIMITED

CONTENTS

	Page
Chair's Report	1 - 3
Trustees' report	4 - 16
Independent examiner's report	18
Statement of financial activities	19
Balance sheet	20
Notes to the financial statements	21 - 29

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2024

FOUNDER / CEO's REPORT

The Directors have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2024. The Directors have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

Cure Alone Is Not Enough

At SUCCESS, we remain steadfast in our belief that curing childhood brain tumours, without also curing the underlying brain injury, is not enough. Survival must come with a future — one that restores health, cognitive potential, independence, and partnership and employment opportunities; the key ingredients to a quality life and one worth living. With 80% of children now looking forward to a near normal life-span, and the rest still subjected to intense experimental therapies, we can no longer ignore their moral right to comprehensive complex needs assessments and neurorehabilitation as part and parcel of their cancer treatment; from the very beginning and throughout the life span.

We now have evidence from the North Thames Cancer Network that less than 50% of patients and their neurooncology professionals recognise a child's need for neurorehabilitation or specific educational support and only 6% received streamlined neurorehabilitation post-operatively. We know it is especially important to keep up with complex needs assessments throughout the four key maturational stages of the growing body and brain, [infancy, childhood, adolescence and young adulthood], and to provide tailored neurorehabilitation, alongside timely growth and other hormone replacement, whilst it has the greatest impact – before maturation is complete at 25 years of age. These services are not comprehensively provided in the cancer / late effects pathway and young adult survivors tell us they struggle to access co-ordinated holistic recovery care lifelong. We estimate 40,000 all-age survivors now exist across the UK, accruing by 1,000 every year, and need our advocacy and support.

Cure alone is not enough when:

- Survivors face lifelong invisible visual, hearing, language, learning, seizure and movement disorders
- Young children, with years of brain development ahead, miss out on crucial early interventions.
- Young adults struggle with peer acceptance, fatigue, education, employment, and mental health
- Rehabilitation, essential from diagnosis, and across the life-span, remains out of reach for many.
- Parents struggle to access targeted educational, neurodevelopmental and psychological support.
- Life-threatening secondary conditions, like hormone deficiencies, could be limited by specialist care from the beginning and across the life span.
- Survival statistics focus on five-year outcomes, ignoring long-term quality of life.

Delivering on Our Vision

While advances in cancer research have improved survival, the cost of treatment to a developing child is often overlooked. SUCCESS remains committed to ensuring that every child's recovery is as complete as their cure, from diagnosis onwards.

To achieve this, we continue to push for a SUCCESS National Recovery Pathway, integrated within the NHS. This parallel system would provide tumour-specific rehabilitation from diagnosis through to adulthood, ensuring survivors thrive - not just survive. SUCCESS also recognises and champions a bespoke pathway for the few (<30 p.a.) very rare tumours of the vital deep midbrain [in the hypothalamus and pituitary] . Such endocrine tumours of the primitive master gland controlling life itself, though often low grade, are particularly problematic to children's development and sensitive to surgery; they require dedicated and experienced pituitary teams [often operating through the nose] for the best chance of a 'harmless' first time cure. This year SUCCESS stepped up its Parliamentary campaign to NHS England for equitable, bespoke pituitary care for those under 16 years, to be concentrated to a few national centres, as already exist for adults.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Our vision and objectives

Streamlining existing NHS services to achieve cost-efficient, evidence-based reform requires navigating speciality and geographical complexity, engaging diverse professionals and commissioners beyond oncology, and making the most of limited resources. SUCCESS is committed to transforming healthcare delivery to improve secondary health outcomes by integrating brain injury evaluation and recovery from the start of the brain tumour journey.

To help us we are proud to have engaged a number of high profile NHS Clinicians and Parliamentarians to our Clinical and Parliamentary Advisory Groups. Key amongst them have been Professors David Walker and Darren Hargrave, together with Lord Sandhurst and Sir Bruce Keogh, alongside our patron Dominic Grieve KC. It is their wise counsel, actions and advocacy on our behalf at our conferences, in Parliament and from the House of Lords, that have gained us credence and an audience at NHSE in 2025.

This is an ambitious vision, and we have limited funds. In order to progress our agenda, we continue to breakdown our projects and initiatives across three key objectives which underpin our long term strategy – the next 5 years are pivotal as we set out our key goals across three strategic pillars:

1. Amplifying the Survivor Voice - Educational Networking & Research Participation

Over the next five years, SUCCESS aims to establish itself as the beacon gold standard in survivor-led advocacy, family education and empowerment, peer support, professional learning in survivorship and health evaluation research engagement. We will expand our biannual conferences, now attracting 100 -150 to close to 200 attendees in both London and at a northern regional centre, to include a CPD-accredited educational component for self-funded professionals a prize for the best research presentation, and a post-conference on-line highlights publication and virtual meeting. A pre-conference satellite meeting of a new national 'SUCCESSCONNECT' advocate group made up of parents / survivors, therapists, nurses and allied community professionals will also be established to promote and endorse the parallel nature of recovery and the recovery pathway.

These events will focus on health-related quality of life (HR-QoL) outcomes for brain tumour survivors, with travel grants and research awards to promote high-quality health evaluation studies. Additionally, SUCCESS will enhance its early role in Patient and Public Involvement (PPI) by actively trying to shape HR-QoL research in academic centres, neuro-oncology clinics, and as partners with major funding bodies like NIHR and brain tumour charities. Through our own BraveHearts Magazine publication, website blogs, and collaborative studies, we will amplify survivor perspectives and drive meaningful research impact in this neglected area.

2. Alleviating Suffering & Isolation - BraveHearts Programme

Building strong peer support networks amongst survivors, siblings and families, but also amongst professionals trying to support survivors beyond the cure itself, remains central to SUCCESS's vision. We will expand our BraveHearts Programme, the voice of SUCCESS, ensuring survivors and families have access to peer-to-peer support groups, interactive webinars, WhatsApp communities, and in-person events across the UK. A Survivor Manual, written by our 'BraveHearts', and further family publications will provide essential guidance, while dedicated summer camps for 15-25-year-olds will promote wellbeing, friendships, independence and vocational support, including the birth of a SUCCESS 'Etsy' shop to showcase their talents. Recognizing the critical gap in mental health services, we will develop an advisory service for education advice, psychology and neuropsychiatry, alongside a professional helpline. Additionally, we will strengthen survivor and parent councils, with lead trustees from each represented on the board, always ensuring dialogue between our beneficiaries and diverse medical experts on hand to provide advice, and fostering a supportive, informed community.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

3. Accelerating & Advocating NHS Service Reform - SUCCESS Recovery Pathway

SUCCESS is committed to transforming survivorship care by driving policy change and service innovation within the NHS. We will innovate with our Digital Therapy Programme with ReAbility UK, provide evidence of need by building on our North Thames Gap Analysis Study and continue to build a head of steam with our lobbying efforts towards endorsing and implementing the SUCCESS Recovery Pathway, integrating parallel complex needs neurorehabilitation and neuroendocrine [pituitary] services into survivorship care. Key milestones include securing commissioned implementation of our world-first national guidelines for centralized paediatric pituitary tumour services, commissioning targeted grant-funded studies into education, career opportunities, neurorehabilitation, and mental health outcomes, and achieving formal service specifications for brain tumour survivorship care. Over the next five years, the Digital Therapy programme will aim to evaluate goal-based and wellbeing outcomes in 300 children under 19 years, the first community programme of its kind to this cohort, providing a baseline report on this new technology against which to benchmark future development and delivery of such innovative platforms to make rehabilitation accessible throughout the life span and hence improve survivorship outcomes. Additionally, we will seek to establish the SUCCESS Keyworker Advocate role, to lead the SUCCESSCONNECT national 'think tank' group with dedicated funding for an inaugural coordinator/trainer and the first cohort of trained advocates, positioning SUCCESS as a leader in survivorship advocacy and professional collaboration.

Thank you


We've made incredible strides this year, yet there is still much to be done ahead – 2024 has built on the success of 2023 and sharpened our focus on turning our vision into reality.

Despite doubling our conference and support offering in the last two years to include a northern cohort and some 1000 beneficiaries, within the same income generation of some £100,000 over the last 5 years, this has been achieved with much voluntary support and expertise from supporters and trustees for which I am exceptionally grateful. Our funds remain limited and there is now an urgency to regroup to generate the income needed to deliver and expand across the UK, the projects we have developed and begun. We are restructuring the board and the executive to prioritise fund raising against the urgency to progress across all fronts — doubling our beneficiary base, enhancing diagnostic complex needs assessments, establishing specialised paediatric pituitary tumour services, improving access to all forms of rehabilitative support, and creating a mandated, fully integrated and commissioned recovery pathway from the moment of diagnosis. After years of being overlooked, it is clear that through SUCCESS, this cause has not only found its voice but is finally being heard. Help us in achieving our vision for enabling a brighter, better future for every childhood brain tumour survivor.

I am so grateful to all our many parent, lay and professional volunteers, our donors, big and small, our board of trustees and patron, and to all the different medical professionals and Parliamentarians, who have contributed the much needed encouragement and valued support, formal and informal advice over the last year. We acknowledge and thank you all.

And last but not least, as always, I extend a heartfelt debt of thanks to our amazing BraveHearts, the cohort of courageous survivors and their families from whom we learn so much every day, whose voices we are proud to represent and for whom we exist to inspire others.

Dr Helen Spoudeas



Chairman

Date: 4 April 2025

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees present their annual report and financial statements for the year ended 31 December 2024.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)".

Objectives and activities

Objectives and aims

Success Charity - Life After Cure exists to enable brighter futures for childhood brain tumour survivors.

To promote and protect the physical and mental health, and relieve the needs of childhood brain tumour survivors ("survivors") treated in the United Kingdom by providing equipment, facilities and services not normally provided by the statutory authorities and in particular:

- i. providing information, resources, advocacy support and education support to the survivors, their families and their education professionals;
- ii. providing multi-disciplinary clinician led rehabilitation treatment ancillary to that provided by the statutory authorities;
- iii. undertaking research into the treatment and outcomes of survivors to identify rehabilitation needs and challenges and publishing the useful results;
- iv. providing mentoring and network groups for survivors and their families; and
- v. providing grants to survivors to access medical support.

The Charity aims to achieve these objectives through a number of activities associated with its three driving ambitions of:

1. Amplifying the voice of survivors and their families
2. Alleviating social isolation for survivors and their families
3. Accelerating rehabilitative services

The Trustees have considered the Charity Commission's guidance on public benefit, including the guidance "public benefit: running a charity (PB2)" and are satisfied that the aims of the Charity are carried out wholly in pursuit of its charitable aims for the public benefit.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Activities

Achievement and performance

Significant activities

Assessing Access to, and Knowledge of, Rehabilitation

North Thames Cancer Network Gap Analysis Study

SUCCESS has worked extensively to assess rehabilitation needs in 2024. Between October 2023 and August 2024, we commissioned a 9-month gap-analysis study with Great Ormond Street Hospital (GOSH) to capture in two time-periods, the knowledge of, availability for, and quality of neurorehabilitative care evaluated against specified best practice NICE guidance since 2005, in a cross-sectional sample population of survivors, parents and clinicians circumscribed to the North Thames Cancer Region.

This record review and questionnaire study showed significant lack of awareness amongst oncology professionals and families in how to refer or access educational and rehabilitative services in some 50%, with little difference between time cohorts, and only 6% receiving streamlined services in line with an acquired brain injury. This study's launch, with generous funding from The Gerald and Gail Ronson Family Foundation, was announced at our March 2024 London conference, initial findings being presented at our October Manchester Roadshow, with more detailed analysis, publication and dissemination to be pursued in 2025.

The Big Survivorship Survey

In Spring 2024 we also launched a national on-line survey through our website, with a BBC local radio-campaign to connect with all survivors of a brain tumour diagnosed before their 25th birthday, and ask them to provide their experiences on aftercure rehabilitation / recovery care in order to inform our NHS England campaign. This is an ongoing survey and to date of 50 responses, only 2 were aware that NICE had recommended rehabilitation to children with brain tumours back in 2005.

Annual conference programmes - London & Manchester

Our Annual London Spring conference during brain tumour awareness month in March remains our flagship national event. We were thrilled to welcome 140 delegates to 1 Wimpole St, the home of The Royal Society of Medicine on March 2nd 2024, as well as Derek Thomas MP, chair of the All Party Parliamentary Group [APPG] on Brain Tumours, to take part in the final panel debate with Lord Sandhurst chaired by our patron Dominic Grieve KC. Our goal was to SHINE-Share, Innovate, Network, and Empower-and achieve 'Success-ful Destinations' across to advance Brighter Futures for Childhood Brain Tumour Survivors. For the first time, we also offered CPD training to new hospital and community professionals supporting recovery beyond cure. SUCCESS will continue to invest in its conference programme and plans are already underway to deliver on our 8th Annual Conference on 15th March 2025.

At the same time we launched our 2nd regional roadshow in Manchester on 19th October 2024, greeting some 70 delegates new to SUCCESS and bringing together 5 northern paediatric neurooncology centres, their professionals and their families [Manchester, Leeds, Liverpool, Nottingham, Sheffield], for the first time. We were delighted to have Professor Simon Kenney, NHSE's national clinical director for children, as our key guest speaker and to create new professional and patient connections supportive of our work. We also engaged with the national group of paediatric neuro-oncology nurses at their annual meeting at the Christie hospital and introduced the idea of creating the SUCCESSCONNECT advocate group we are developing in 2025. We have scheduled our 3rd northern roadshow for 11th October 2025.

Lobbying NHS England

This programme is critical to our desire to expand engagement across major paediatric neuro-oncology centres and engage decision-makers in NHSE and government to define a cost-efficient, safe and effective, integrated rehabilitation pathway, setting measurable goals for national implementation. To this end, we have had initial positive response from both NHS England and the Department of Health indicating their willingness to work with us to assess key gaps in service for this vulnerable population. This is indicative of the increasingly successful way in which we are lobbying for change through Parliament and NHSE with vital leadership from Lord Sandhurst and the support of our patron.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Building a sense of community

The cornerstone of our existence is building our community of survivors, their parents and families across the UK. We strive to support some 1000 current beneficiaries at face to face events such as our conferences, summer picnic and FUN-draising events and our much loved Christmas Carol Concert. We are expanding our Peer mentoring programmes to include parents and siblings whilst bringing training in-house, and enlarging our mediated online offering of weekly friendship and monthly themed Q/A groups, parent and survivor whatsapp support groups, an international health unlocked forum and increasing presence on social media, as well as our survivors' quarterly Braveheart magazine. We are also building a network of professionals and professional advisors making up our clinical advisory group, refreshing our website to make it user- and disabled- friendly, and with dedicated survivor and professional information sections. Our website is currently the main way in which our income is received.

More effective fundraising

This year, our second year in community fundraising, we doubled our community goals and achieved £28,000 and £33,000 with our Summer of FUN-draising and the Carol Concert respectively, whilst at the same time generating positive goodwill amongst our supporters, our beneficiaries and our major donor and corporate base. We also benefitted from £15,000 restricted grants (this is included in deferred income) from the William Rudd Trust to encourage beneficiary attendance at our conferences and £25,000 from a major donor to launch the Digital Therapy programme opening in 2025 after a 4-year delay to raise funds and insurance costs.

Achievements against objectives

Reducing Social Isolation for Survivors and their Families.

SUCCESS continues to develop peer networks that recognize cultural and social differences, helping survivors build relationships, improve mental health, and enhance education and employment outcomes.

Conference Programme

Annual London Conference

The 2024 SUCCESS Annual Conference, held at 1 Wimpole Street, London, on March 2nd, focused on "Successful Destinations" and brought together 140 participants at the Royal Society of Medicine. The event remains a powerful platform for survivors, families, professionals, and policymakers from which to raise awareness, foster positive interdisciplinary relationships, bridge gaps in care and forge change. The conference empowers survivors and professionals in both oncology and non-oncology disciplines, through sharing experiences and knowledge, highlighting service gaps, and advocating for a National SUCCESS Recovery Pathway determined by tumour location. Survivor- and professionally-led workshops, expert debate panels with patient representation, and expert networking sessions continue to provide invaluable support and education to families whilst also bringing together a diverse group of professionals striving to support many, as yet, under-recognised secondary health care needs.

We were delighted to welcome old and new faces from London and the South East, survivors from as young as 8 years and their families but also professionals including Mr Simon Cudlip, pituitary surgeon and Prof Marta Korbonits, pituitary tumour specialist, who explained the importance of new world-first guidelines for children and ensuring specialist care to outcomes. We are grateful to Drs Hoong We Gan, Manuela Cerbone, Charlotte Malcolm, Mr Kristian Aquilina, Profs Naomi Dale and Darren Hargrave, for their insight and understanding of how deep midbrain injury to the vital primitive hypothalamus affects all aspects of physiological and emotional well being and how effects might be minimised if rehabilitated in the right way. We also had a parallel symposium on specialist health and education services ably chaired by our new trustee Dr Jane Williams, a neurorehabilitation specialist, with her colleagues Drs Bishoti and Denise Crozier and a neuropsychiatrist Dr Ashley Liew, and a workshop led by the young people themselves with employment lawyers, educationalists and occupational therapist on overcoming barriers to education and employment. These conferences are unique in the way they bring together patients and diverse professionals, but also for having the attendance and support of eloquent Parliamentarians who are prepared to debate and help us shape our parliamentary and NHSE lobby towards implementation of both our new pituitary tumour management guidance and the tumour-site-specific parallel SUCCESS recovery pathway (Lord Sandhurst our lead, Derek Thomas MP and chair of the brain tumour APPG), and Dominic Grieve KC, our supportive and thoughtful patron.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Our post-conference survey confirmed that over 90% of participants valued the conference as worthwhile and felt it addressed key objectives, namely: providing clarity on the importance of a parallel recovery pathway; improving understanding of the Charity's mission and aims; feeling more inclined to support us and to support survivors.

What participants liked most about the conference was gaining a better understanding of key challenges and finding support for them (54%) and feeling inspired and more hopeful about the future (31%). Overwhelmingly 85% of participants agreed the charity should continue to advocate for a parallel recovery pathway, from diagnosis and alongside oncology treatment.

Autumn Roadshow

Success Charity's 2nd Autumn Roadshow took place in Manchester on Saturday 19th October 2024, an ongoing educational initiative reaching all UK paediatric neurooncology centres was supported by satellite events on the 18th of October 2024. The primary goal of this event in line with the grant objectives, was to introduce SUCCESS to northern audience; educate, support and connect survivors of childhood brain tumours and their families with diverse oncology and rehabilitation healthcare professionals; raise awareness of gaps in neurological and endocrine recovery; highlight areas of good practice and connect with NHSE commissioners.

SUCCESS campaigns to raise awareness of the individual brain injury underlying each brain tumour, and the need for a parallel recovery pathway alongside cure, to improve long term health outcomes for the 80% that now survive and live long lives across the UK. This conference brought together a patient and professional audience from 5 northern paediatric neuro-oncology hospitals for the first time. In total 72 people attended this Roadshow, the majority of whom were beneficiaries of, and professionals linked to, the Charity.

Key activities included:

- an Educational Programme, as a CPD-approved event, featuring survivors and family talks, medical expert sessions on pituitary tumours, neurorehabilitation of acquired brain injury, and survivorship, plus interactive parental psychology and children's art therapy workshops; a community poet 'transcribed' conversations into poems later read out by survivors at our Christmas Carol Concert.
- workshops where holistic rehabilitation was emphasized through therapy sessions, providing survivors and families with understanding emotional support and opportunities to connect;
- professional engagement, by fostering collaboration among neuro-oncology, nursing, endocrinology, psychology, and physiotherapy professionals, promoting best practices for survivorship care, especially for early neurorehabilitation, hormone assessment and replacement and for very rare pituitary tumours;
- advocacy and peer support, enabling survivors and professionals to share personal experiences, highlight gaps in rehabilitative and pituitary care, and in health-related quality-of-life outcomes beyond survival alone, to Prof Simon Kenney, who oversees Children's NHS Commissioning .

After the event, 89% of those surveyed told us they felt equally "inspired" and that "cure alone was not enough", whilst all felt a recovery pathway was indeed needed over and above what the NHS currently offered. Only 10% felt they had been supported through their recovery journey.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Voices of SUCCESS- The BraveHeart Programme

SUCCESS continues to amplify survivor stories and experiences through various initiatives:

- **BraveHearts Magazine:** A quarterly survivor-led on-line publication, with a growing reach, in print for key fundraising events such as the carol concert.
- **Online Support:** The weekly friendship group and monthly BraveHearts Live focus groups (7-10 survivors) as well as a mediated 50+ member WhatsApp 16+ community provide a safe space for sharing experiences, artistic and fundraising inspiration, ideas for projects and practical support.
- **Public Engagement:** Survivors are centre-stage at our annual Christmas Carol Concert led by a SUCCESS parent and choirmaster, speaking publicly about their experiences to 230 attendees, and at the annual conference and roadshow where their brave voices are always a programme highlight.
- **Peer-to-Peer Programme:** Peer support remains central to SUCCESS, is requested by survivors and is well regarded as a programme by professionals who support our initiative. A training session for new mentors (16+) and interviews for new mentees (13+) was held this year but more funding is required to bring the training in-house, make it SUCCESS-specific and to support more mentors to undertake mentee support subsequent to being trained and receiving certification. Fundraising efforts in 2025 will prioritize relaunching this initiative as a core charity program and making mentee-ship mandatory to certification.

Being a Catalyst for Innovation and Rehabilitative Services for Survivors

SUCCESS aims to facilitate and develop better access to, and increasing investment in, holistic (neuroendocrine) rehabilitation and health research interventions targeted at improving existing services, identifying new ones and facilitating better community health and educational access. This year, it has progressed this area through two major projects.

Survivorship Services Gap-Analysis Study in partnership with GOSH

SUCCESS commissioned a study evaluating access to rehabilitation services for childhood brain tumour survivors at the North Thames Paediatric Cancer Network (ODN), developed with Professor Darren Hargrave and therapists at GOSH with restricted funds from The Ronson Foundation and a smaller grant from our founder. A SUCCESS-GOSH working group formed in 2022 led to the idea of the SUCCESS Recovery Pathway. The study, defined in July 2023 with Professor Hargrave and Dr Michalski, GOSH professionals and SUCCESS Trustees began in October 2023 with a part-time, neurophysiotherapist project lead.

The project aimed to survey recovery services against NICE recommendation standards (2005) and conduct a retrospective service review at 1-2 and 5-6 years post-diagnosis. Led by a Specialist Physiotherapist in Paediatric Neuro-Oncology at GOSH, Daniel Bell, it ran from November 2023 to August 2024, with main preliminary findings presented to trustees in September and in Manchester at the Autumn 2024 roadshow.

Amongst several interesting conclusions, the results of this retrospective gap-analysis reported that less than half (49) of 100 survivors surveyed, had received any rehabilitative or educational support and just 6% had received planned integrated support, even in the most recent cohort. None were aware of any educational tools to support cognitive weaknesses whilst under 50% knew how to access educational health care plan funding, and this figure was similar amongst oncology professionals.

With SUCCESS professionals and beneficiaries involved in designing the gap-analysis study and questionnaires, these findings support the proposed SUCCESS Survivorship Standards (SSS) for potential national endorsement in Phase 2, to be defined in 2025 and beyond, including our support of a collaborative PPI in the context of the Brain Tumour Charity and NIHR Quality of Life research. In this context we have also provided £5,505 to fund the PPI element of an NIHR grant awarded to Dr Charlotte Malcolm at GOSH to develop educational tools for strengthening cognitive weaknesses which SUCCESS will have access to once developed.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Digital Therapy Bursary Programme with our Partner ReAbility UK

SUCCESS has partnered with ReAbility Online UK to introduce a cutting-edge, games-based neurotherapy platform for children with brain tumours. Developed at the Gertner Institute, Israel, and widely used in Austria, this platform is unavailable in the UK, making SUCCESS the gateway for national implementation and evaluation.

Following a successful pilot study in 2020, presented at the British Paediatric Neurology Association, SUCCESS committed to fundraising, patient recruitment, and long-term programme evaluation. However, COVID insurance and funding challenges in 2021 delayed progress. In 2023, the project was revived, with a restructured protocol and renewed partnership, aiming to evaluate benefits in a total of 300 patients - recruited in tranches of 12-15 per quarter and treated over a 12 week period - according to adherence. Trustees Drs Jenny Limond and Helen Spoudeas and Jane Hobson have led clinical and legal protocol preparation and contractual agreements, and secured restricted funds to start the 12-week therapy programme for the first 25 patients. This has occurred alongside newly secured project management to finalise contractual terms to ensure the interests of beneficiaries and the Charity are prioritised, which has taken longer than anticipated. The launch was postponed with an anticipated date of 1.3.25 for training of UK therapists and patient recruitment, and a study start date of 1.6.25 . Continued efforts to prioritise fundraising to ensure the programme's success for the first 12 months and beyond this phase into 2nd and 3rd years .

Amplify the Voice of Survivors and their Families

SUCCESS strives to amplify the voices of survivors and families, addressing unmet needs, especially in hard-to-reach and disadvantaged groups. SUCCESS believes that lobbying is vital to amplify the voices of survivors, ensuring their needs are heard at the highest levels. Without advocacy, critical gaps in rehabilitation, education, and healthcare remain overlooked. By engaging policymakers, SUCCESS aims to drive systemic change in the long term in order to secure equitable services for all, funding, and recognition for brain tumour survivors and their lifelong recovery needs.

The Charity's lobbying and advocacy efforts focus on key areas.

Lobbying Committee

Led by Lord Guy Sandhurst and Dr Helen Spoudeas since 2022, with input from SUCCESS parents, Lords Stewart Wood and Sharpe, and our Patron Dominic Grieve KC, this group advocates for national representation of the unmet recovery needs of survivors at parliamentary and NHSE levels. Over the last 12 months, our desire to expand engagement across major centres and decision-makers in NHSE and government to define a cost-efficient, safe, and effective integrated recovery pathway alongside cure, setting measurable goals for national implementation has been taken a step further with the recruitment of a neurorehabilitation trustee, Dr Jane Williams, to the board and to this initiative, and strategic advice from Sir Bruce Keogh, the outgoing NHSE National Clinical Director. We have pursued our request for a face to face audience with childrens cancer commissioners and those responsible for highly specialised funding pertinent to the need for bespoke pituitary tumour services, which has been scheduled for 14th January 2025. This is a significant opportunity granted to SUCCESS and is an early hopeful indication of the appropriateness of our approach to lobbying through Parliament and NHSE, which also includes an approach to the Department of Health by Dr Spoudeas through her local MP. We continue to reinforce this group and formalise its governance as part of the Charity's overall structure.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

We need to continue to expand engagement across major paediatric neurooncology centres and decision-makers in NHSE and government to define and endorse a cost-efficient, safe, and effective integrated recovery pathway, setting measurable goals for national implementation. This is something we are currently working on with Lord Sandhurst and our Patron, Dominic Grieve, and will continue to develop further in 2025. We will also continue to collaborate closely with the Children and Young People's Cancer Coalition of Charities and the Brain Tumour APPG, and are alert to any new initiatives launched by the new Labour Department of Health and Social Care [DHSC] in the area of children's cancer, which work streams were first announced by Dame Caroline Dinnenage before the general election.

Additionally, we will begin feasibility assessments about the possibility of developing designated paediatric pituitary centres of expertise, with associated HR-QOL outcome national data registries, integrating new CCLG-commissioned and RCPCH-endorsed national guidelines for rare pituitary tumours affecting <50 CYP annually. This will be subject to funding, but continues to be a priority for the charity.

Clinical Advisory Experts/Group.

Launched in early 2024, this initiative, started by our founder and now led by trustee Dr Jane Williams with Dr Jenny Limond as deputy, brought together NHSE commissioning and health research experts in neurooncology, neurosurgery, neuropsychology, neuroendocrinology and allied therapy. The goal is to ensure we support equitable healthcare evaluation studies in the survivorship field and quality improvements in any medically-related projects we undertake or commission. Membership of this Expert Group has generated significant support from the clinical community which can be found on our website.

Parent Council

2025 will also see the development of a Parent Council with a lead parent trustee and at least six volunteer parents of survivors already engaged and charged with developing further engagement from their community to feedback to the Board on a quarterly basis.

Survivor Council

In recognition of the importance of the survivor voice to be heard at the board, we are also launching a Survivor Council to work alongside the parents' council with a lead survivor trustee and deputy, ensuring the survivor voice is formally recognised in the Governance of the Charity, and reporting to the Board on a quarterly basis.

Contribution made by volunteers

In the absence of a large charitable endowment at its start-up, much of the Charity's activity, is necessarily still carried out by volunteers, including the role of our CEO which is undertaken by our Founder trustee. As well as the Board of Trustees, other volunteers have given time and expertise with matters such as organising events, producing educational and information resources and providing support and legal and governance advice. The charity has had a part-time administrator for 3 years and a fixed term appointment part-time project manager this year, utilising consultants to assist with the operations, web-site development, marketing and communications, and fundraising. Due to limited funding, the Charity and the Board are restructuring in 2025, to increase volunteer involvement and skills, prioritise income generation and fundraising, optimise the activities of committees reporting to the board, and limit administrative expenses.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Achievements and performance

Significant activities and achievements against objectives

Performance of fundraising activities against objectives set

Sector challenges

SUCCESS continues to face significant fundraising difficulties as competition for grants and donations intensifies in an increasingly challenging environment for the third-sector. Further, this chronic survivorship area of cancer care is notoriously difficult to secure funding for, competing as it does with the much easier fundraising call for the cancer cure itself. Securing sustainable funding has thus become doubly harder. Many corporate donors only prioritize larger charities, and/or make donations proportionate to 10% of annual income streams, making it difficult for small, specialist organisations like SUCCESS to access critical funding streams. The eventual drying up of EU funding since Brexit, and the economic uncertainty has generated unprecedented competition for grants from Trusts, Foundations and the National Lottery and reduced individual giving, while complex grant application processes require resources that small charities must use prudently. Despite these difficulties, we remain committed to our mission, focusing on diversifying income streams and strengthening donor engagement. We have, as a Board, decided to invest more fully in an integrated CRM system, consolidate our stakeholder base, create a legacy opportunity and engage in more specific targeting of donor groups to maximise our ability to raise funds from a category of donors more likely to provide initial funds.

Engaging our community

A key strategy for overcoming these sector challenges has been to strengthen our engagement with our community of fundraisers and donors through meaningful events. These not only serve as vital fundraising opportunities but also enable stronger meaningful connections, ensuring our supporters feel involved in our mission and appreciate the lasting impact of their contributions.

They included:

- **SUCCESS Summer of Fundraising:** Building on last year's SUCCESS picnic, we encouraged our community to raise funds for Success Charity with our Summer of FUN-raising activities. Throughout the month, we shared fundraising tips on our social channels and encouraged our supporters to share their journey with us. Overall, we managed to raise £28k including contribution from Helen's Tangathon (£5.5k), Fernando De Jesus and the team at Stow Ho House Event (£5.4k), Patricia Grady's Rusty Bike Cafe week (£1.8k), Jane Hobson's afternoon tea, tombola and silent auction (£8k) Sara Levy's fundraiser (£1.7k), and John Evason's donation (£1.5k). We were delighted so many of our supporters managed to raise donations and awareness and have committed to building on this initiative in 2025 with 3 additional marathon places at the London Parks half-marathon. We also continue to sell the 10,000 £1 printed 'Successful Experiences' raffle tickets which we will draw at our Spring conference on 15th March 2025, and which prizes and printing costs have been generously donated by our consultants, Waring Stewart Associates.
- **SUCCESS Carol Concert:** this is now a central celebratory and fundraising event in SUCCESS's calendar, taking place annually with the prestigious Norfolk Cathedral Choir, their choirmaster Ashely Grote, himself a SUCCESS parent, and our patron, in different historic, City of London Churches. It attracts an audience from London and its hospitals and as far afield as Nottingham and Edinburgh, creates a sense of community, hope, giving and solidarity, bringing the survivor voice to a wider donor and supporter audience from whom we have identified new trustees and volunteers, whilst raising awareness of our need for crucial support during challenging times. This year, SUCCESS managed to raise some £33k (65% more than last year) welcoming 230 guests. As in previous years, we are very grateful to Gino Palmieri of GPIM for his company's continuing committed contribution of £5,000 towards the choir, venue and production costs, but also to our other sponsors, BUPA Cromwell who gave £10,000, as well as The Belgravia Centre (£2,000), Burnett Hodd and Tam Optometry (£1,000k) and to Lord Lee of Trafford who donated £1,000 to our Light in the Shadows Appeal alongside many others, whilst tickets sales and the collection totalled some £10,000 on the night. A post-event reception for 80, catered generously by the Wallbrook Club and hosted by Dr Spoudeas attracted key donors, with support from our Patron, Dominic Grieve and Lord Sandhurst.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

SUCCESS Will continue to build on what has now become an iconic event in its community and fundraising diary, and has committed to venues in 2025 and 2026.

- **Annual SUCCESS conference and Roadshows:** Although SUCCESS views these events as a service to our beneficiaries - our survivor and clinical community - we nevertheless attracted just over £15,000 in sponsorship, professional CPD ticket sales and voluntary donations, which included £1,000 from Bolt Burdon Kemp lawyers towards travel costs and a £12,000 grant for patient benefit from Pfizer Global Shared Services Europe. The charity is extremely grateful for their ongoing support. We are also grateful to the William Arthur Rudd Memorial Trust who have generously increased their annual grant to us, gifting £15,000 in December to support our conference programme in 2025.
- **Digital Therapy:** SUCCESS is also grateful to its founder, Helen Spoudeas, for her donation of £25,000 towards our Digital Therapy programme with ReAbility Online UK, which supplements the £5,000 restricted to this project from the William Arthur Rudd Memorial Trust ("Hunter's Law").

Overall, SUCCESS managed to generate income amounting to £114,900 across all activities. We are enormously grateful to all our supporters and donors, large and small for this vital development support, which means so much to us, our board and to our beneficiaries at this early time of our foundation.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Financial review

Overview

SUCCESS's income has decreased from £117,355 in 2023 to £114,975 in 2024, boosted by restricted funds of £47,000 including a personal donation of £25,000 from SUCCESS's founder, Helen Spoudeas, towards our Digital Therapy project. Other material donations included Pfizer Global Shared Services Europe amounting to £12,000, BUPA Cromwell's £10,000 sponsorship of our 'Light in the Shadows' Christmas Carol Concert at GPIM Ltd's £5,000 contribution towards the same appeal.

The Summer of FUN-raising generated twice as much income this year as in 2023; this is a cost effective activity the Charity will continue to focus on as a major fundraising event in its calendar, together with the Carol Concert which generated £33,428 in 2024 (some 65% more than in 2023). The Charity was less successful than in previous year in generating sustainable, other income from its supporter base, amounting to just £7,813 (against approximately £16,476 last year). Planned investment in a more integrated CRM will hopefully provide opportunities for more targeted campaigns aimed at generating a regular income from its donor base.

In 2024, SUCCESS committed £96,409 to charitable activities (71% of its total expenditure – against a similar level last year), with £46,376 attributable to the conference and roadshow, £22,500 to fund the Gap Analysis (drawn from restricted reserves brought forward). The conference used to attract more pharmaceutical companies prepared to support this type of event, but obtaining funds from this group of stakeholders has become increasingly restricted and challenging. The 2025 conference and roadshow will go ahead, with some restricted funds of £15,000 secured from William Arthur Rudd trust, but it is anticipated this will be a cost leader in the context of SUCCESS' endeavour to grow its base of supporters and deliver on its mission.

The Carol Concert fundraising event was delivered at a similar cost to last year, but managed to generate more income, providing a greater contribution to general reserves.

Overall, the Charity made a deficit of £26,857 in 2024 against a deficit of £11,300 in 2023 further depleting its general reserves.

Included in prepayment and accrued income of £5,980 is £6,072 deposit for SUCCESS' 2025 Annual Conference, and accruals and deferred income includes a balance of £15,000 from the William Arthur Memorial Trust towards our conference programme in 2025, and a provision for costs of £3,100 attributable to the Norwich Cathedral Choir incurred in December 2024.

As in previous years, the charity's limited capacity to generate sustainable revenue streams for its initiatives and the staffing salaries to support them continues to be a material risk. To address this, SUCCESS engaged a business consulting and fundraising firm two years ago. Excluding costs attributable to the Survivorship Gap Analysis Study funded by reserves brought forward, this cost represents 25% of the total in 2024 (an increase from 21% last year). The expectation is that this proportion will continue to increase in 2025 as the Charity loses the administrator role and shifts its investment in salaried costs (fixed costs) to variable costs, to address economic uncertainties faced by the sector and continue to operate as a going concern.

The Board and Risk Committee continue to acknowledge that an urgent focus on fundraising is needed to deliver on the broader projects identified as part of its strategic plan.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Reserves policy

The Charity continues to monitor reserves on an ongoing basis, including at the last two Board Meetings on 6th December 2024 and 28th January 2025. The Board appreciates the need to balance reserves with sufficient fund allocation for progression of charitable activities as detailed above.

Total unrestricted reserves carried forward stand at £71,759 for the year ended 31 December 2024 (a decline of approximately 30% on last year), with an additional £31,317 restricted funds allocated to the delayed launch of SUCCESS' Digital Therapy project. Total reserves therefore stand at £103,076 (against £129,993 at the end of last year).

The Trustees continue to believe a formulaic reserve policy is not commercially meaningful, but agrees to monitor costs and revenues on a quarterly basis as part of its risk and control procedures. Current reserves cover at least six months of operational expenses, now that a reorganisation to reduce fixed costs has been effected. At this stage, the Trustees feel this is a reasonable commercial buffer to maintain and review it quarterly at Board meetings.

Principal funding sources

The charity's principal sources of funds (including any fundraising)

The charity raises income through individual giving, community fundraising, corporate support and grants. Last year, we registered with Stripe and Just giving, receiving donations through these methods. Credit card and PayPal donations can be made directly through the website. In 2025, a fundraising strategy will be developed with a new fund-raising committee in a re-aligned board structure, alongside a refreshed board of more trustees with time and relevant skill sets. Our goal is to provide detailed 12 month, and high level 5- year fundraising targets, as well as a legacy programme, against which we can budget for the projects we aim to deliver.

Major risks

Risk Policy

The Risk Committee conducts a review of the major risks to which the charity is exposed using the Charity Commission framework and has a risk register updated at least annually by the Governance Committee and presented to the Board).

Where appropriate, systems or procedures have been established to mitigate the risks the charity faces, including ensuring all trustees and patient facing staff have appropriate DBS checks within 6 weeks of appointment as well as updating our safeguarding and recruitment policies, ensuring safeguarding training at the earliest opportunity as a condition of appointment, given the vulnerable children and adults we help. We also take cybersecurity seriously and are aware our safety needs testing as a priority, despite the limited funds to allocate to this at present. We currently have two levels of authorisation for all financial transactions, though one is salaried staff and requires reconsideration.

The main risks identified remain similar to previous years:

- generating sustainable income in order to deliver services for its beneficiaries – SUCCESS believes it should continue to drive income generation and leverage on the investment its CEO has made to date in a firm of fundraising and business consultants; and
- operational delivery of projects – rests with the voluntary CEO and the outsourced support from Waring Stewart Associates and other contractual staff for project delivery. The Board is committed to reviewing this cost on an ongoing basis.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, governance and management Governing document

Success is a charitable company limited by guarantee and established under its Memorandum and Articles of Association. In the event of the company being wound up every member of the charity undertakes to contribute such amount as may be required (not exceeding £1).

Trustee selection methods including details of any constitutional provisions:

The Board spent time reviewing the Charity Commission guidance, the Charity Governance Code and other governance reference material. Trustee role descriptions and a Code of Conduct were produced and implemented.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the 31st December 2024 were:

Philip Austin
Jane Hobson
Hugh Stewart
Jennifer Limond
Marco Previero
Dr Helen Spoudeas
Dr Jane Williams
Richard Crowther

(Retired by rotation,
9th February 2024)

Recruitment and appointment of trustees

Trustee recruitment, selection and succession planning will be agreed as part of the ongoing governance of the organisation. This will include consideration of the requirements for a diverse board membership, ensuring that trustees have different backgrounds and experiences to enable better decisions.

A comprehensive programme of governance training was included in board meetings, to ensure that trustees were aware of the responsibilities and expectations of them, and to be able to review their effectiveness. Plans to ensure ongoing board development and training are in progress.


The charity is governed by the Board of Trustees, with advice and support from external freelance consultants, who operate as project managers for some aspects of charitable activity. A series of sub-groups [committees] and steering [Advisory] groups support the work of the Board and the operational delivery of its charitable aims and objectives. External HR and legal advice is provided on a pro bono basis by a legal firm.

The charity operates within the wider environment of children's cancer, brain tumour and brain injury charities and services and has formed links with other charities and NHS services, through informal discussions, with the ultimate aim of enhancing the lives of childhood brain tumour survivors.

SUCCESS LIFE AFTER CURE LIMITED

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) *FOR THE YEAR ENDED 31 DECEMBER 2024*

The trustees' report was approved by the Board of Trustees.



Hugh Stewart
Director

Date: 18 03 2025

SUCCESS LIFE AFTER CURE LIMITED

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees, who are also the directors of Success for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select the most suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on a going concern basis unless it is not appropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Management Committee and signed on its behalf by

Hugh Stewart (Chair)



Director

SUCCESS LIFE AFTER CURE LIMITED

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF SUCCESS LIFE AFTER CURE LIMITED

I report to the trustees on my examination of the financial statements of Success Life After Cure Limited (the charity) for the year ended 31 December 2024.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law), you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006.


Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the Companies Act 2006 and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the Companies Act 2006.
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the Companies Act 2006 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Tom Wilcox

Counterculture Partnership LLP
Bank Chambers
Main Street
Hawes
North Yorkshire
DL8 3QL
8 April 2025

SUCCESS LIFE AFTER CURE LIMITED

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

		Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
	Notes						
Income from:							
Donations and legacies	3	67,975	47,000	114,975	79,973	37,382	117,355
Total income		<u>67,975</u>	<u>47,000</u>	<u>114,975</u>	<u>79,973</u>	<u>37,382</u>	<u>117,355</u>
Expenditure on:							
Raising funds	4	7,670	-	7,670	11,079	4,374	15,453
Charitable activities	5	90,979	43,183	134,162	80,535	32,667	113,202
Total expenditure		<u>98,649</u>	<u>43,183</u>	<u>141,832</u>	<u>91,614</u>	<u>37,041</u>	<u>128,655</u>
Net income/(expenditure)		<u>(30,674)</u>	<u>3,817</u>	<u>(26,857)</u>	<u>(11,641)</u>	<u>341</u>	<u>(11,300)</u>
Transfers between funds		(463)	463	-	(10,836)	10,836	-
Net movement in funds	6	<u>(31,137)</u>	<u>4,280</u>	<u>(26,857)</u>	<u>(22,477)</u>	<u>11,177</u>	<u>(11,300)</u>
Reconciliation of funds:							
Fund balances at 1 January 2024		102,896	27,037	129,933	125,373	15,860	141,233
Fund balances at 31 December 2024		<u>71,759</u>	<u>31,317</u>	<u>103,076</u>	<u>102,896</u>	<u>27,037</u>	<u>129,933</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

SUCCESS LIFE AFTER CURE LIMITED

BALANCE SHEET

AS AT 31 DECEMBER 2024

	Notes	2024 £	£	2023 £	£
Fixed assets					
Tangible assets	10		468		209
Current assets					
Debtors	11	16,750		48,785	
Cash at bank and in hand		115,322		94,950	
		132,072		143,735	
Creditors: amounts falling due within one year	12	(29,464)		(14,011)	
Net current assets			102,608		129,724
Total assets less current liabilities			103,076		129,933
The funds of the charity					
Restricted income funds	14	31,317		27,037	
Unrestricted funds	15	71,759		102,896	
		103,076		129,933	

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2024.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 4 April 2025



Hugh Stewart

Director

Company registration number 11785842 (England and Wales)

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

Charity information

Success Life After Cure Limited is a private company limited by guarantee incorporated in England and Wales. The registered office is 280 Bishopsgate, London, EC2M 4RB.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Memorandum of Association, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a statement of cash flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings	20% on reducing balance basis
Computer equipment	33% on reducing balance basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Donations and gifts	67,975	47,000	114,975	79,973	37,382	117,355

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

4 Expenditure on raising funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Fundraising and publicity						
Seeking donations, grants and legacies	7,670	-	7,670	11,079	4,374	15,453

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

5 Costs of charitable activities by fund type

	Unrestricted Funds 2024 £	Restricted Funds 2024 £	2024 £	2023 £
Amplify voice of survivors	4,885	-	4,885	6,559
Reduce solical isolation	42,653	5,000	47,653	60,620
Catalyst for post-cure recovery	5,688	38,183	43,872	13,403
Support costs	37,752	-	37,752	32,620
	<u>90,978</u>	<u>43,183</u>	<u>134,162</u>	<u>113,202</u>

Costs of charitable activity by activity type

	Undertaken directly £	Support costs £	2024 £	2023 £
Support costs				
Amplify voice of survivors	4,885	1,913	6,798	9,215
Reduce solical isolation	47,653	18,660	66,313	85,171
Catalyst for post-cure recovery	43,872	17,179	61,051	18,816
	<u>96,409</u>	<u>37,752</u>	<u>134,162</u>	<u>113,203</u>

Analysis of support costs

	Amplify voice £	Reduce isolation £	Catalyst post-cure £	2024 £	2023 £
Managment	397	3,877	3,569	7,844	17,031
General overheads	1,242	12,115	11,153	24,510	8,201
Website development	122	1,192	1,097	2,411	6,217
General Governance	151	1,476	1,359	2,987	1,171
	<u>1,913</u>	<u>18,659</u>	<u>17,179</u>	<u>37,752</u>	<u>32,720</u>

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

6	Net movement in funds	2024	2023
		£	£

The net movement in funds is stated after charging/(crediting):

Fees payable for the independent examination of the charity's financial statements

Depreciation of owned tangible fixed assets

-	-
180	-

7 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

8 Employees

The average monthly number of employees during the year was:

2024	2023
Number	Number
1	1

There were no employees whose annual remuneration was more than £60,000.

9 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

10 Tangible fixed assets

	Fixtures and fittings	Computer equipment	Total
	£	£	£
Cost			
At 1 January 2024	209	-	209
Additions	-	648	648
Disposals	(209)	-	(209)
At 31 December 2024	-	648	648
Depreciation and impairment			
Depreciation charged in the year	-	180	180
At 31 December 2024	-	180	180
Carrying amount			
At 31 December 2024	-	468	468
At 31 December 2023	209	-	209

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

11 Debtors

	2024 £	2023 £
Amounts falling due within one year:		
Trade debtors	10,770	1,534
Other debtors	5,980	47,251
	<u>16,750</u>	<u>48,785</u>

12 Creditors: amounts falling due within one year

	Notes	2024 £	2023 £
Deferred income	13	20,004	-
Trade creditors		8,210	12,839
Accruals		1,250	1,172
		<u>29,464</u>	<u>14,011</u>

13 Deferred income

	2024 £	2023 £
Other deferred income	20,004	-
	<u>20,004</u>	<u>-</u>

Deferred income is included in the financial statements as follows:

	2024 £	2023 £
Deferred income is included within:		
Current liabilities	20,004	-
	<u>20,004</u>	<u>-</u>
Movements in the year:		
Deferred income at 1 January 2024	-	-
Resources deferred in the year	20,004	-
	<u>20,004</u>	<u>-</u>
Deferred income at 31 December 2024	<u>20,004</u>	<u>-</u>

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

14 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2024	Incoming resources	Resources expended	Transfers	At 31 December 2024
	£	£	£	£	£
	-	-	-	-	-
Conference	-	12,000	(12,000)	-	-
Nurse Appeal/MDT	22,037	-	(22,500)	463	-
ReAbility	5,000	30,000	(3,683)	-	31,317
Carol Concert 2024	-	5,000	(5,000)	-	-
	<u>27,037</u>	<u>47,000</u>	<u>(43,183)</u>	<u>463</u>	<u>31,317</u>
	<u><u>27,037</u></u>	<u><u>47,000</u></u>	<u><u>(43,183)</u></u>	<u><u>463</u></u>	<u><u>31,317</u></u>
Previous year:	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
	-	-	-	-	-
Conference	11,760	11,930	(23,690)	-	-
Nurse Appeal	4,100	20,000	(2,063)	-	22,037
ReAbility	-	5,452	(11,288)	10,836	5,000
	<u>15,860</u>	<u>37,382</u>	<u>(37,041)</u>	<u>10,836</u>	<u>27,037</u>
	<u><u>15,860</u></u>	<u><u>37,382</u></u>	<u><u>(37,041)</u></u>	<u><u>10,836</u></u>	<u><u>27,037</u></u>

Note to the restricted funds

SUCCESS received a £12,000 grant for patient benefit from Pfizer Global Shared Services Europe for the 2024 conference. ReAbility is an online rehabilitative tool that helps people with neurological damage get better; and enables them to lead better lives. The Charity was the beneficiary of a donation of £25,000 from Helen Spoudeas, restricted for the use of this project, and £5,000 received from The Albert Hunt Trust as a contribution towards this project, making up £30,000. £5,000 related to sponsorship of the Carol Concert from GPIM Ltd as contribution towards the choir, venue and production costs.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

15 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2024	Incoming resources	Resources expended	Transfers	At 31 December 2024
	£	£	£	£	£
General funds	102,896	67,975	(98,649)	(463)	71,759
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Previous year:	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
General funds	125,373	79,973	(91,614)	(10,836)	102,896
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>

16 Analysis of net assets between funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
At 31 December 2024:			
Tangible assets	468	-	468
Current assets/(liabilities)	71,291	31,317	102,608
	<u>71,759</u>	<u>31,317</u>	<u>103,076</u>
	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 31 December 2023:			
Tangible assets	209	-	209
Current assets/(liabilities)	102,687	27,037	129,724
	<u>102,896</u>	<u>27,037</u>	<u>129,933</u>

17 Related party transactions

There were no disclosable related party transactions during the year (2023 - none).

SUCCESS LIFE AFTER CURE LIMITED

England & Wales - Charity number 1188298

Accounts

Charity registration number 1188298

Company registration number 11785842 (England and Wales)

SUCCESS LIFE AFTER CURE LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

SUCCESS LIFE AFTER CURE LIMITED

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Philip Austin Jane Hobson Hugh Stewart Jennifer Limond Marco Previero Dr Helen Spoudeas Dr Jane Williams (Appointed 13 September 2023)
Charity number	1188298
Company number	11785842
Registered office	280 Bishopsgate London EC2M 4RB
Independent examiner	Tom Wilcox Counterculture Partnership LLP Unit 115, Ducie House Ducie Street Manchester M1 2JW

SUCCESS LIFE AFTER CURE LIMITED

CONTENTS

	Page
Chair's Report	1 - 3
Directors report	4 - 15
Independent examiner's report	16
Statement of financial activities	17
Balance sheet	18
Notes to the financial statements	19 - 26

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2023

Chair's report - Cure Alone Is Not Enough

The Directors have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2023. The Directors have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

Chair's report - Cure Alone Is Not Enough

Another year has gone by, and SUCCESS continues to make progress in a difficult economic environment for the Charity sector.

Cure Alone Is Not Enough

Here at SUCCESS, we believe that curing children from brain tumours or brain cancers simply isn't enough. It's not enough to just give them back a life. It is incumbent on the health service to also restore their full health, maturational and intellectual potential. This is especially important now that 80% are deemed cured and live long lives. We estimate there are over 30,000 such survivors across the UK who need our advocacy and help. This is what we mean when we say, "**Cure Alone is Not Enough.**"

- **Cure alone is not enough** when one considers survival costs, in terms of current and future lived experience, health and mental well-being, independence and employment potential.
- **Cure alone is not enough** when one considers that it is the youngest children who have the longest time in which to mature (and hence accrue developmental gaps) until brain development completes at 25 years of age approximately.
- **Cure alone is not enough** when, although they need that rehabilitative support from diagnosis and will most benefit from it, they are least likely to get it.
- **Cure alone is not enough** when targeted educational and psychological support is a particular issue that parents tell us they struggle to access, especially for an innately gifted child.
- **Cure alone is not enough** if we allow them to fall intellectually to below the 2nd centile before they get their specific needs recognised.
- **Cure alone is not enough** if secondary life-threatening conditions such as hormone deficiencies, can be prevented or supported from tumour diagnosis by commissioning appropriate pituitary and endocrine specialists.
- **Cure alone is not enough** if children with rare very high survival [>90-95%] midbrain tumours are not accessing the highly specialised surgical and medical pituitary care we know will reduce collateral brain injury as do adults.
- And finally, **cure alone** - as is currently measured from 5y survival – is not enough as a statistical measure of outcomes. We need to measure secondary health-related quality of survival.

Redressing the balance – delivering on our vision

Whilst investment in cancer research and intensified treatments have translated into a 5-year cure for 80% of children with a brain tumour, this heavy price of 'cure' on the developing child is often overlooked.

Our long-term ambition to enable better futures for survivors of childhood cancer remains unchanged. Closely linked to this vision is the need to rationalise and improve both diagnostic treatment pathways for specific sub cohorts of very rare tumour and individualised rehabilitative services for all children. These require different specialist expertise during and beyond treatment.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

In order to do this, SUCCESS continues to advocate for the urgent development of a SUCCESS National Recovery Pathway, preferably integrated within the NHS, running in parallel to the current treatment pathway, tailored to the location of the tumour and whether in the deep midbrain or peripheral, but present from diagnosis and integrated beyond cure and into adult transition for every childhood brain tumour.

Our vision and objectives

Lobbying for a new service in the NHS involves navigating the complexities of healthcare systems, coordinating with diverse professionals, including new non-oncology services, and managing limited resources. This demands time, planning, effective communication, and alignment with existing resources and importantly a multi-faceted and stepped approach; our plan, over the next five years is to deliver on our vision, to create transformational change in the way health care is delivered to improve secondary health outcomes by delivering across **6** key milestones. This means encompassing brain injury evaluation and recovery from the beginning now that the majority survive.

1. **2023/2024 - Preliminary Assessment:** Much work has been undertaken to establish an initial assessment of rehabilitation needs over the last 3 years. We were therefore delighted to collaborate with GOSH and to commission from October 2024 a 9-month gap-analysis study of service gaps against current best standard for survivors of brain tumours at set points during and after treatment, and to have patient and parent representatives feeding into the questionnaires devised. SUCCESS also opened preliminary discussions with Birmingham neuroncology services in November 2023
2. **2024/2025 - Refining and Rationalizing the model of care:** SUCCESS will continue to work in this area and seek further assessments and engagement both at GOSH and across other major regional centres in the north as well as with key decision-makers in NHSE and government. This will further our collective understanding of both the need, and the organisational commissioning possibilities, professionals and patient requirements and desired key health outcome data across several stakeholders including patients, healthcare providers, and specialists, and set measurable goals for a national integrated diagnostic and rehabilitative pathway that is cost-efficient, safe and effective and which demonstrates quality improvement
3. **2025 - Achieve designated centres:** with designated standards and integrated care pathways for bespoke paediatric pituitary centres of expertise with highly specialised commissioning [HSCT] and CEO of NHSE to Implement new nationally endorsed CCLG guidelines for a sub cohort of very rare pituitary tumours affecting <100 CYP p.a.
4. **2025 SUCCESS Advocate Implementation:** initiate the integration of the enhanced diagnostic and new rehabilitative/recovery pathway with a focus on training and recruiting one or two SUCCESS nurse, psychology or OT advocates [case managers] in two key centres [north and south] which include a centralised bespoke pituitary sub cohort, to coordinate and facilitate specialized and individualised interventions and integrated care plans across the age span, progressively build on foundational elements for broader integration.
5. **2026/2027 - Focussed Multi-Disciplinary Collaboration Pilot:** broaden the scope of support in those centres to include all elements of augmented diagnostic assessment and decision-making by tumour location and the integrated rehabilitative therapies identified by initial needs assessments in Year 1 and 2. Ensure quality of survival secondary health outcome data are captured to demonstrate quality improvement and NHS efficiency savings

2028 - Expand Integration Across All Major Paediatric Centres: Gradually expand integration to include all major paediatric neuroncology centres in the UK and their adult transition counterparts, coordinate the management of standardized best practice integrated care pathways and capture parallel secondary health outcomes to oversee the implementation of a long-term, cohesive and unified approach to patient care.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

In order to deliver on this ambitious goal, we have worked holistically across several key objectives closely linked to the development of our long-term vision:

- 1. Amplify the voice of survivors and their families:** by advocating for better characterisation of, and interventional remediation for, the collective unrecognised and unmet holistic rehabilitative needs of this vulnerable group. We have made good progress in this area by securing the support of several Parliamentarians and Peers, as well as key influencers within professional services linked to brain tumour rehabilitation. I have further led three publications in high impact peer – reviewed international journals [Lancet and Nature] on best practice for a 'trio' of rare pituitary tumours [first worldwide] affecting fewer than 100 children and young people in the UK every year, for whose equitable implementation we will continue to advocate for children as in adults.
- 2. Reducing social isolation for survivors and their families:** by creating self-supporting communities and informal and formal peer networks and forums to enable friendships and significant relationships and improve mental health and employment outcomes. Much of our activities are focused in this critical area of the charity and we have delivered real value for a wider national community through our weekly virtual support group, WhatsApp survivor community and magazine, our two conferences in London and Birmingham and our London summer picnic and Christmas carol concert linked to fundraising events.
- 3. Being a catalyst for rehabilitative services:** by bettering access to, and increasing investment in, holistic (neuroendocrine) rehabilitation and health research interventions. 2023 proved pivotal in this area. We established our current questionnaire study in collaboration with GOSH on gaps in service for survivors at 1-2 years post-diagnosis and 5-6 years post treatment, as against best practice standards. Additionally, our annual London Spring conference and, this year, our first regional Autumn roadshow, continue to serve as powerful advocacy platforms showcasing the needs of survivors, by the survivors themselves and a wider group of rehabilitative professionals, to important stakeholder groups such as neurooncology and community professionals, policy-makers, major donors, and survivors and their families. They also provide a growing and much needed educational role in this new area of chronic care and 'survivorship'.

A pivotal year for SUCCESS

So much has been achieved in 2023, so much more remains to be done - but 2023 feels like a pivotal year for the Charity allowing us to set our sights on delivering our vision.


Progress continues to be urgently needed in all areas relating to augmented diagnostic assessments and bespoke pituitary services, better diagnostic rehabilitative support, and to facilitate and develop an individualised and integrated recovery pathway from diagnosis. After years of neglect, it has become clear to me that in SUCCESS, this cause has finally found a voice and a hearing.

I am grateful to all our many parent, lay and professional volunteers, our donors, big and small, our board of trustees and patron, and to all the different medical professionals and Parliamentarians, who have contributed much appreciated support and informal advice over the last year.

In particular I extend my debt of gratitude to the cohort of courageous survivors and their families from whom we learn and for whom we exist and who never cease to inspire us.

Dr Helen Spoudeas

Chair

Date:


SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2023

Objectives and activities

Success Charity - Life After Cure exists to enable brighter futures for childhood brain tumour survivors.

To promote and protect the physical and mental health, and relieve the needs of childhood brain tumour survivors ("survivors") treated in the United Kingdom by providing equipment, facilities and services not normally provided by the statutory authorities and in particular:

- i. providing information, resources, advocacy support and education support to the survivors, their families and their education professionals;
- ii. providing multi-disciplinary clinician led rehabilitation treatment ancillary to that provided by the statutory authorities;
- iii. undertaking research into the treatment and outcomes of survivors to identify rehabilitation needs and challenges and publishing the useful results;
- iv. providing mentoring and network groups for survivors and their families; and
- v. providing grants to survivors to access medical support.

The Charity aims to achieve these objectives through a number of activities associated with its three driving ambitions of:

1. Amplifying the voice of survivors and their families
2. Reducing social isolation for survivors and their families
3. Being a catalyst for rehabilitative services

The Trustees have considered the Charity Commission's guidance on public benefit, including the guidance "public benefit: running a charity (PB2)" and are satisfied that the aims of the Charity are carried out wholly in pursuit of its charitable aims for the public benefit.

Significant activities

In the past year, SUCCESS has achieved several significant milestones, marking a transformative period for the charity.

SUCCESS has invested in furthering its relationship with strategic consultants Wareing Stewart, recognizing the need to enhance our fundraising and communication efforts. This partnership enabled the charity to secure £20,000 towards staffing from the National Lottery and thus to continue its focus on delivering key projects. It is currently working to build on this win in 2024 across several Grant giving organisations and for a portfolio of projects. This collaboration has not only amplified our national reach but has also enhanced donor engagement, laying the foundation for sustained, long-term support.

Our community engagement programme grew considerably in 2023, with the assistance of Wareing Stewart; it was encouraging to see our beneficiaries and their families come together over the summer to engage and raise funds for the charity through various activities.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

We have continued to secure the support of several Peers who are set to become influential allies in lobbying for our cause at a national level as well as the respected parliamentary and legal voice of our patron. Their backing has elevated our advocacy efforts, building on our credibility and influence in this space.

Our Annual London conference [our 6TH] remains our flagship national event as part of our conference programme, and we added a regional roadshow this year, which we plan to expand and develop in 2024 and beyond.

We have maintained our focus and investment in the Bravehearts magazine, launched in 2022 and written by and for survivors. The magazine features contributions from survivors and interviews with our Founder – Dr Helen Spoudeas, and showcases the voices, experiences, images, poetry and art of the survivors themselves.

Finally, we were delighted to secure the support of the Ronson Foundation granting £15,000 towards a collaborative study with GOSH in which our beneficiaries contributed, which is a pivotal service gap project, and a key first step towards raising awareness of the urgent need for transformational health care change and our long-term vision of enabling brighter futures for childhood brain tumour survivors.

Achievements against objectives

Reducing Social Isolation for Survivors and their Families.

SUCCESS strives to develop self-supporting communities and informal and formal peer networks and forums, recognising specific cultural and social differences, to enable friendships and significant relationships and improve mental health and employment outcomes.

This year, it has addressed this key objective as follows:

Conference programme

Our Annual London Spring Conference (March 2023)

Our Annual London Spring Conference (March 2023) was the first in person national conference for almost 3 years [after Covid], and brought together 140 survivors, their families, and a diverse group of professionals supporting the brain tumour survivor community throughout the cure and post-cure journey at the prestigious Royal College of Physicians Regents Park venue.

The conference itself is always focused on empowering survivors to share their stories and showcased their ability to harness professional understanding of service gaps and need for change. As part of the day, participants were able to engage in survivor-led creative workshops, demonstrating their talents, providing peer to peer support and a 'healing' space. This connected them not only with other survivors and families to form lasting friendships, but also with Success's growing platform of peer-to-peer opportunities, and therapeutic bursary programmes.

The conference brought together not just survivors and their families, but also professionals and, for the first time, politicians. It provided education and empowerment through medical and legal update talks and meet the expert sessions. This enabled us to increase our educational webinar library for beneficiaries further afield and harder to reach.

Participants shared a common belief, and one of the charity's core aim: that everyone diagnosed with a brain tumour during their first 25 developmental years deserves lifelong support to achieve their potential, to live the lives they choose, to be employed and live independently for the whole of the rest of their lives.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

This requires a unified voice and our drive as a charity is to facilitate this and develop a **National SUCCESS Recovery Pathway** to set a commissioning standard. It was particularly pleasing to see that **89% of participants**, when asked, understand why a parallel recovery pathway, tailored by tumour location in the periphery or deep midbrain, is essential.

Conference in numbers:

- 140 participants including survivors, parents, carers, professionals and political representatives.
- 10 Experts at everyone's disposal in "meet the experts" roadshow
- 6 survivors sharing their stories on stage
- 4 sessions on practical tips for accessing education and employment
- 4 survivor-led workshops focusing on creativity
- 1 panel discussion on achieving the SUCCESS recovery pathway for complete cure
- 1 Marketplace to introduce SUCCESS and its programmes, network, meet and share stories with other survivors and their families.

Feedback was captured following the conference. When asked what participants gained from attending it, the top three answers were:

- **Better lives:** inspiration and hope for the future;
- **Greater clarity:** and greater visibility of some of the issues facing survivors
- **Brain injury:** a better appreciation that brain tumours are brain injuries requiring their own rehabilitation, alongside treatment

For a full and **comprehensive feedback on our conference, please see QR code below.**

2024 Conference

The 2024 Success annual conference was held at 1 Wimple Street in London on the 2nd of March 2024. The theme for 2024 was "successful destinations" and we look forward to sharing achievements from this conference as part of next year's Annual Report.

Autumn Roadshow

The London conference itself, the positive feedback obtained and the need to reach more distant beneficiaries following the event, led directly to initiating a new satellite autumn roadshow conference of similar format in Birmingham (October 2023). This in turn led to focussed discussions and a follow-up local action plan with SUCCESS to support enhancement of the existing survivorship clinic with additional neurorehabilitation consultant sessions to be developed with Birmingham Children's hospital charity in 2024.

The regional roadshow programme continued to focus on the post-cure experience of brain tumour patients treated at this large centre in Birmingham and shared with their treating professionals. This first roadshow welcomed over 70 participants including survivors, siblings, parents, carers and professionals.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The key outcome from the day was building lasting relationships with the clinical teams in Birmingham, alerting neurooncology professionals to stark unaddressed patient needs beyond cure, along with introducing new survivors to our community. Topics covered a broad spectrum from inspirational survivors' stories to hearing the experts on subjects ranging from Neurorehabilitation to diet and nutrition, a round table discussion on the proposed SUCCESS recovery pathway and an opportunity for questions and answers.

We also had the opportunity to gather feedback at the end of the day and were pleased that participants felt positive about several aspects of the roadshow. When asked through our online poll:

- 100% agreed that cure alone was not enough
- 83% agreed that Local Education Authorities should prioritise children and young people's return to school and organise for them to see an education psychologist
- 100% agreed no child with a brain tumour should receive oncology treatment without a complex neuro-psychological and health care assessment from diagnosis

Our Voices of SUCCESS programme

SUCCESS has actively engaged with its beneficiaries across a range of activities in 2023, to promote the sharing of information and advice for life during and beyond treatment, telling survivors' stories from their lived experience as survivors or siblings, and sharing the work of SUCCESS's wonderful contributors (known as 'Brave Hearts'). This included:

Braveheart Magazine

SUCCESS's quarterly online 'Braveheart' magazine - by survivors for survivors – regularly featuring a survivor story, survivors' articles on achievements and ambitions, survivors quiz, Q&A interviews with a professional or 'celebrity', updates on survivor group meetings, peer to peer experiences, calls for contributions and showcasing art and craft made by survivors.

Issue 5, with an increasing 'opt-in' circulation, was printed at Christmas as part of SUCCESS's Christmas Carol fundraising event to disseminate powerful messages of hope to patients, professionals and donors.

Our growing "unfocused"- focus group

This is a safe weekly Wednesday hour for approx. 7-10 survivors to meet online with Elaine, the Charity Administrator, and Helen Spoudeas and sent out to some 50 expressing interest. The focus group runs:

- as a means of welcoming new beneficiaries from across the UK, with at least 4 new active participants this year from Wales, Wye Valley, Derby;
- as a support and brain storming group;
- to share ideas about conferences, events and inspirational guests – e.g. Ryan Penniston
- to gain speakers and advocates and encourage organisational leaders /ambassadors
- to discuss how to improve quality of life within this community

Mediated WhatsApp Group

SUCCESS launched a mediated voluntary WhatsApp group in 2023, following interest by a growing community of survivors aged 16+ as a safe platform to share experiences, news, successes, anxieties, field questions, make contact with each other and provide support. The group has grown into a community of 40+ participants who are mutually supportive and get to make friendships they build on at conferences and networking events.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Ongoing engagements by survivors

Our survivor speaker contributions, which are key to all our public-facing events, include participation at our conferences (see section on conference as part of this Annual Report) and our annual Christmas Concert Fund Raising Event (our "light In The Shadow" appeal), where 6 survivors shared their hopes and fears in front of 230 carol concert guests and celebrated their achievements to inspire others on their journey to better lives.

Online community engagement

In 2023 SUCCESS began to consider developing a Survivor dedicated webpage, to be made up of survivors' blogs and a growing social media and communication strategy. This is still in its infancy and will be expanded in 2024 alongside dedicated pages for professionals and supporters

Peer to Peer Programme

Peer support continues to be a central tenet of the charity's offer for survivors. Other young people who have a shared lived experience of surviving a brain tumour are, with appropriate training and supervision, well placed to provide support for others going through a similar experience, earlier in that journey.

For background, a more formal service, training survivors to gain the skills to become Peer Mentors, planned in 2020, started in 2021 with an initial pilot scheme. Our partner in this area, Young People Matter, ran an accredited training course in Effective Mentoring Skills. Seven survivors older than 18 years of age, out of eight who applied, achieved a recognised qualification, and also gained confidence and valuable work/life experiences and skills, enhancing their self-esteem and employability.

Despite this initial positive engagement only 3 trained mentors subsequently supported mentees. Problems faced were due to 16+ age limitation of mentees, time availability of mentors, the need for appropriate interviews allocation and supervisory support and lack of subsequent ongoing funding to continue the rolling programme of training and recruiting.

This is an area that needs reviving and at the 2023 conference a new recruitment video was shown, and a decision made to train new mentors, and evaluate the programme by feedback from both mentees from as young as 13+, and mentors from 16+. Interviews to pair mentors with mentees were held in June 2023 and as a special parental request, two 13-year-olds were also introduced as 'friends.' As such, SUCCESS will realign fundraising efforts towards this initiative in 2024 with a view to re-launching Peer support as a key deliverable and priority project for the charity.

Being a Catalyst for Innovation and Rehabilitative Services for Survivors

SUCCESS aims to facilitate and develop better access to, and increasing investment in, holistic (neuroendocrine) rehabilitation and health research interventions targeted at improving existing services, identifying new ones and facilitating better community health and educational access. This year, it has progressed this area through two major projects.

Study project in partnership with GOSH

SUCCESS is delighted to be funding this project reviewing the provision and user experience of rehabilitation services following the diagnosis of a childhood brain tumour. which it developed in partnership with and neurooncology survivorship professionals at GOSH and the North Thames Paediatric Cancer Network [ODN]

This collaboration, debated with GOSH neuro-oncology since 2020, saw the formation of a successful working group engaged in 2022 to consider the SUCCESS Recovery Pathway, a study principle approved by London Cancer ODN in December 2022. The project was defined by SUCCESS with Professor Darren Hargrave and GOSH professionals in July 2023 and an 'in-house' part time Project lead identified. The formal study started in October 2023. The project is both. In alignment with the charity's overarching goals of providing brighter futures for survivors of childhood brain tumours and testament to the recognition that more needs to be done to improve their quality of life during and after treatment

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The aim of the project is to develop a patient-informed questionnaire survey of recovery service provision against best practice standards defined since 2005 NICE Children and Young People's Cancer Guidance and conduct a retrospective service review at two time points 1-2 and 5-6 years prior, led by a Specialist Physiotherapist in Paediatric Neuro-Oncology at GOSH supervised by Professor Hargrave. This started in November 2023 and is expected to be completed in August 2024.

The involvement of SUCCESS professionals and its's beneficiaries in devising the gap-analysis study as well as the questionnaires ensures the standards for comparison includes the rehabilitation services SUCCESS is proposing for consideration as the SUCCESS Survivorship Standard [SSS] of care which might be endorsed nationally – Phase 2 of this initiative.

The expected outcomes include:

- a review of access to and provision of rehabilitation services not only at 5y post cure [traditional 'late effects' monitoring] but also within the first year or two of diagnosis and treatment starting
- a detailed summary of views of patients and their carers on the provision of rehabilitation and the disciplines seen as being necessary
- feedback from therapists on the provision of rehabilitation services at different stages against long recommended standards of best practice
- insights and recommendations for phase 2 - formulating and enhancing individualised and integrated rehabilitation provision towards professional endorsement of the 'TRIPLE S' success survivorship standard

Telerehabilitation Bursary Programme with our Partner ReAbility UK

SUCCESS have teamed up with ReAbility Online UK to provide affordable, accessible, daily remote neuro-therapy sessions that are individualised and supervised (weekly) and delivered by a novel and highly sophisticated, games-based, cognimotion platform. The platform was developed at the leading Gertner Institute Israel where it has been widely adopted for adult neurorehabilitation, and also in Austria. It is not available in the UK and SUCCESS will be the gateway to its national use and evaluation in children with brain tumours.

After a successful pilot feasibility study in 2020, whose outcomes were presented and well received at a national meeting of the British Paediatric Neurology Association [BPNA] interest group for acquired brain injury [ABI] SUCCESS remained committed to raising funds for the second phase of the project, assist with the national recruitment of patients and commit to developing, rolling out and continuously evaluating the efficacy of the programme year on year, including integration of the model in SUCCESS's recovery pathway (separate proposal for supporting dedicated NHS centres).

The project stalled in late 2021 due to difficulties in raising the high costs needed for specialist insurance cover for this novel UK platform. The programme protocol was redeveloped over summer 2023 and the project group and partnership with ReAbility UK was re-instated in September 2023, with lead trustees Jenny Limond and Jane Hobbs heading the effort. Additionally, SUCCESS was able to secure funding to employ a project management resource to dedicate some time to the implementation and evaluation of this programme.

SUCCESS goal's is to prioritise the raising of funds specifically for this project with a view to start the first 12-weekly phase of recruitment of survivors in April 2024.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Achievements and performance

Significant activities and achievements against objectives

Amplify the Voice of Survivors and their Families

SUCCESS aspires to be the voice of survivors and their families by advocating for, and better understanding, their individual and collective unrecognised and unmet needs, with emphasis on 'hard to reach' and culturally or socially disadvantaged groups.

SUCCESS's lobbying and advocacy programme includes three strands.

Parliamentary advisory group

A Parliamentary Advisory Group led by Lord Guy Sandhurst, a retired medicolegal negligence barrister and me since 2022, taking advice from SUCCESS parents and cross-party peers Lords Stewart Wood and Sharpe, Derek Thomas MP, chair of the APPG on Brain Tumours, and our Patron and former attorney-general Dominic Grieve KC. The primary objective of this group is to advocate for the best interests of the charity's beneficiaries (past, present and future) and ensuring their representation at national parliamentary and NHSE level.

Medical Advisory Group

This will be a new initiative agreed in late 2023, with planned implementation during the first quarter of 2024. The Medical Advisory Group proposed will be led by our new trustee and neurorehabilitation specialist, Jane Williams with Jenny Limond as deputy, and will consist of key individuals with experience of NHSE commissioning and health service research for quality improvement to ensure equity of service provision in children and young people when evaluating projects with a medical component.

Their remit will be to ensure alignment with the charity's broader objectives of improving and driving transformational change across a broad spectrum of services.

"CHANGE" working party

A "CHANGE" working party will be created in 2024 after the annual conference. It will be involved in Standard Setting and Effecting Transformation by ensuring implementation of a 'trio' of National Multisociety and RCPCH-Endorsed Consensus Guidelines that set new standards for commissioning bespoke equitable services for CYP with rare Midbrain and Pituitary Tumours, in advising on the development and endorsement of the Success Survivorship Standard for a Mult Professional Recovery Pathway and I debating and providing update progress reports towards effecting transformational change at each SUCCESS Conference.

These endeavours are currently unfunded and voluntary contributions from interested experts. Nevertheless, they are a powerful voice which can be harnessed at our conferences, donor and fundraising events and for which we need to budget, in order to grow the endeavour and succeed.

Contribution made by volunteers

In the absence of a large charitable endowment at its start-up, much of the Charity's activity, is necessarily still carried out by volunteers, with our first p/t employee only starting in September 2021. As well as the Board of Trustees, other volunteers have given time and expertise with matters such as organising events, producing educational and information resources and providing support and legal advice. The charity has utilised consultants to assist with the operations, web-site development, marketing and communications, fundraising and governance although it is looking at integrating these capabilities by investing in additional in-house roles in 2024. A volunteer application process and role descriptions have been developed.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Performance of fundraising activities against objectives set

Sector challenges

The charity sector continues to face challenges, navigating through complexities arising post-COVID-19. Traditional fundraising methods have been disrupted shifting donor priorities and making fundraising more difficult. SUCCESS has worked hard to confront these challenges head-on, recognizing the importance of adapting to the new normal and has continued its investment partnering with a strategic fundraising consultant.

This investment is beginning to yield positive results, positioning SUCCESS for further growth in the coming year. In particular, we were pleased to secure a staffing grant of £20,000 in December 2023 from The National Lottery Community Fund to help the charity focus on delivering key projects for its community in 2024, and £5,000 from the Albert Hunt Trust to contribute towards SUCCESS's tele rehabilitation project set to re-launch in 2024.

Enhancing visibility

One of the Charity's key strategies to counter the challenges faced by the sector has been to enhance its visibility through a variety of events. These events not only provided platforms for fundraising but also strengthened our connection with the community. They included:

- **SUCCESS Annual June Picnic and Summer of Fun Raising:** This was our very first SUCCESS picnic and we were delighted at the uptake from our beneficiaries and select supporters who brought their own picnic to join us in Regents Park or held their own BBQ's and raised funds for us. This activity proved enormously fruitful in terms of networking, generating goodwill and also raising general funds from our own beneficiary supporters totalling approximately £20,000.

SUCCESS Carol Concert: this has turned into one of our major fundraising events in SUCCESS's calendar, taking place annually with the prestigious Norfolk Cathedral Choir and our patron, in different historic, City of London Churches. It creates a sense of community and solidarity, brings the survivor voice to a wider donor audience, whilst reinforcing the importance of supporting our cause during challenging times. This year, SUCCESS managed to raise just over £20k by welcoming over 230 guests. As in previous years, we are grateful to Gino Palmieri of GPIM for his company's contributing of £7,500 for the choir, venue and production costs, whilst the additional income was generated through ticket sales, raffle prizes and donations to our Light in the Shadows Appeal.

A post-event VIP reception for 50, catered and served by the trustees in the magnificent atrium of Temple Church, was also held this year, attracting key donors, with support from our Patron, Dominic Grieve and our Parliamentary lobbying group including Lord and Lady Sandhurst.

SUCCESS has already booked a date for its December 2024 Carol Concert at St Stephen's Walbrook.

- **Annual SUCCESS conference:** whilst SUCCESS does not view this particular forum as a fundraising event as such, it still managed to attract just over £21,000 in sponsorship, £11,930 of the total coming from one of the Charity's long-term pharma supporters, Pfizer, as part of its Patient benefit Grant, with further contributions from Sandoz and Merck Pharmaceuticals. The charity is extremely grateful for their ongoing support.
- **Service Gap Analysis in partnership with GOSH:** SUCCESS is particularly proud of its collaboration with GOSH on this project, which attracted the Ronson Foundation's grant of £15,000 and an additional £5,000 contribution from SUCCESS's founder, Helen Spoudeas further reinforcing her commitment to this important area of focus. The Charity had additional restricted reserves of £4,100 which it is allocating against this project. This will cover the total £22,500 cost for the operational delivery of the study later in 2024.

Overall, SUCCESS managed to generate income amounting to £119k across all activities. We are enormously grateful to all our supporters and donors, large and small for this vital support which means so much to us our board and to our beneficiaries as we continue to develop.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Fundraising performance

Performance of fundraising activities against objectives set

Fundraising continues to be challenging in a post-COVID market environment, where Charities are competing for ever more selective donors and cancer research into cure still takes priority despite the 80% survival rate in this paediatric field. Nevertheless, Success managed to raise some funds and donations in the year.

SUCCESS held its annual Christmas Carol Concert in December 2022. This Carol Concert was in support of our Christmas Appeal ('Light in the Shadows' Appeal). The aim was to raise £27,000, in order to pay for half the costs of employing our very first Success Nurse (and seek match-funding for the other half), to be an advocate for the many young survivors. In time, Success would like specially trained SUCCESS nurses, of which this would be the first, to bridge the gap between a legacy rehabilitative pathway currently available, and a second parallel non-oncology specialist team at each major treatment centre -neurodevelopmentalists, endocrinologists, psychiatrists, psychologists, allied rehabilitation therapists, dieticians and educationalists – working in parallel and alongside them from tumour diagnosis.

The concert itself had an excellent turnout, including a pre-concert reception attended by key potential donors of Success, members of parliament and the house of Lords and other influencers. We were extremely grateful to the Norwich Cathedral Choir School and their choirmaster and parent of a survivor, Ashley Grote, for their generosity and much enjoyed and admired performance, as well as to the vicar and staff of the Church where it was held- St Stephen Walbrook in London and the neighbouring Walbrook Club which hosted the reception.

Together with the sale of Christmas cards, the carol concert managed to raise £27,500. After associated costs, the amount raised still falls short of the Charity's net target and we continue to seek further funds to reach the stated amount required. These are restricted funds in the accounts as at 31 December 2022.

As in previous years, the Charity was grateful to Gino Palmeri of GPIM who continues to be a key supporter of Success and part-sponsored the carol concert again this year- with a donation of £5,000. We are also thankful to The Belgravia Centre for their ongoing and continued support of our cause, donating £1,000 towards the costs of our Light in Shadow Appeal.

We are thankful to Merck Serono Limited for their donation of £5,820 to continue to improve Success' website and digital platforms. The website is now a key asset of the Charity through which it publishes all its news and updates for beneficiaries, their families and professionals. Additionally, Success' presence on Twitter continues to increase with the Charity making better use of this platform to communicate key events and updates.

Success was pleased to support *Walking on the Edge: Thoughts on life and parenting after childhood brain cancer*, a book written by one of the Charity's own Trustee (Marco Previero) with a foreword by Helen Spoudeas. The book was written in support of Success to raise awareness of late side effects experienced by many survivors following treatment of brain cancer, with a donation by Marco Previero of £6,000 to cover costs associated with the publication and exposure of the story. Mentions of Success charity included several national BBC radio stations, a front cover feature on The Times on Saturday, and other mentions on online magazines such Bookbrunch.

Dr Helen Spoudeas continues to personally support the charity with a substantial donation at the start of the financial year of £20,000 as clear demonstration of the commitment she has in the delivery of the charity's stated objectives.

These donations are very important to us as a new charity and we desperately need to raise more funds to continue to develop and deliver on our ongoing projects and future ambitious goals. We are enormously grateful to all our supporters and donors, large and small for this vital support which means so much to us and to our board, to continue to develop.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

Financial review

Overview

The charity sector continues to face ongoing challenges with economic uncertainty negatively impacting income generation from fundraising events and individual and corporate donations generally. There are optimistic signs that this is reversing over the coming 12 months as more individuals express their intent to increase donations rather than cease giving, driven by a growing awareness of needs and a desire to contribute to solutions. This cautious optimism is reflected in SUCCESS's results for the year.

SUCCESS's income has increased from £85,312 in 2022, to £117,355 in 2023, boosted at the end of the year by a grant of £20,000 from The National Lottery Community Fund. This reflects a more focused fundraising strategy which included for the first time cost-effective sponsored "fun raising" challenges by our beneficiaries and supporters themselves which also raised close to £20,000.

This is validation that our message appears to be beginning to be better understood generally and by our donors and future supporters. However, our traditional pharmaceutical supporters for our conferences were unable to provide as much support as in previous years and this has led to us considering how to make the conferences self-supporting in the future with professional CPD.

This increased in income generation required greater investment in fundraising efforts, including strategic consultancy and marketing activities leading to a deficit for the year of £11,300.

In 2023, SUCCESS committed £89,682 to charitable activities (69% of its total expenditure – against 67% last year), with 55% of this being attributable to the London Annual Conference. After the 2.5 years Covid break, this was the first and largest face to face conference (attracting 180 against the 300 the Charity had originally paid for) and generated a deficit of £27,403. As a result the decision was made to reduce the number to 150 the following year and find a more cost effective but equally prestigious venue with which to partner, given the clear benefits to our beneficiary base and the positive feedback we obtained from key professionals and decision makers at both venues about what the charity stands for and its plan of action for transforming health care services to children with brain tumours.

The Carol Concert fundraising event was delivered much more cost effectively this year by gifting and serving the post conference catering we and at a larger venue which attracted 280 guests. Costs amounted to £11,316 against £23,248 income from this winter appeal.

Included in prepayment and accrued income of £47,343 is £22,358 deposit for SUCCESS' 2024 Annual Conference and £20,000 accrued grant income awarded by The National Lottery Fund in December 2023 but received in 2024.

The charity's objectives and mission involve complex projects that necessitate collaboration and dedication from various healthcare stakeholders. To have an impact, these initiatives demand building "a head of steam" by sustained effort over time, thereby gradually transforming the charity into a positive force for advocacy and transformational change in the healthcare landscape. This year has certainly felt transformative in that sense, and the Board remains cautiously optimistic that investing in this way will reap long-term benefits for our beneficiary base including a growing educational digital library of professional talks, and training and empowering new non-oncology professionals who will care for this new niche cohort of patients.

Continuing from the previous year, a notable risk was the charity's limited capacity to generate sustainable revenue streams for its initiatives and the staffing salaries to support them. To address this, SUCCESS engaged a business consulting and fundraising firm last year, and whilst this cost represents 21% of the total in 2023, the Charity is beginning to see some positive results from a fundraising perspective with some £20,000 and £25,000 awarded from grants and our supporters directly attributable to this investment out of our total £122k. The expectation is that this proportion will continue to increase in 2024, despite a slow start to income generation in the first quarter of 2024.

The Board and Risk Committee continue to acknowledge that an urgent focus on fundraising is needed to deliver on the broader projects identified as part of its three-year plan.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Reserves policy

The Charity continues to monitor reserves on an ongoing basis, including at the last two Board Meetings to date on 9th February 2024 and 8th March 2024. SUCCESS is still in the growing phase, and the Board appreciates the need to balance reserves with sufficient fund allocation for progression of charitable activities as detailed in above.

Total unrestricted reserves carried forward stand at £102,896 for the year ended 31 December 2023 (a decline of approximately 15% on last year), with an additional £22,038 of restricted funds allocated to SUCCESS' GOSH gap analysis project and £5,000 restricted funds for ReAbility in 2024.

The Trustees continue to believe it would not be commercially meaningful to set a formulaic reserve policy but agree to monitor costs and revenues on a quarterly basis as part of its risk and control procedures. Additionally, current reserves cover at least six months of operational expenses, and at this stage, the Trustees feel this is a reasonable commercial buffer to maintain – and this is reviewed quarterly as part of our Board meetings.

Principal funding sources

The charity's principal sources of funds (including any fundraising)

The charity raises income through a combination of events, individual giving, corporate support and grants. Last year, the charity registered with Stripe and Just giving, and donations have been received through these methods. Credit card and PayPal donations can be made directly through the website.

Major risks

Risk Policy

The Risk Committee has conducted a review of the major risks to which the charity is exposed using the Charity Commission framework. SUCCESS's risk register has reviewed (it is updated at least annually by the Risk Committee and presented to the Board).

Where appropriate, systems or procedures have been established to mitigate the risks the charity faces. Internal control risks are minimised by the implementation of procedures for two levels of authorisation of all financial transactions.

The main risks identified remain similar to previous years:

- generating sustainable income in order to deliver services for its beneficiaries – SUCCESS believes it should continue to drive income generation and leverage on the investment it has made to date in a firm of fundraising business consultant; and
- operational delivery of projects - SUCCESS has allocated £20,000 annually for a project administrator role. An individual has been identified and has started with the charity in February 2024.

Risk Policy

The Board of Trustees has conducted a review of the major risks to which the charity is exposed using the Charity Commission framework. A risk register has been established and is reviewed and updated at least annually by the Board. A small working group has been formed to undertake this work, meeting more regularly and reporting directly to the Board for oversight. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces. Internal control risks are minimised by the implementation of procedures for two levels of authorisation of all financial transactions.

The main risk identified is:

- a. generating sustainable income in order to deliver services for its beneficiaries.

This item was therefore given higher priority on the next Board agenda with the decision to recruit a full-time COO and engage a firm of fundraising business consultants to directly address and mitigate this risk.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Structure, governance and management

Governing document

Success is a charitable company limited by guarantee and established under its Memorandum and Articles of Association. In the event of the company being wound up every member of the charity undertakes to contribute such amount as may be required (not exceeding £1).

Trustee selection methods including details of any constitutional provisions:

The Board spent time reviewing the Charity Commission guidance, the Charity Governance Code and other governance reference material. Trustee role descriptions and a Code of Conduct were produced and implemented.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Philip Austin

Jane Hobson

Hugh Stewart

Richard Crowther

(Resigned 9 February 2024)

Jennifer Limond

Marco Previero

Dr Helen Spoudeas

Dr Jane Williams

(Appointed 13 September 2023)

Recruitment and appointment of trustees


Trustee recruitment, selection and succession planning will be agreed as part of the ongoing governance of the organisation. This will include consideration of the requirements for a diverse board membership, ensuring that trustees have different backgrounds and experiences to enable better decisions.

A comprehensive programme of governance training was included in board meetings, to ensure that trustees were aware of the responsibilities and expectations of them, and to be able to review their effectiveness. Plans to ensure ongoing board development and training are in progress.

The charity is governed by the Board of Trustees, with advice and support from external freelance consultants, who operate as project managers for some aspects of charitable activity. A series of sub-groups and steering groups support the work of the Board and the operational delivery of charitable aims and objectives. External support is provided on a pro bono basis by a legal firm, as well as several volunteers.

The charity operates within the wider environment of brain tumour charities and services and has formed links with other charities and NHS services, through informal discussions, with the ultimate aim of enhancing the lives of brain tumour survivors.

The Directors report was approved by the Board of Trustees.



.....
Dr Helen Spoudeas

Director

Date: 14.08.2024

SUCCESS LIFE AFTER CURE LIMITED

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF SUCCESS LIFE AFTER CURE LIMITED

I report to the trustees on my examination of the financial statements of Success Life After Cure Limited (the charity) for the year ended 31 December 2023.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).


Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Tom Wilcox
Counterculture Partnership LLP
Unit 115, Ducie House
Ducie Street
Manchester
M1 2JW

Dated: 14 August 2024

SUCCESS LIFE AFTER CURE LIMITED

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
	Notes						
Income from:							
Donations and legacies	3	79,973	37,382	117,355	59,675	25,637	85,312
Total income		<u>79,973</u>	<u>37,382</u>	<u>117,355</u>	<u>59,675</u>	<u>25,637</u>	<u>85,312</u>
Expenditure on:							
Raising funds	4	11,079	4,374	15,453	3,789	945	4,734
Charitable activities	5	80,535	32,667	113,202	48,638	20,592	69,230
Total expenditure		<u>91,614</u>	<u>37,041</u>	<u>128,655</u>	<u>52,427</u>	<u>21,537</u>	<u>73,964</u>
Net income/(expenditure)		(11,641)	341	(11,300)	7,248	4,100	11,348
Transfers between funds							
		(10,836)	10,836	-	-	-	-
Net movement in funds		<u>(22,477)</u>	<u>11,177</u>	<u>(11,300)</u>	<u>7,248</u>	<u>4,100</u>	<u>11,348</u>
Reconciliation of funds:							
Fund balances at 1 January 2023		125,373	15,860	141,233	118,125	11,760	129,885
Fund balances at 31 December 2023		<u>102,896</u>	<u>27,037</u>	<u>129,933</u>	<u>125,373</u>	<u>15,860</u>	<u>141,233</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

SUCCESS LIFE AFTER CURE LIMITED

BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Fixed assets					
Tangible assets	9		209		209
Current assets					
Debtors	10	48,785		58,410	
Cash at bank and in hand		94,950		96,196	
		143,735		154,606	
Creditors: amounts falling due within one year	11	(14,011)		(13,582)	
Net current assets			129,724		141,024
Total assets less current liabilities			129,933		141,233
Net assets			129,933		141,233
The funds of the charity					
Restricted income funds	12	27,037		15,860	
Unrestricted funds		102,896		125,373	
		129,933		141,233	

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 14.08.24



Marco Previero
Director

Company registration number 11785842 (England and Wales)

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Charity information

Success Life After Cure Limited is a private company limited by guarantee incorporated in England and Wales. The registered office is 280 Bishopsgate, London, EC2M 4RB.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings	20% reducing balance basis
-----------------------	----------------------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Donations and gifts	79,973	37,382	117,355	59,675	25,637	85,312

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

4 Expenditure on raising funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fundraising and publicity						
Seeking donations, grants and legacies	11,079	4,374	15,453	3,789	945	4,734

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

5 Costs of charitable activities by fund type

	Unrestricted Funds 2023 £	Restricted Funds 2023 £	2023 £	2022 £
Amplify voice of survivors	6,559	-	6,559	40,808
Reduce solical isolation	41,303	19,317	60,620	6,700
Catalyst for post-cure recovery	53	13,350	13,403	2,242
Support costs	32,620	-	32,620	24,213
	<u>80,535</u>	<u>32,667</u>	<u>113,202</u>	<u>73,964</u>

Costs of charitable activity by activity type

	Undertaken directly £	Support costs £	2023 £	2022 £
Support costs				
Amplify voice of survivors	6,559	2,656	9,215	60,462
Reduce solical isolation	60,620	24,551	85,171	9,927
Catalyst for post-cure recovery	13,403	5,413	18,816	3,574
	<u>80,582</u>	<u>32,620</u>	<u>113,202</u>	<u>73,964</u>

Analysis of support costs

	Amplify voice £	Reduce isolation £	Catalyst post-cure £	2023 £	2022 £
Managment	1,387	12,818	2,826	17,031	16,258
General overheads	668	6,172	1,361	8,201	5,022
Website development	506	4,679	1,032	6,217	1,661
General Governance	95	882	194	1,171	1,172
	<u>2,656</u>	<u>24,551</u>	<u>5,413</u>	<u>32,620</u>	<u>24,213</u>

6 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

7 Employees

The average monthly number of employees during the year was:

2023 Number	2022 Number
1	1

There were no employees whose annual remuneration was more than £60,000.

8 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

9 Tangible fixed assets

	Fixtures and fittings £
Cost	
At 1 January 2023	209
At 31 December 2023	209
Carrying amount	
At 31 December 2023	209
At 31 December 2022	209

10 Debtors

	2023 £	2022 £
Amounts falling due within one year:		
Trade debtors	1,534	7,398
Other debtors	47,251	51,012
	48,785	58,410

11 Creditors: amounts falling due within one year

	2023 £	2022 £
Trade creditors	12,839	12,410
Accruals and deferred income	1,172	1,172
	14,011	13,582

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

12 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
	-	-	-	-	-
Conference	11,760	11,930	(23,690)	-	-
Nurse Appeal	4,100	20,000	(2,063)	-	22,037
ReAbility	-	5,452	(11,288)	10,836	5,000
	<u>15,860</u>	<u>37,382</u>	<u>(37,041)</u>	<u>10,836</u>	<u>27,037</u>
	<u><u>15,860</u></u>	<u><u>37,382</u></u>	<u><u>(37,041)</u></u>	<u><u>10,836</u></u>	<u><u>27,037</u></u>
Previous year:	At 1 January 2022	Incoming resources	Resources expended	Transfers	At 31 December 2022
	£	£	£	£	£
Conference	11,760	-	-	-	11,760
Nurse Appeal	-	25,637	(21,537)	-	4,100
	<u>11,760</u>	<u>25,637</u>	<u>(21,537)</u>	<u>-</u>	<u>15,860</u>
	<u><u>11,760</u></u>	<u><u>25,637</u></u>	<u><u>(21,537)</u></u>	<u><u>-</u></u>	<u><u>15,860</u></u>

Note to the restricted funds

ReAbility is an online rehabilitative tool that helps people with neurological damage get better; and enables them to lead their very best lives. The Charity as a beneficiary of a grant for £5,000 received from The Albert Hunt Trust as contribution towards this project which is due to start in 2024.

MDT relates predominantly to a donation by H Spoudeas (£5,000) and grant by the Ronson Foundation (£20,000) has been used for the ongoing delivery of a project started in February 2024 reviewing the provision and user experience of rehabilitation services following the diagnosis of a childhood brain tumour. which the Charity has developed in partnership with and neuroncology survivorship professionals at GOSH and the North Thames Paediatric Cancer Network [ODN]. The project is due to complete in August 2024.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

13 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
General funds	125,373	79,973	(91,614)	(10,836)	102,896
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Previous year:	At 1 January 2022	Incoming resources	Resources expended	Transfers	At 31 December 2022
	£	£	£	£	£
General funds	118,125	59,675	(52,427)	-	125,373
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>

14 Analysis of net assets between funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 31 December 2023:			
Tangible assets	209	-	209
Current assets/(liabilities)	102,687	27,037	129,724
	<u> </u>	<u> </u>	<u> </u>
	102,896	27,037	129,933
	<u> </u>	<u> </u>	<u> </u>
	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
At 31 December 2022:			
Tangible assets	209	-	209
Current assets/(liabilities)	125,164	15,860	141,024
	<u> </u>	<u> </u>	<u> </u>
	125,373	15,860	141,233
	<u> </u>	<u> </u>	<u> </u>

SUCCESS LIFE AFTER CURE LIMITED

England & Wales - Charity number 1188298

Accounts

Charity registration number 1188298

Company registration number 11785842 (England and Wales)

SUCCESS LIFE AFTER CURE LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

SUCCESS LIFE AFTER CURE LIMITED

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Philip Austin Jane Hobson Hugh Stewart (Appointed 15 September 2022) Richard Crowther Jennifer Limond Marco Previero Dr Helen Spoudeas
Charity number	1188298
Company number	11785842
Registered office	100 New Bridge Street London EC4V 6JA
Independent examiner	Tom Wilcox Counterculture Partnership LLP Unit 115, Ducie House Ducie Street Manchester M1 2JW

SUCCESS LIFE AFTER CURE LIMITED

CONTENTS

	Page
Chair's Report	1 - 3
Directors report	4 - 14
Independent examiner's report	15
Statement of financial activities	16
Balance sheet	17
Notes to the financial statements	18 - 24

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2022

The Directors have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2022. The Directors have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

Chair's report - Cure Alone Is Not Enough

Whilst investment in cancer research and intensified treatments have translated into a 5-year cure for 80% of children with a brain tumour, the heavy price of 'cure' on the developing child is often overlooked. Almost two-thirds of survivors experience significant, long-term, life-threatening disabilities and often feel socially alienated and unable to thrive emotionally and professionally. This then later impacts on their ability to live full independent and rewarding adult lives over a subsequent average lifespan of 68 additional years from diagnosis.

Back in 2021, a year in which the pandemic crisis stifled many businesses' ability to operate in a regular way, including this Charity, SUCCESS took the opportunity to review and re-launch its three-year plan. Behind this strategy is a philosophy that improving quality of life is just as important as life itself; this must necessarily include addressing the underlying brain injury when we know we can make the greatest recovery impact; that is from the very beginning of the injury and throughout a child's developmental years. This means until the age of 25 years when physical and brain maturation are fully complete.

The effect of the pandemic on the charitable world extended beyond 2021. Financial pressures on charities continued in 2022 with a more challenging commercial environment for the sector, a greater need to use reserves and more care in ensuring cost-effective management of charitable activity. However, it also provided opportunities to meet more easily on-line, facilitating communication with a wider beneficiary and colleague stakeholder base than our London starting home, and to extend our national reach.

Nevertheless, Success was able to progress several key aspects of its strategy during 2022, which it pursues with resolute commitment – with an overall aim to redress the funding and service balance to ensure each one of those 80% children who now survive brain tumours, truly regain their future, beyond cure.

Our vision and objectives

Success exists to enable brighter futures for childhood brain tumour survivors. Underpinning our vision are two driving principles: to ensure every survivor across the UK achieves their full potential and ensure their needs are fully researched, recognised and represented

Our three-year plan, established in 2021, was reviewed in the early parts of 2022, and the Board of Trustees agreed to continue its focus on three broad objectives for the Charity against which all key projects and investment will align, namely:

1- Amplify the voice of survivors and their families

The Charity aims to achieve this by advocating for better characterisation of, and interventional remediation for, the collective unrecognised and unmet holistic rehabilitative needs of this vulnerable group, throughout their critical developmental phases to maturity, and ensuring the 2005 NICE-recommended 'lifelong postcure' rehabilitative pathways are fully implemented and accessible to every individual, regardless of their innate ability and, with emphasis on 'hard to reach' and culturally or socially disadvantaged groups. In practice this will mean investing in the following areas:

- a. Strengthening relationships with government and other statutory and charitable organisations
- b. Advocating for this brain injured minority of childhood cancer survivors through lobbying efforts in Parliament and within the NHS and NHSE

Significant activity has taken place in this area, so further details on this has been included in our Achievement against objective section under Advocacy.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

2- Reduce social isolation for survivors and their families

SUCCESS is working hard to create a national network of self-supporting communities and informal and formal peer networks and support forums which recognise specific cultural and social differences, thereby enabling friendships and significant relationships.

In particular, the Charity wants to continue investment in:

- a. **An annual national flagship conference for survivors by survivors.** Unfortunately, due to a national train strike, SUCCESS had to postpone its conference planned for October 2022 to March 2023. Whilst this was disappointing, SUCCESS managed to contain costs and ensure the successful delivery of a 6th conference earlier this year at the prestigious Royal College of Physicians in Regents Park London. We further decided to undertake our annual national conference every Spring and to offer a second smaller satellite conference in different UK regions every autumn, starting in late 2023.
- b. **Expanding peer to peer mentoring support.** SUCCESS' effort to train survivors to gain the skills to become Peer Mentors, planned in 2020, started in 2021 with an initial pilot scheme. In 2022 SUCCESS performed an analysis of the programme and completed an action plan of how to grow and improve the service, with a view to expanding it in 2023. Both mentees and mentors spoke at our conference and we plan to continue to showcase testimonials and recruit both mentors and mentees through a structured programme of support increasingly tailored to the specific needs of our beneficiaries and for which training we are actively fund-raising.
- c. **Finding a voice:** SUCCESS was proud to work with young people from age 16, encouraged by our very small but inspirational in-house team, to find their voice and produce a quarterly 'BraveHearts' magazine edited by survivors themselves, showcasing their hidden creative talents and 'tips for survivor success'. We plan to continue to support this initiative in 2023 and beyond with dedicated sections on our website for the young people themselves and a survivor 'blog'. In addition young people were helped to lead their own creativity workshops and meet every week with our inhouse team for an 'unfocussed group' hour on zoom.
- d. **Structured workshops:** Our programme of structured digital workshop and webinars which began in 2021, continued in 2022 with the aim of providing in-depth opportunities to explore topics ranging from (but not limited to) supporting survivors through developing an understanding of how brains function and how this affects stress responses and behaviours post cure, making sense of job advertisements & CV Writing, preparing for Interview, building resilience to cope with stress and a legal perspective on accessing education and health care plans. A programme of workshop topics and a library of webinars for 2023 will be designed following feedback from the Conference and adapting the professional conference presentations themselves with author permission.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

3- Be a catalyst for rehabilitative services for survivors and their families

Success is focusing on bettering access to, and increasing investment in, holistic (neuroendocrine) rehabilitation and providing evidence for benefit of targeted, informed and individualised interventions, improving and expanding existing services, identifying novel and digitally accessible opportunities for ongoing rehabilitation, and facilitating access to community health, special/specific educational needs and vocational support and transition to dedicated adult services for ongoing chronic health care needs.

Specifically, SUCCESS has focused on the following:

- a. **Rehabilitative centres** - Investment in projects that enhance developmental and mental health, educational and vocational support. SUCCESS continues to focus on developing relationships with paediatric neuro-oncology treatment centres and their adult counterparts across the UK. In particular, in 2022, SUCCESS gained commitment in principle from Great Ormond Street Hospital to work collaboratively and explore the possibility of developing a neuro-oncology rehabilitative multi-disciplinary team, initially associated with GOSH and UCLH. The first stage would be to explore gaps in neuro-rehabilitative services from diagnosis through to transition and beyond in this largest national complex London centre which we can replicate with similar endeavours in 2023 in the North. An initial project outline in December 2022 received positive feedback from the London Children's Cancer Commissioning Network [renamed ODN] from whom matched funding was being actively sought with a planned delivery in 2023.
- b. Our "**light in the shadow**" Christmas appeal as part of our 2022 Carol Concert, began the process of raising awareness to a much wider community and will lay the foundations for a much broader fund-raising appeal strategy in 2023.
- c. **National Telerehabilitation** – Between December 2019 and April 2020, before the pandemic forced closure of the recruitment, we undertook a successful feasibility pilot of a novel digital telerehabilitation package developed at the Gertner Institute and Sheba Hospital Israel on fifteen GOSH patients recovering from brain tumours. During 2020 and 2021 the Israeli developers continued to improve this remarkable on-line, games-based platform for children and we signed a collaborative partnership in 2021 with ReAbility UK, committing to being the portal of their first paediatric offering in the UK. We planned an evaluable community-based, 3-monthly rolling 'bursary programme', free to our beneficiaries across the UK in 2022. However insurance and legal agreements have delayed its start, despite a list of waiting recruits and trained therapists, until 2023 and will actively fundraise towards this in 2023.

I am grateful to all our many parent, lay and professional volunteers, our donors, big and small, our board of trustees and patron, and to all the professionals, who have contributed much appreciated support and advice over the last year. In particular I would like to single out Lord Sandhurst who together with Dominic Grieve, encouraged me to create a Parliamentary lobby group with Derek Thomas MP and made 'SUCCESS' his mission. Our Parliamentary voice and increased awareness is in no small part thanks to him, and our progress greatly facilitated by the support of Elaine our enterprising administrator and Doug our flexible charity business adviser. In particular I extend my debt of gratitude to the cohort of courageous survivors and their families from whom we learn and for whom we exist and who never cease to inspire us.

Dr Helen Spoudeas

Chairman



Date: 12.10.2023

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2022

Objectives and activities

Success Charity - Life After Cure exists to enable brighter futures for childhood brain tumour survivors.

To promote and protect the physical and mental health, and relieve the needs of childhood brain tumour survivors ("survivors") treated in the United Kingdom by providing equipment, facilities and services not normally provided by the statutory authorities and in particular:

- i. providing information, resources, advocacy support and education support to the survivors, their families and their education professionals;
- ii. providing multi-disciplinary clinician led rehabilitation treatment ancillary to that provided by the statutory authorities;
- iii. undertaking research into the treatment and outcomes of survivors to identify rehabilitation needs and challenges and publishing the useful results;
- iv. providing mentoring and network groups for survivors and their families; and
- v. providing grants to survivors to access medical support.

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The Charity aims to achieve these objectives through a number of activities associated with its three driving ambitions of:

1. Amplifying the voice of survivors and their families
2. Reducing social isolation for survivors and their families
3. Being a catalyst for rehabilitative services

The Trustees have considered the Charity Commission's guidance on public benefit, including the guidance "public benefit: running a charity (PB2)" and are satisfied that the aims of the Charity are carried out wholly in pursuit of its charitable aims for the public benefit.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

2022 has been a year focused on consolidating key activities for SUCCESS, in its third year as an independent registered Charity. Throughout the course of the year the Board of Trustees has worked hard to deliver on SUCCESS' strategic plan. The year has been a continuation of SUCCESS' core services, such as workshops, peer mentoring programme, and planning the annual conference as well as improving its communications and PR strategy and social media campaigns through an upgrade of its website and administration system.

Looking ahead, the board of trustees has been laying the foundations to start building an operational team to drive forward growth and development of these services. Appointing Waring Stewart as our charity consultant to provide our fundraising and communications roles on the executive has been of key strategic benefit in helping us to raise our profile and awareness of our survivors' predicament.

Achievements for 2022 include delivering a series of workshops and webinars, aimed at empowering survivors and giving them tools to be able to succeed. Topics included 'Finding your inner strength: Building resilience to cope with stress', 'Making sense of job advertisements & CV Writing,' and 'Developing an understanding of how brains function and how this affects stress responses and behaviours post cure'.

2022 was due to include the 6th annual conference. As a result of last-minute rail strikes the event had to be postponed to March 2023. Nevertheless, the event for up to 300 delegates was fully planned and contractually pre-paid with several parallel events for different age groups from aged 8 years upwards for the first time, parents and professionals, and many survivor speakers, supporters, Parliamentarians and decision-makers and medical professionals due to attend from across the UK.

Other activity has included broadening our lobbying efforts to advocate for improved access to rehabilitative care for every survivor across the UK and nurturing relationships with the APPG on Brain Tumours and other charitable organisations to strengthen our voice and provide for future collaboration. In particular, SUCCESS obtained the commitment in principle from Great Ormond Street Hospital to look at the possible implementation of an audit project aimed at identifying current gaps in rehabilitation services against accepted NHS standards. This would be the stepping stone of SUCCESS' much broader ambition to identify an endorsed SUCCESS recovery standard of excellence against which NHS services could be commissioned and to pump-prime the creation and development of national centres of rehabilitative excellence for survivors from diagnosis through to transition into adulthood and beyond. It is our belief that those with midbrain hypothalamic tumours require more dedicated pituitary expertise and neuroendocrine and neurodevelopmental research than those with peripheral tumours, and the position of the tumour, more than the treatment, dictates the neuroendocrine injury and rehabilitative need and commissioned pathways should acknowledge these differences in such rare disease including a dedicated national pituitary forum.

Finally, 2022 saw us begin to update our website with information for parents and professionals, a potentially interactive forum dedicated to the survivors themselves and the beginning of our social media and communications strategy; these were a vital missing link to ensuring our accessibility to our beneficiaries and supporters. The regular weekly 'unfocussed' zoom meetings with our founder and administrator has proved a popular way of sharing ideas and providing support. It has also led directly to the creation our quarterly editions of our 'Bravehearts' magazine, written and edited by and for survivors. The magazine features contributions from survivors and from our Founder – Dr Helen Spoudeas. This magazine showcases the voices, images and art from survivors themselves and also includes a Q/A with inspiring individuals the survivors choose.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

Prior to our 2020 Charity registration

Prior to registering as a Charity, Success was an allocated charitable fund within University College London Hospitals Charities, which was created specifically to support the growth of a novel, nationally recognised 'beacon' and award-winning service to the increasing survivors of childhood cancer and brain tumours and their families across both Great Ormond Street Hospital for Children and University College London Hospital (for the emerging numbers of adolescent and young adult survivors).

Over a period of some 20 years since its inception in 2000 by Dr Helen Spoudeas, a paediatric neuroendocrinologist, its aim was to provide age-appropriate, holistic and interdisciplinary assessments of complex health needs to a growing group of survivors of childhood cancer and brain tumours, in a one-stop outpatient setting. Activities included the provision of neuroendocrine holistic support services, with a focus on late treatment consequences, and raising awareness of the effects of cancer treatment and brain tumour location, on the hormone (endocrine) system.

Since 2017 it focussed on the more complex and unpredicted consequences of curing brain tumours, especially those in the deep, primitive midbrain, close to vital visual, memory, behaviour and life-sustaining metabolic pathways, by part-funding clinical research, developing graphic educational tools for use in clinics with families and leading on a series of national guidelines for interprofessional management to improve health outcomes for such tumours:

<https://mediapigeon.io/newsroom/pressat/releases/en/cclg-releases-first-in-a-series-of-guidelines-to-help-with-the-management-of-rarechildhood-tumours-9399>

[https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642\(21\)00088-2/fulltext](https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(21)00088-2/fulltext)

Since 2018 it has advocated in Parliament and lobbied professionally for earlier recognition, characterisation and comprehensive rehabilitation of the brain injury incurred by the tumour's position in the brain - not simply the tumour's grade and treatment imposed - and from diagnosis and throughout the growing years not, as for other childhood malignancies, 5 years after the last treatment imposed. It has accessed the voice of the survivors through three annual conferences 'for survivors by survivors', as a precursor of the November 2020 conference held digitally and as a registered charity for the first time.

Contribution made by volunteers

In the absence of a large charitable endowment at its start-up, much of the Charity's activity is necessarily still carried out by volunteers, with our first employees only starting in September 2021. As well as the Board of Trustees, other volunteers have given time and expertise with matters such as organising events, producing educational and information resources and providing support and legal advice. In particular Lord Sandhurst has provided an inspirational lead to our first Parliamentary lobbying efforts and together with our patron Dominic Grieve, this endeavour is bearing early fruit and we will continue to build a head of steam towards our goal of achieving transformational change in the way brain tumour care for children is delivered. The charity has utilised consultants to assist with the operations, web-site development, marketing and communications, fundraising and governance although it is looking at integrating these capabilities by investing in additional in-houses roles in 2023 and beyond. A volunteer application process and role descriptions have been developed.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Achievements against objectives

Whilst the charity continues to grow, the focus has been on maintaining the Charity's core services and objectives, while laying the seeds to grow the charity and increase the outreach. Despite still being in the initial growth stages, the charity has made good steps towards a number of initiatives for beneficiaries.

Success Annual Survivor Conference

SUCCESS' flagship event continues to be its annual Survivors' Conference. For 2022 – due to be the 6th annual conference - a decision was made to return to an in-person event, following previous years of holding the event online due to COVID restrictions. In addition, we aimed to offer parallel sessions to a national audience of as large as 300 made up of both survivors [from as young as 8 years for the first time] their families and professionals with an interactive debate with decision-makers. Unfortunately, the rail strikes of 2022 interfered with the chosen date. The board of trustees decided to postpone the event to March 2023 to ensure safe and convenient travel for attendees and a national audience with well-publicised outcomes.

The event has now been held and has proved to be hugely successful and very well received. Broadly, the conference attracts around 150 delegates; including a mix of medical professionals and survivors sharing their stories and experiences and interacting with key decision-makers and politicians. Through the conference we continue to address one of Success Charity's core aims -the unmet rehabilitation and ongoing lifelong support needs of survivors of brain tumours diagnosed and treated in childhood. The conference updated beneficiaries on the ongoing Peer to Peer mentoring and ReAbility bursary programmes. The event is also an opportunity for professionals and key speakers to debate controversies on the practical implications of delivering specialist services to children with rare, complex, mid-brain tumours, the principles that should drive access to pituitary (midbrain) specialists, how and what quality of survival health data should be collected and how best to disseminate it and share it in order to improve long term health and quality of life outcomes. This year we also filmed it and edited the content so it is freely available on our own You-tube channel. It is also an excellent lobby platform and an opportunity to provide and share our information leaflets, resources and support offerings as well as interacting with centres across the UK, and generating useful webinars for our on-line library.

As always, survivors were involved both as attendees but also as participants, sharing their inspirational stories, and bringing their own 'voice' into the challenges encountered across each of the four key maturational stages of development, and the coping strategies they developed to mitigate some of the late consequences of treatment and cure. A variety of workshops was also held, led by both survivors and professionals on topics ranging from business and employment to arts and crafts and drama.

Feedback was captured following the conference, so we can continually grow and develop as an organisation. Details of its impact on beneficiaries, together with detailed evaluation will be published as part of the 2023 annual report, and separately later this year as part of our ongoing commitment to demonstrate value against the Charity's stated objectives.

Workshop programme

In 2022 digital workshops and webinars were held to provide in-depth opportunities to explore topics introduced at the conference, namely

- Supporting survivors through developing an understanding of how the brain functions and how this affects stress responses and behaviours post cure
- Making sense of job advertisements & CV Writing
- Preparing for Interview
- Finding your inner strength: Building resilience to cope with stress
- Adult transition – your advocacy rights as a parent
- Securing & Protecting your Child's Education Rights: An introduction to EHCPs
- Social Benefits

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Peer Support

Peer Support is a central tenet of the charity's offer for survivors. Other young people who have a shared lived experience of surviving a brain tumour are, with appropriate training and supervision, well placed to provide support for others going through a similar experience. An informal peer support network was established in previous years using a recognised online community forum (Health Unlocked) to enable survivors to meet and chat about their experiences together.

As indicated in our previous Annual Report, but worth a reminder here, a more formal service, training survivors to gain the skills to become Peer Mentors, planned in 2020, started in 2021 with an initial pilot scheme. Our partner in this area, Young People Matter, ran an accredited training course in Effective Mentoring Skills. Following an initial period of review, recruitment and selection, seven survivors older than 18 years of age, out of eight who applied, achieved a recognised qualification, and also gained confidence and valuable work/life experiences and skills, enhancing their self-esteem and employability.

At present, five mentors are now actively involved in providing support to mentees, themselves survivors, who have requested the opportunity to be provided with emotional and social support from another young person who has successfully navigated a common brain tumour journey. Recognising that life events both past, present and future can also impact the well-being of our mentors, some monthly supervision sessions of our mentors by our project lead nurse (who is able to deliver level 2 psychological support according to the NHS national cancer peer review measures) took place in the year under review. This afforded development of the group by sharing experiences and tips of mentoring others and another level of collaborative problem-solving peer support for the individual mentor and their mentee.

In 2022 we also performed an analysis of the programme and completed an action plan of how to grow and improve the service. Over the course of 2023 we aim to market the programme to potential mentees and increase the number of applicants for both mentees and mentors. Through our conference and creating a video containing testimonials, we will show the value of the joining the programme and how both the mentees and mentors benefit from taking part.

At SUCCESS' annual conference some mentors spoke about why they volunteered for, and their experience of, training as mentors and their aspirations for development of the peer-to-peer programme.

ReAbility UK

ReAbility Online UK and Success continues their partnership to provide individually tailored and supervised digital neurophysiotherapy, cognitive and occupational rehabilitation exercises, available to practice daily from home or community educational settings. The Charity seeks to train and fund UK therapists on this game changing novel telerehabilitation platform developed in Israel and not otherwise available in the UK. It is offered 'pro bono' to our beneficiaries in a 3-monthly rolling bursary programme which is continuously evaluated for benefit. Following a successful feasibility study in 2020 presented at a dedicated brain tumour neurorehabilitation meeting of the British Paediatric Neurology Association, we identified 30 potential recruits and potential funding streams for the first 3-month phase of this programme.

Progress started in 2021 to complete the project protocol, agree funding streams, individual and shared responsibilities between Success and ReAbility UK, and appointing a data administrator to recruit and evaluate the project, and oversee aspects of project governance in relation to safeguarding participants, GDPR and research outcomes. Whilst GDPR agreements and policies, therapist disclosures and licenses to use the relevant paediatric psychological questionnaires (i.e. Peds QL and BRIEF) outcome measures, are now complete, the project has been significantly delayed by the difficulty and cost of obtaining liability insurance for such an innovative therapeutic intervention for which there was no comparable UK benchmarking against which insurance companies could assess cover. Success and ReAbility Online UK continue to work with the underwriters in the development of the relevant paperwork, with the aim of starting to enrol from our existing list of registrants in September 2022.

We can now report that the insurance issues further delayed the project development and contributed to the loss of the project administrator's role from September 2022. Since the spring of 2023 when the insurance funding was obtained, the project has been re-energised and we are progressing the finalised project proposal, database accessibility, questionnaire collection, and legal permissions with volunteers, whilst actively applying for funds.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Website

The charity continued development of its new website begun in 2020 alongside enhancing its communications strategy, improving functionality, visibility, marketing, and accessibility compared to the previous version. In 2021 SUCCESS contracted 'Waring Stewart Associates' to continuously improve the user interface with the website and facilitate beneficiaries' and supporters' ready and timely access to information about the charity and its events and programmes, our educational information and activities and easy signposting for appropriate support. This has been ongoing in 2022 with the creation of a space for professionals' information and our lobbying strategy and a dedicated space for the young people themselves. We launched our first social media strategy and our own YouTube channel for holding our educational videos and webinar and our own shopping and ticketing site. In this way we were able to offer our own online Christmas cards in 2022 designed by the young people themselves and will increase our offering in 2023.

Advocacy

SUCCESS aims to advocate for both the individual as well as the collective unrecognised and unmet rehabilitative needs of children surviving brain tumours and ensure that we reach every child, whatever their ability or degree of brain injury but with particular emphasis on highlighting the specifically differing needs of those with rare hypothalamo-pituitary tumours in the deep midbrain and those who are 'hard to reach' and culturally or socially disadvantaged. Several initiatives were undertaken during the year under review:

- SUCCESS has continued to explore possible relationships with tertiary specialist NHS paediatric neuro-oncology and two new national proton radiation centres, in its bid to expand, upskill and optimise holistic rehabilitative multiprofessional services alongside and beyond cure pathways, to meet the developmental needs of survivors throughout all their key life stages. This is part of an ambitious long-term plan to create an endorsed SUCCESS recovery standard which will require long-term focus and investment from SUCCESS. In particular, SUCCESS has been exploring the possibility of emulating the 10-year pump-primed charity investment in the Cambridge ('Brainbow') brain tumour survivorship service across the UK and to improve on this in collaboration with NHS key centres. We aim to explore areas for co-investment in new clinical and allied therapy roles in neurodevelopment and neuropsychiatry as well as neuroendocrinology, and to investigate the feasibility of fully integrating a parallel broader multidisciplinary rehabilitative service from diagnosis alongside the acute treatment and cure pathway within paediatric NHS neuro-oncology treatment centres, tailored to meet the differing needs of those with midbrain vs peripheral tumours.
- In 2022 a major new Parliamentary lobby initiative was created at the invitation of Lord Sandhurst, a retired medico-legal negligence barrister with knowledge of complex brain injury cases. He was keen to offer support in the House of Lords to SUCCESS. Over 2022, we had a series of meetings to create a lobbying paper 'Cure Alone is Not Enough' with evidence to support our view that children with brain tumours should have a right to dedicated and guaranteed rehabilitation, and that this would be a cost-effective policy in health economic terms. Further we have support from two further Lords [who are both parents of survivors] and Derek Thomas MP, chair of the APPG on brain tumours who named SUCCESS and our survivors' needs in his Parliamentary debate which coincided with our conference in March 2023 during brain tumour awareness month. Our 'call to action' panel debate chaired by Dominic Grieve at that conference will form the basis of the next Parliamentary lobby paper in 2023/24 which we also propose to put towards commissioners – both NHS cancer and neurodevelopment commissioners. We propose to create a campaigning section of our website and raise funds in 2023/24 for further development of this campaigning aspect of our work to achieve our goals.
- SUCCESS offers an open access email and telephone enquiry helpline monitored daily (Monday to Friday) with clinical queries triaged to Success' advocacy nurse or founder trustee (Dr Spoudeas) or neuropsychology trustee [Dr Jenny Limond].
- In 2022, the trustees created a 'think tank' with charity advisers and fundraisers from Waring Stewart Associates in Yorkshire. Together we created a 'case for support' for a separate multiprofessional SUCCESS Recovery Standard of care encompassing 'spoke and wheel' outpatient assessment and implementation service of **non-oncology** professionals with expertise in brain injury and neuroendocrine development.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

- At the same time we formed a Parliamentary campaign group with cross-party members of the House of Lords, former Attorney general and our patron Dominic Grieve KC and Derek Thomas MP, chair of the APPG in Brain Tumours. The aims and activity of this group are specifically geared to lobbying for the survivorship needs of all those diagnosed with a brain tumour before the age of 25years and creating a 'head of steam' towards ensuring the rights of every child with a brain tumour to have parallel, guaranteed and dedicated complex care recovery embedded within the cure itself . We continue to create a medical and legal evidence base as to why this is a necessary part of any promised cure and not a need which can be met within either the wider acquired brain injury health commissioning or the low key 'late effects' surveillance monitoring children's cancer services offer when they do not affect the brain. This group has representation within the brain tumour APPG and links to other general brain tumour charities and children's brain injury and cancer charities to bridge the gap in the dual aetiologies which affect survivorship needs.
- In addition we are delighted to report the successful publication and conclusion of another 10year collaborative effort with some 100 multiprofessional adult and paediatric pituitary and oncology colleagues, to produce the first nationally endorsed, [to a NICE standard] management guidelines for children with three rare pituitary brain tumours [thickened pituitary stalk, pituitary adenoma and craniopharyngioma] . This endeavour – started in 2012 and commissioned by the Children's Cancer and Leukaemia Group [CCLG], the British Society of Paediatric Endocrinology and Diabetes [BSPED] and SUCCESS when still at UCLH -is endorsed by the Royal College of Paediatrics and Child Health and hence sets a new standard for equity in children's pituitary services just as pituitary tumour services exist for adults. This is another area of lobbying SUCCESS aims to continue setting a new standard for excellence against which these midbrain tumours must be managed. These are now freely and internationally available, are published in full on the CCLG society website, with links to our own website, the BSPED, RCPCH and other endorsing endocrine and oncology societies. <https://successcharity.org.uk/rare-endocrine-tumour-guidelines/> .Further awareness is being raised by simultaneous publication in a summative form in prestigious high impact peer reviewed journals [Lancet Oncology, Lancet Endocrinology and Diabetes and Nature Reviews] . A further personal publication on the long term neuroendocrine outcome of 90 infants under 3 with hypothalamic tumours is a seminal paper providing evidence for the import of a tumour's hypothalamic position on the brain injury and rehabilitation needs and the lack of effectivity of repeated chemotherapy in controlling tumour growth, which is controversial but changing practice, particularly with respect to radiation-avoidance in the youngest . <https://successcharity.org.uk/a-40-year-cohort-study-of-evolving-hypothalamic-dysfunction-in-infants-and-young-children/>

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Performance of fundraising activities against objectives set

Fundraising continues to be challenging in a post-COVID market environment, where Charities are competing for ever more selective donors and cancer research into cure still takes priority despite the 80% survival rate in this paediatric field. Nevertheless, Success managed to raise some funds and donations in the year.

SUCCESS held its annual Christmas Carol Concert in December 2022. This Carol Concert was in support of our Christmas Appeal ('Light in the Shadows' Appeal). The aim was to raise £27,000, in order to pay for half the costs of employing our very first Success Nurse (and seek match-funding for the other half), to be an advocate for the many young survivors. In time, Success would like specially trained SUCCESS nurses, of which this would be the first, to bridge the gap between a legacy rehabilitative pathway currently available, and a second parallel non-oncology specialist team at each major treatment centre -neurodevelopmentalists, endocrinologists, psychiatrists, psychologists, allied rehabilitation therapists, dieticians and educationalists – working in parallel and alongside them from tumour diagnosis.

The concert itself had an excellent turnout, including a pre-concert reception attended by key potential donors of Success, members of parliament and the house of Lords and other influencers. We were extremely grateful to the Norwich Cathedral Choir School and their choirmaster and parent of a survivor, Ashley Grote, for their generosity and much enjoyed and admired performance, as well as to the vicar and staff of the Church where it was held- St Stephen Walbrook in London and the neighbouring Walbrook Club which hosted the reception.

Together with the sale of Christmas cards, the carol concert managed to raise £27,500. After associated costs, the amount raised still falls short of the Charity's net target and we continue to seek further funds to reach the stated amount required. These are restricted funds in the accounts as at 31 December 2022.

As in previous years, the Charity was grateful to Gino Palmeri of GPIM who continues to be a key supporter of Success and part-sponsored the carol concert again this year- with a donation of £5,000. We are also thankful to The Belgravia Centre for their ongoing and continued support of our cause, donating £1,000 towards the costs of our Light in Shadow Appeal.

We are thankful to Merck Serono Limited for their donation of £5,820 to continue to improve Success' website and digital platforms. The website is now a key asset of the Charity through which it publishes all its news and updates for beneficiaries, their families and professionals. Additionally, Success' presence on Twitter continues to increase with the Charity making better use of this platform to communicate key events and updates.

Success was pleased to support *Walking on the Edge: Thoughts on life and parenting after childhood brain cancer*, a book written by one of the Charity's own Trustee (Marco Previero) with a foreword by Helen Spoudeas. The book was written in support of Success to raise awareness of late side effects experienced by many survivors following treatment of brain cancer, with a donation by Marco Previero of £6,000 to cover costs associated with the publication and exposure of the story. Mentions of Success charity included several national BBC radio stations, a front cover feature on The Times on Saturday, and other mentions on online magazines such Bookbrunch.

Dr Helen Spoudeas continues to personally support the charity with a substantial donation at the start of the financial year of £20,000 as clear demonstration of the commitment she has in the delivery of the charity's stated objectives.

These donations are very important to us as a new charity and we desperately need to raise more funds to continue to develop and deliver on our ongoing projects and future ambitious goals. We are enormously grateful to all our supporters and donors, large and small for this vital support which means so much to us and to our board, to continue to develop.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

Financial review

The post-COVID environment continues to be tough for charities. The flat growth period which followed the pandemic (and continues through 2023), sees increasing demand for crucial services provided by the third sector but an overall decline in the ability of the sector to raise funds. It is a time of economic uncertainty for charities and voluntary organisations and people, corporates and grant donors tend to either give less or be more selective on how they distribute funds, and generally give less per charity. Success has experienced this difficulty first-hand in 2022.

Despite such unprecedented uncertainties, Success has managed to turn a small surplus in the year of £11,348 and deliver a major fund-raising event through the Carol Concert at the end of 2022. Additionally, it managed to raise more income in the year amounting to £85,312, against £79,559 in 2021.

Costs remain under control with careful periodic review of management accounts as part of its quarterly trustee meetings.

In 2022, Success committed £49,751 to charitable activities, 67% of its total expenditure (up from 62% in 2021), with just over 40% attributable to the Carol Concert and conference, and 20% for the development of the pilot magazine "Braveheart".

Included in prepayment is an amount of £43,000 being associated costs relating to the conference which was due to be held in 2022, but was postponed to March 2023. These costs will be recognised in 2023. No income related to the conference has been recognised in 2022.

The pandemic and post-pandemic period have undoubtedly delayed the development and growth of Success as a charity. Additionally, Success' stated objectives and aims comprise complex projects requiring the buy-in and commitment of several interdisciplinary healthcare-related stakeholders. These projects cannot grow and be delivered quickly and require long-term focus to reach some level of critical mass.

A risk identified last year was the Charity's underdeveloped capability to generate ongoing revenue streams for its activities and projects. Success appointed a firm of business consultants in 2022 which is beginning to make inroads into the Charity having better visibility to external potential donors and bodies of influence.

Despite these difficulties, the Charity's unrestricted reserves have risen from £118,125 to £125,373 and the Board of Trustees believes it remains a going concern for the foreseeable future. It does acknowledge that rapid investment in fundraising is needed to deliver on the broader projects identified as part of its three-year plan.

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

The Charity continues to monitor and consider appropriate levels of reserves on an ongoing basis. As a business, Success is still in start-up mode and we appreciate the need to balance the maintenance of adequate reserves with sufficient fund allocation to progress its charitable activities as detailed above.

Total unrestricted funds carried forward stand at £125,625 for the year ended 31 December 2022, with an additional £15,860 of restricted funds allocated to the conference in 2023 and the development of a monthly workshop series in 2023. Given its early stage of development, the Trustees do not believe it would be commercially meaningful to set a formulaic reserve policy, but agree to monitor costs and revenues on a quarterly basis as part of its risk and control procedures. Additionally, current reserves cover at least six months of operational expenses, and at this stage, the Trustees feel this is a reasonable commercial buffer to maintain - and this is reviewed quarterly as part of our Board meetings.

The charity's principal sources of funds (including any fundraising)

The charity raises income through a combination of events, individual giving, corporate support and grants. During the year, the charity registered with Stripe, Just giving and Easy Fund Raising and donations have been received through these methods. Credit card and PayPal donations can be made directly through the website.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Risk Policy

The Board of Trustees has conducted a review of the major risks to which the charity is exposed using the Charity Commission framework. A risk register has been established and is reviewed and updated at least annually by the Board. A small working group has been formed to undertake this work, meeting more regularly and reporting directly to the Board for oversight. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces. Internal control risks are minimised by the implementation of procedures for two levels of authorisation of all financial transactions.

The main risk identified is:

- a. generating sustainable income in order to deliver services for its beneficiaries.

This item was therefore given higher priority on the next Board agenda with the decision to recruit a full-time COO and engage a firm of fundraising business consultants to directly address and mitigate this risk.

Structure, governance and management

Governing document

Success is a charitable company limited by guarantee and established under its Memorandum and Articles of Association. In the event of the company being wound up every member of the charity undertakes to contribute such amount as may be required (not exceeding £1).

Trustee selection methods including details of any constitutional provisions:

The Board spent time reviewing the Charity Commission guidance, the Charity Governance Code and other governance reference material. Trustee role descriptions and a Code of Conduct were produced and implemented.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Philip Austin

Jane Hobson

Hugh Stewart

(Appointed 15 September 2022)

Richard Crowther

Jennifer Limond

Marco Previero

Dr Helen Spoudeas

Trustee recruitment, selection and succession planning will be agreed as part of the ongoing governance of the organisation. This will include consideration of the requirements for a diverse board membership, ensuring that trustees have different backgrounds and experiences to enable better decisions.

A comprehensive programme of governance training was included in board meetings, to ensure that trustees were aware of the responsibilities and expectations of them, and to be able to review their effectiveness. Plans to ensure ongoing board development and training are in progress.

The charity is governed by the Board of Trustees, with advice and support from external freelance consultants, who operate as project managers for some aspects of charitable activity. A series of sub-groups and steering groups support the work of the Board and the operational delivery of charitable aims and objectives. External support is provided on a pro bono basis by a legal firm, as well as several volunteers.

The charity operates within the wider environment of brain tumour charities and services and has formed links with other charities and NHS services, through informal discussions, with the ultimate aim of enhancing the lives of childhood brain tumour survivors.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

The Directors report was approved by the Board of Trustees.

DR Helen Spoudeas
.....

Dr Helen Spoudeas

Director

Date: 12.10.2023
.....

SUCCESS LIFE AFTER CURE LIMITED

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF SUCCESS LIFE AFTER CURE LIMITED

I report to the trustees on my examination of the financial statements of Success Life After Cure Limited (the charity) for the year ended 31 December 2022.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).


Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Tom Wilcox
Counterculture Partnership LLP
Unit 115, Ducie House
Ducie Street
Manchester
M1 2JW

Dated: 18.10.2023...

SUCCESS LIFE AFTER CURE LIMITED

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2022

		Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £
	Notes						
<u>Income from:</u>							
Donations and legacies	3	59,675	25,637	85,312	37,365	3,102	40,467
Charitable activities	4	-	-	-	-	39,092	39,092
Total income		59,675	25,637	85,312	37,365	42,194	79,559
<u>Expenditure on:</u>							
Raising funds	5	3,789	945	4,734	8,025	-	8,025
Charitable activities	6	48,638	20,592	69,230	35,796	34,615	70,411
Total expenditure		52,427	21,537	73,964	43,821	34,615	78,436
Gross transfers between funds		-	-	-	(4,181)	4,181	-
Net income for the year/ Net movement in funds		7,248	4,100	11,348	(10,637)	11,760	1,123
Fund balances at 1 January 2022		118,125	11,760	129,885	128,762	-	128,762
Fund balances at 31 December 2022		125,373	15,860	141,233	118,125	11,760	129,885

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

SUCCESS LIFE AFTER CURE LIMITED

BALANCE SHEET

AS AT 31 DECEMBER 2022

	Notes	2022 £	£	2021 £	£
Fixed assets					
Tangible assets	10		209		-
Current assets					
Debtors	11	58,410		7,407	
Cash at bank and in hand		96,196		128,286	
		154,606		135,693	
Creditors: amounts falling due within one year	12	(13,582)		(5,808)	
Net current assets			141,024		129,885
Total assets less current liabilities			141,233		129,885
Income funds					
Restricted funds	13	15,860		11,760	
Unrestricted funds		125,373		118,125	
		141,233		129,885	

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2022.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 12/10/23



Marco Previero
Trustee

Company registration number 11785842

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

Charity information

Success Life After Cure Limited is a private company limited by guarantee incorporated in England and Wales. The registered office is 100 New Bridge Street, London, EC4V 6JA.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings	20% reducing balance basis
-----------------------	----------------------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2022 £	2022 £	2022 £	2021 £	2021 £	2021 £
Donations and gifts	59,675	25,637	85,312	32,365	627	32,992
Grants received	-	-	-	5,000	2,475	7,475
	59,675	25,637	85,312	37,365	3,102	40,467

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

4 Income from charitable activities

	2022 £	2021 £
Restricted Funds		
<i>Reduce social isolation</i>		
Income from charitable activities	-	39,092
	<u>-</u>	<u>39,092</u>
	<u>-</u>	<u>39,092</u>

5 Expenditure on generating donations and legacies

	2022 £	2022 £	2022 £	2021 £
<u>Unrestricted funds</u>				
Donations	3,789	945	4,734	8,025
	<u>3,789</u>	<u>945</u>	<u>4,734</u>	<u>8,025</u>
	<u>3,789</u>	<u>945</u>	<u>4,734</u>	<u>8,025</u>

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

6 Costs of charitable activities by fund type

	Unrestricted Funds 2022 £	Restricted Funds 2022 £	2022 £	2021 £
Amplify voice of survivors	19,271	21,537	40,808	1,574
Reduce social isolation	6,700	-	6,700	42,183
Catalyst for post-cure recovery	2,242	-	2,242	4,935
Support costs	24,213	-	24,213	21,719
Staff costs	41,039	-	41,039	15,188
	<u>52,427</u>	<u>21,537</u>	<u>73,964</u>	<u>70,411</u>

Costs of charitable activity by activity type

	Undertaken directly £	Support costs £	2022 £	2021 £
Support costs				
Amplify voice of survivors	40,808	19,654	60,462	5,917
Reduce social isolation	6,700	3,227	9,927	48,699
Catalyst for post-cure recovery	2,242	1,332	3,574	15,795
	<u>49,751</u>	<u>24,213</u>	<u>73,964</u>	<u>70,411</u>

Analysis of support costs

	Amplify voice £	Reduce isolation £	Catalyst post-cure £	2022 £	2021 £
Management	13,335	2,190	733	16,258	19,114
General overheads	4,119	676	326	5,022	1,585
Website development	1,362	224	75	1,661	-
General Governance	837	137	198	1,172	1,020
	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
	<u>19,654</u>	<u>3,227</u>	<u>1,332</u>	<u>24,213</u>	<u>21,719</u>

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

7 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

8 Employees

The average monthly number of employees during the year was:

2022 Number	2021 Number
1	1

There were no employees whose annual remuneration was more than £60,000.

9 Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

10 Tangible fixed assets

	Fixtures and fittings £
Cost	
Additions	209
At 31 December 2022	209
Carrying amount	
At 31 December 2022	209

11 Debtors

	2022 £	2021 £
Amounts falling due within one year:		
Trade debtors	7,398	500
Other debtors	51,012	6,907
	58,410	7,407

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

12 Creditors: amounts falling due within one year

	2022 £	2021 £
Trade creditors	12,410	4,788
Accruals and deferred income	1,172	1,020
	<u>13,582</u>	<u>5,808</u>

13 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds				Movement in funds		
	Incoming resources	Resources expended	Transfers	Balance at 1 January 2022	Incoming resources	Resources expended	Balance at 31 December 2022
	£	£	£	£	£	£	£
Conference	39,719	(27,959)	-	11,760	-	-	11,760
Nurse Appeal	2,475	(6,656)	4,181	-	25,637	(21,537)	4,100
	<u>42,194</u>	<u>(34,615)</u>	<u>4,181</u>	<u>11,760</u>	<u>25,637</u>	<u>(21,537)</u>	<u>15,860</u>

The Charity generated a surplus of £11,760 against the Conference in 2021. The balance will be re-invested in the Conference planned for March 2023.

The Nurse Appeal aims to develop a long term project of training nurses to bridge the gap between legacy rehabilitative pathways and second non-oncology pathways. This includes funding projects aimed at facilitating the long-term development of this specialist team.

14 Analysis of net assets between funds

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total Unrestricted funds 2022 £	Restricted funds 2021 £	Total 2021 £
Fund balances at 31 December 2022 are represented by:					
Tangible assets	209	-	209	-	-
Current assets/(liabilities)	125,164	15,860	141,024	11,760	129,885
	<u>125,373</u>	<u>15,860</u>	<u>141,233</u>	<u>11,760</u>	<u>129,885</u>

SUCCESS LIFE AFTER CURE LIMITED

England & Wales - Charity number 1188298

Accounts

Charity number: 1188298
Company number: 11785842
(England and Wales)

Success Life After Cure Limited

Report of the Directors and Unaudited Financial Statements

For the year ended 31 December 2021

Success Life After Cure Limited
Contents Page
For the year ended 31 December 2021

Report of the Directors	1 to 11
Independent Examiner's Report to the Directors	12
Statement of Financial Activities	13
Statement of Financial Position	14
Notes to the Financial Statements	15 to 20

Success Life After Cure Limited

Report of the Directors

For the year ended 31 December 2021

The Directors have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2021. The Directors have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

Chair's report - Cure Alone Is Not Enough

Whilst investment in cancer research and intensified treatments have translated into a 5-year cure for 80% of children with a brain tumour, the heavy price of 'cure' on the developing child is often overlooked. Almost two-thirds of survivors experience significant, long-term, life-threatening disabilities and often feel socially alienated and unable to thrive emotionally and professionally. This then later impacts on their ability to live full independent and rewarding adult lives over a subsequent average lifespan of 68 additional years from diagnosis.

In 2021, a year in which the pandemic crisis stifled many businesses' ability to operate in a regular way, including this Charity, Success took the opportunity to review and re-launch its three-year plan. Behind this strategy is a philosophy that improving quality of life is just as important as life itself; this must necessarily include addressing the underlying brain injury from the very beginning and throughout a child's development. Our strategy sets out how we aim to redress the balance to ensure each child regains their future, beyond cure.

Our vision and objectives

Success exists to **enable brighter futures for childhood brain tumour survivors**. Underpinning our vision are two driving principles: to ensure every survivor achieves their full potential and ensure their needs are fully researched, recognised and represented.

In developing our three-year plan, the Board of Trustees agreed on three broad objectives for the Charity against which all key projects and investment will align, namely:

1- Amplify the voice of survivors and their families

The Charity will aim to achieve this by advocating for better characterisation of, and interventional remediation for, the collective unrecognised and unmet holistic rehabilitative needs of this vulnerable group, throughout their critical developmental phases to maturity, and ensuring the 2005 NICE-recommended 'lifelong postcure' rehabilitative pathways are fully implemented and accessible to every individual, regardless of their innate ability and, with emphasis on 'hard to reach' and culturally or socially disadvantaged groups. In practice this will mean investing in the following areas:

- a) Strengthening relationships with government and other statutory and charitable organisations
- b) Advocating for this brain injured minority of childhood cancer survivors through lobbying efforts in Parliament and within the NHS and NHSE

During the pandemic, the usual activity of the all party parliamentary group (APPG) on brain tumours was suspended. Instead, in 2021, Success met with the CEO of Brain Tumour Research (BTR), an established charity holding the APPG's secretariat and raising funds for research into cure, and with the CEO and/or key representatives of the Brain Tumour Charity, the Little Brains Trust, the Child Brain Injury Trust and Together for Short Lives. These discussions were fruitful in generating:

- collaborative agreement for the 'timeliness' of Success' efforts to focus a light on childhood survivors' developmental rehabilitative needs to effect a 'real' cure from the brain tumour itself,
- in developing a Parliamentary advocacy working group within the board and with our patron, from which to develop and deliver our campaign.
- agreement to interact with two more APPGs (for childhood cancer and acquired brain injury) and the allied clinical reference groups (CRG's) and leaders in NHSE, in 2022 and beyond.
- 100% endorsement from our beneficiaries at the annual survivors' conference, to progress our campaign Cure Alone is Not Enough.
- 100% professional agreement to lobby NHSE for specialist national commissioning of pituitary-tumour specific services for children, as is in place for adults and mandated by recently endorsed childhood guidance.

2- Reduce social isolation for survivors and their families

Success is working hard to create self-supporting communities and informal and formal peer networks and forums which recognise specific cultural and social differences, thereby enabling friendships and significant relationships, and improving mental health and employment outcomes.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2021

In particular, the Charity wants to continue investment in:

- a) An annual conference for survivors by survivors, with a 5th conference delivered in 2021 and another planned for October of 2022, with the possibility of expanding this effort to hold two conferences a year
- b) Expanding peer to peer mentoring support to increase the number of both mentors and mentees following a successful pilot in 2021
- c) Developing a programme of structured workshops, as requested by beneficiaries, throughout 2022. Success managed to secure £24,000 in October 2021 to invest in this programme which has already delivered five in depth workshops, including a dedicated professionals' workshop, following the 2021 conference, and three subsequent ones in early 2022, with an ongoing monthly themed series planned in that year.

3- Be a catalyst for rehabilitative services for survivors and their families

Success is focusing on bettering access to, and increasing investment in, holistic (neuroendocrine) rehabilitation and providing evidence for benefit of targeted, informed and individualised interventions, improving and expanding existing services, identifying novel and digitally accessible opportunities for ongoing rehabilitation, and facilitating access to community health, special educational need and vocational support and transition to dedicated adult services for ongoing chronic health needs. Specifically, Success will focus on the following:

- a) Investment in projects that enhance developmental and mental health, educational and vocational support. Success has already started to develop relationships with 4 of 16 NHS paediatric neuro-oncology treatment centres and their adult counterparts, with the aim of providing supervised and fully trained, key nursing / psychological advocates to each centre. This is the first part of an ambitious, long-term project to pump-prime, sustainable investment in strengthening existing early NHS survivorship services and equalising access to multidisciplinary, nursing, neurodevelopmental, endocrine and mental health professionals, as well as allied therapists (physio- occupational and speech and language therapy, and neuropsychology).
- b) Continuing to work with ReAbility UK to complete the first year of our telerehabilitation bursary programme and expand it nationally over the next three years.

I am grateful to all our volunteers, our donors, big and small, our board of trustees and patron, and to all the professionals, who have contributed much appreciated support and advice over the last year. In particular I extend my debt of gratitude to the cohort of survivors and their families from whom we learn and for whom we exist and who never cease to inspire us.

Dr Helen Spoudeas

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2021

OBJECTIVES AND ACTIVITIES

Objectives and aims

Success Charity - Life After Cure exists to enable brighter futures for childhood brain tumour survivors.

To promote and protect the physical and mental health, and relieve the needs of childhood brain tumour survivors ("survivors") treated in the United Kingdom by providing equipment, facilities and services not normally provided by the statutory authorities and in particular:

- (i) providing information, resources, advocacy support and education support to the survivors, their families and their education professionals;
- (ii) providing multi-disciplinary clinician led rehabilitation treatment ancillary to that provided by the statutory authorities;
- (iii) undertaking research into the treatment and outcomes of survivors to identify rehabilitation needs and challenges and publishing the useful results;
- (iv) providing mentoring and network groups for survivors and their families; and
- (v) providing grants to survivors to access medical support.

The Charity aims to achieve these objectives through a number of activities associated with its three driving ambitions of:

- 1. Amplifying the voice of survivors and their families
- 2. Reducing social isolation for survivors and their families
- 3. Being a catalyst for rehabilitative services

The Trustees have considered the Charity Commission's guidance on public benefit, including the guidance "public benefit: running a charity (PB2)" and are satisfied that the aims of the Charity are carried out wholly in pursuit of its charitable aims for the public benefit.

ACHIEVEMENTS AND PERFORMANCE

Significant activities

2021 has been a year focused on consolidating key activities for Success, in its second year as an independent registered Charity. We sought to maintain momentum on key projects throughout the ongoing challenge of the COVID pandemic, despite which Success delivered on several planned objectives. In particular, the Board of Trustees worked hard to launch **Success' three year plan** and its related objectives, **Cure Alone Is Not Enough**, at the start of 2021.

Achievements in the year included a **5th annual conference and related workshop programme** for survivors by survivors, held online again this year due to COVID restrictions, the **redevelopment of its website platform** to improve functionality, messaging and accessibility, completion of the first phase of certified training for **six peer mentors in its to peer mentoring programme**, and ongoing investment in progressing the **telerehabilitation protocol agreement**, training its therapists and co-ordinating its planned delivery and evaluation across the UK .

2021 is also the year in which Success became an employer and recruited two part time roles for the Charity; a charity administrator to effect timely administrative support to Success and a Success nurse advocate and project lead, to progress clinical initiatives such as our telerehabilitation project and nurse advocacy projects detailed in later sections of this annual report.

Other activity has included broadening our **lobbying efforts** to advocate for ready and improved access to rehabilitative care for every survivor across the UK and **nurturing relationships with other charitable organisations** to strengthen our voice and provide for future collaboration.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2021

Prior to our 2020 Charity registration

Prior to registering as a Charity, Success was an allocated charitable fund within University College London Hospitals Charities, which was created specifically to support the growth of a novel, nationally recognised 'beacon' and award-winning service to the increasing survivors of childhood cancer and brain tumours and their families across both Great Ormond Street Hospital for Children and University College London Hospital (for the emerging numbers of adolescent and young adult survivors).

Over a period of some 20 years since its inception in 2000 by Dr Helen Spoudeas, a paediatric neuro-endocrinologist, its aim was to provide age-appropriate, holistic and interdisciplinary assessments of complex health needs to a growing group of survivors of childhood cancer and brain tumours, in a one-stop outpatient setting. Activities included the provision of neuroendocrine holistic support services, with a focus on late treatment consequences, and raising awareness of the effects of cancer treatment and brain tumour location, on the hormone (endocrine) system.

Since 2017 it focussed on the more complex and unpredicted consequences of curing brain tumours, especially those in the deep, primitive midbrain, close to vital visual, memory, behaviour and life-sustaining metabolic pathways, by part-funding clinical research, developing graphic educational tools for use in clinics with families and leading on a series of national guidelines for interprofessional management to improve health outcomes for such tumours
<https://mediapigeon.io/newsroom/pressat/releases/en/cclg-releases-first-in-a-series-of-guidelines-to-help-with-the-management-of-rarechildhood-tumours-9399>

[https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642\(21\)00088-2/fulltext](https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(21)00088-2/fulltext)

Since 2018 it has advocated in Parliament and lobbied professionally for earlier recognition, characterisation and comprehensive rehabilitation of the brain injury incurred by the tumour's position in the brain - not simply the tumour's grade and treatment imposed - and from diagnosis and throughout the growing years not, as for other childhood malignancies, 5 years after the last treatment imposed. It has accessed the voice of the survivors through three annual conferences 'for survivors by survivors', as a precursor of the November 2020 conference held digitally and as a registered charity for the first time.

Contribution made by volunteers

In the absence of a large charitable endowment at its start-up, much of the Charity's activity is necessarily still carried out by volunteers, with our first employees only starting in September 2021. As well as the Board of Trustees, other volunteers have given time and expertise with matters such as organising events, producing educational and information resources and providing support and legal advice. The charity has utilised consultants to assist with the operations, web-site development, marketing and communications, fundraising and governance in 2021 although it is looking at integrating these capabilities by investing in additional in-house roles in 2022. A volunteer application process and role descriptions have been developed.

Achievements against objectives

The pandemic continued to create a challenging environment for much of 2021. As in the previous year, the COVID crisis has inevitably caused disruption and delay to many planned activities and cancellation of fundraising events.

Nevertheless, the charity has made good steps towards a number of initiatives for beneficiaries.

Success Annual Survivor Conference

The Success flagship event continued to be its annual **Survivors' Conference**. This was our 5th Annual Conference, held on 6th November 2021, and the 2nd one to be held online as we waited for the world to return to normal after two challenging years of COVID restrictions. The theme was Steps To Success focusing on the maturational needs of the growing body and brain across 4 key developmental stages from infancy to adulthood. The conference attracted over 200 household registrations and once again we were pleased to welcome twice the number of delegates than had been possible at previous, physical events, and to extend the reach to survivors and families from across the world.

The conference included a mix of medical professionals, survivors sharing their stories and experiences and supporters as we continue to address one of Success Charity's core aims -the unmet rehabilitation and ongoing lifelong support needs of survivors of brain tumours diagnosed and treated in childhood. This is one of the Charity's core aims.

Success Life After Cure Limited Report of the Directors Continued For the year ended 31 December 2021

It was particularly gratifying to see that, when asked during an online poll, 100% of responding participants agreed with Success' key contention, that cure alone is not enough and 95% of them understood the Charity's aims and objectives. The conference updated beneficiaries on the ongoing Peer to Peer mentoring and ReAbility bursary programmes, with over two-thirds expressing interest in telerehabilitation. Derek Thomas MP, chair of the brain tumour APPG, kindly participated with a pre-recorded message, praising the Charity for its efforts in seeking to give all childhood brain tumour survivors a better life ahead, and voicing his support for this cause.

The Conference was also an opportunity for professionals and key speakers to debate controversies on the practical implications of delivering specialist services to children with rare, complex, mid-brain tumours, the principles that should drive access to pituitary (midbrain) specialists, how and what quality of survival health data should be collected and how best to disseminate it and share it in order to improve long term health and quality of life outcomes.

As always, the most highly rated sessions were those featuring the survivors themselves, each bringing their own inspirational 'voice' into the schooling and educational challenges encountered across each of the four key maturational stages, and the coping strategies they developed to mitigate some of the late consequences of treatment and cure.

Over 50% of our 200 delegates were beneficiaries. Once again, the conference was very well received with 100% of survey participants saying they would recommend the conference to other survivors, and overall good ratings on the various sessions, from survivors' talks (100% very good and excellent) to keynote speakers (100% very good and excellent).

Workshop programme

The first series of digital workshops was held immediately post-conference to afford a virtual networking opportunity and gain maximum exposure to beneficiaries on that day, start generating engagement and set expectations for future workshops throughout the year. This initial series comprised 5 workshops aligned with the theme of the conference and providing in-depth opportunities to explore topics introduced at the conference, namely

- Legal advocacy for education and employment support,
- Supported return to mainstream education and employment,
- Meet the new mentors and hear about the peer mentoring programme,
- Expressions of interest for the TeleRehabilitation bursary programme and
- The closed Professional BSPED/CCLG HPAT networking group facilitated by Success

The latter workshop was targeted at professionals (the other four being targeted at our main survivor and parent beneficiaries) and provided an update and forum for discussion on the perceived challenges to implementation and audit of newly published, inter-professional paediatric oncology (CCLG) and paediatric endocrinology (BSPED) pituitary tumour management guidelines, ensuring the patient's best interests were considered and endorsed by the national professional membership body of paediatricians (RCPCH).

In answer to a structured post-conference feedback questionnaire, 33% thought further workshops across the year would be the single most helpful next step, 29% felt they had gained inspiration and hope for the future, 22% left with a better understanding of key challenges at each development stage, and a greater visibility of issues facing survivors and their families.

Several more workshops have been planned for 2022 (3 delivered and 4 in the planning stage currently).

Peer Support

Peer Support is a central tenet of the charity's offer for survivors. Other young people who have a shared lived experience of surviving a brain tumour are, with appropriate training and supervision, well placed to provide support for others going through a similar experience. An informal peer support network was established in previous years using a recognised online community forum (Health Unlocked) to enable survivors to meet and chat about their experiences together.

A more formal service, training survivors to gain the skills to become Peer Mentors, planned in 2020, started in 2021 with an initial pilot scheme. Our partner in this area, Young People Matter, ran an accredited training course in **Effective Mentoring Skills**. Following an initial period of review, recruitment and selection, seven survivors older than 18 years of age, out of eight who applied, achieved a recognised qualification, and also gained confidence and valuable work/life experiences and skills, enhancing their self-esteem and employability. At present, five mentors are now actively involved in providing support to mentees, themselves survivors, who have requested the opportunity to be provided with emotional and social support from another young person who has successfully navigated a common brain tumour journey. Recognising that life events both past, present and future can also impact the well-being of our mentors, we have now implemented monthly supervision sessions of our mentors by our project lead nurse (who is able to deliver level 2 psychological support according to the NHS national cancer peer review measures). This affords development of the group by sharing experiences and tips of mentoring others and another level of collaborative problem solving peer support for the individual mentor and their mentee.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2021

Over the course of 2022, we aim to expand the scheme by further identifying and pairing eligible mentees over 16 years of age, with existing and newly recruited mentors for training, whilst exploring the need for similar 'buddy' schemes that support younger survivors under 16 years of age, siblings and parents alike.

At Success' annual conference mentors spoke about why they volunteered for, and their experience of, training as mentors and their aspirations for development of the peer to peer programme. They subsequently hosted a virtual post-conference workshop in which they answered questions put to them by their peers and recruited further individuals for mentoring support and mentor training.

This is what some of our mentors and mentees had to say:

"I thought a recognised formal qualification such as the one offered by the mentoring programme would support my future employment opportunities as unfortunately I was unable to achieve qualifications at GCSE level"

"It could not have come at a better time. During lockdown everyone felt isolated and quite low. This gave us a platform to build on and feel part of a network"

"The best thing is getting to know everyone on the course. I feel like part of a team, and I know I could get support if I needed it"

"It was nice to belong to a group working towards a common goal"

"As Mentors we get just as much out of the relationship as the mentees do"

ReAbility UK

ReAbility Online UK and Success continues their partnership to provide individually tailored and supervised digital neurophysiotherapy, cognitive and occupational rehabilitation exercises, available to practice daily from home or community educational settings. The Charity seeks to train and fund UK therapists on this game changing novel telerehabilitation platform developed in Israel and not otherwise available in the UK. It is offered 'pro bono' to our beneficiaries in a 3-monthly rolling bursary programme which is continuously evaluated for benefit. Following a successful feasibility study in 2020 presented at a dedicated brain tumour neurorehabilitation meeting of the British Paediatric Neurology Association, we have 30 potential recruits to, and funding for, the first 3-month phase of this programme.

Progress was made in 2021 in completing the project protocol, agreeing funding streams, individual and shared responsibilities between Success and ReAbility UK, and appointing a data administrator to recruit and evaluate the project, and oversee aspects of project governance in relation to safeguarding participants, GDPR and research outcomes. Whilst GDPR agreements and policies, therapist disclosures and licenses to use the relevant paediatric psychological questionnaires (ie Peds QL and BRIEF) outcome measures, are now complete, the project has been significantly delayed by the difficulty and cost of obtaining liability insurance for such an innovative therapeutic intervention for which there was no comparable UK benchmarking against which insurance companies could assess cover. Success and ReAbility Online UK continue to work with the underwriters in the development of the relevant paperwork, with the aim of starting to enrol from our existing list of registrants in September 2022.

Website

The charity continued development of its new **website begun in 2020 alongside enhancing its communications strategy**, improving functionality, visibility, marketing, and accessibility compared to the previous version. In 2021 Success contracted 'Waring Stewart Associates' to continuously improve the user interface with the website and facilitate beneficiaries' and supporters' ready and timely access to information about the charity and its events and programmes, our educational information and activities and easy signposting for appropriate support.

Advocacy

Success aims to advocate for both the individual as well as the collective unrecognised and unmet rehabilitative needs of children surviving brain tumours and, ensure that we reach every child, whatever their ability or degree of brain injury but with particular emphasis on those who are 'hard to reach' and culturally or socially disadvantaged. Several initiatives were undertaken during the year under review:

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2021

- Success has continued to explore possible relationships with tertiary specialist NHS paediatric neuro-oncology and two new national proton radiation centres, in its bid to expand, upskill and optimise holistic rehabilitative multiprofessional services alongside and beyond cure pathways, to meet the developmental needs of survivors throughout their key life stages. This is part of an ambitious long-term plan which will require long-term focus and investment from Success. In particular, Success has been exploring the possibility of emulating the 10-year pump-primed charity investment in the Cambridge ('Brainbow') brain tumour survivorship service across the UK and to improve on this in collaboration with NHS key centres. We aim to explore areas for co-investment in new clinical and allied therapy roles in neurodevelopment and neuropsychiatry as well as neuroendocrinology, and to investigate the feasibility of fully integrating a parallel broader multidisciplinary rehabilitative service from diagnosis alongside the acute treatment and cure pathway within paediatric NHS neuro-oncology treatment centres
- Success offers an open access email and telephone enquiry helpline monitored daily (Monday to Friday) with clinical queries triaged to Success' advocacy nurse or founder trustee (Dr Spoudeas). In 2021 we provided strong support letters to 4 beneficiaries who successfully appealed to their local educational authorities for supported Educational and Health Care Plans for special needs and also helped effect adult access to rehabilitative late effects services for another 4-5 patients whose transition to adult services had not been effected during the pandemic. In addition our nurse advocate delivered an experimental, open monthly virtual friendship and coffee morning to beneficiaries to discuss any individual questions, educational health care plans, peer relationships (mentoring), and rehabilitation from September 2021 which needs developing and marketing next year to improve uptake.

Some feedback from this helpline, in particular in relation to support provided to secure additional educational provision was received as follows:

"Wow! Thank you! Massively appreciated. This is spot on and so compelling. I really appreciate this wonderful effort towards our application to the Borough."

"I am so incredibly pleased to inform you that the local authority have agreed to cover the costs of the School that Laurence needs to attend and that they cover 4 full years. Very grateful to Success."

"Thank you for the very useful booklets you sent me in the post and the links for the website that I can pass to the school."

- With support from, and in collaboration with, Novo Nordisk Pharmaceuticals, Success produced and published printed and digital versions of its educational tools in the form of an information booklet for parents, survivors and professionals in childhood cancer survivorship centres, entitled Surviving a Childhood Brain Tumour: Life After Cure. The leaflet is designed to inform all survivors of the specialised and service needs of those experiencing health effects as a result of a brain tumour, and to empower them to seek support and surveillance.
- Finally, 2021 saw the long awaited endorsement by the Royal College of Paediatrics and Child Health (RCPCH) and publication launch on the professional paediatric oncology CCLG website, of two of three novel national collaborative inter-professional guidelines on managing rare pituitary tumours in children and young people, the first to address this topic worldwide. . <https://www.cclg.org.uk/professionals/rare-endocrine-tumour-guidelines>. These guidelines are part of a national endeavour to create a series of guidelines for rare endocrine tumours throughout the body specific for children, to improve outcomes from these conditions which differ in significant ways from those in adults. They were supported by funds from Success amongst other sponsors and devised, co-ordinated and led to their conclusion by our founder Dr Helen Spoudeas. Now Success will use this best practice mandate to lobby for specialist commissioning of age-appropriate national pituitary specialist services for these conditions, as in adults, alongside a national registry from which to determine effectiveness and future guideline change. This is an important milestone achieved in the journey to improve awareness and data-driven understanding of the complex aetiology behind poor health outcomes after tumours in the deep midbrain misattributed to radiation alone .

Performance of fundraising activities against objectives set

The COVID pandemic limited our event fundraising efforts during the year. Nevertheless, we persisted with our planned Christmas Carol Concert in December 2021 and were extremely grateful to the Norwich Cathedral Choir School and their choirmaster and parent of a survivor, Ashley Grote, for their generosity and much enjoyed and admired performance, as well as to the vicar and staff of the Church where it was held- St Stephen Walbrook in London. We were pleased to be able to sell enough tickets to cover our expenses and raise an additional £9,728 despite many being unable to attend the concert due to new restrictions at the last minute, and to launch our new booklet and raise awareness of our projects at that event.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2021

Fundraising performance remained relatively good during the year, in particular against some of the Charity's stated objectives.

We are particularly grateful to Novo Nordisk and Sandoz Pharmaceuticals for providing £15,092.40 and £24,000.00 respectively for the running of the annual conference and a new post conference series of workshops. These were educational grants from pharmaceutical companies and were in line with the regulations governing these.

Gino Palmeri of GPIM continues to be a key supporter of the charity by sponsoring the carol concert again this year again with a donation of £10,000 and facilitating our online and in person Christmas appeal raising just over £9,000 as detailed above.

We are thankful for ongoing PZ Cussons support and the third instalment of £25,000 (recognised in 2020) as part of their three year programme to help establish the charity's infrastructure, as well as for the Spurway Charitable Trust's £5,000 (the second of three instalments - recognised in 2020).

Other general income was raised mainly from Trusts and Individual donors, including CMC market (£5,000), the Albert Hunt Charitable Trust (£2,000) and the National Lottery fund (£2,475), the latter specifically in support of our Peer Mentoring programme.

Last year the charity set up its ability to receive donations directly through the website, as well as via an online fundraising platform. Several donations have come in through this route in 2021 totalling some £8,000 in total.

These donations are very important to us as a new charity and we desperately need to raise more funds to continue to develop and deliver on our ongoing projects and future ambitious goals. We are enormously grateful to all our supporters and donors, large and small for this vital support which means so much to us and our board, to continue to develop.

FINANCIAL REVIEW

Like for many other Charities, the global COVID pandemic impacted on Success' ability to both deliver on its projects and raise funds accordingly, especially as we were just starting up as a registered charity. Whilst it seems that the most restrictive period of the pandemic is behind us, it is likely the recent crisis will have long-term repercussions on the economy, and the charitable sector.

Despite the pandemic, Success has been able to manage its resources efficiently, finishing the year with a modest surplus of £1,123. It achieved income of £79,559 considered a good result in the circumstances. Costs remain under control with careful periodic review of management accounts as part of its quarterly trustee meetings.

In 2021, Success committed £48,692 to charitable activities, 62% of its total expenditure, with just over 50% attributable to the running of the conference and associated workshops - which remain Success' most material event for beneficiaries - and just under £5,000 for our peer mentoring programme.

Success remains in its early stages of development and the pandemic has unavoidably lengthened the period in which it finds itself operating as a start-up. As such, the Charity has not developed an ability to integrate resources and capabilities to generate ongoing revenue streams for its activities and projects. This was identified as a risk and the Board agreed to appoint a firm of business consultants to focus on Success' fundraising strategy in 2022 whilst longer term resources can be identified.

Given the managed cost control environment, and a good level of unrestricted reserves (standing at £118k), the Board of Trustees believes it remains a going concern for the foreseeable future but acknowledge that rapid investment in fundraising is needed to deliver on the broader projects identified as part of its three-year plan.

Reserves

The Charity continues to monitor and consider appropriate levels of reserves on an ongoing basis. As a business, Success is still in start-up mode and we appreciate the need to balance maintaining adequate reserves with sufficient funding allocation to progress its charitable activities as detailed in above sections.

Total unrestricted funds carried forward stand at £118,125 for the year ended 31 December 2021, with an additional £11,760 of restricted funds allocated to the conference in 2022 and the development of a monthly workshop series in 2022. Given its early stage of development, the Trustees do not believe it would be commercially meaningful to set a formulaic reserve policy, but agree to monitor costs and revenues on a quarterly basis as part of its risk and control procedures. Additionally, current reserves cover at least six months of operational expenses, and at this stage, the Trustees feel this is a reasonable commercial buffer to maintain - and this is reviewed quarterly as part of our Board meetings.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2021

The charity's principal sources of funds (including any fundraising)

The charity raises income through a combination of events, individual giving, corporate support and grants. During the year, the charity registered with Stripe and Justiving and donations have been received through these methods. Credit card and Paypal donations can be made directly through the website.

Risk Policy

The Board of Trustees has conducted a review of the major risks to which the charity is exposed using the Charity Commission framework. A risk register has been established and is reviewed and updated at least annually by the Board. A small working group has been formed to undertake this work, meeting more regularly and reporting directly to the Board for oversight. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces. Internal control risks are minimised by the implementation of procedures for two levels of authorisation of all financial transactions.

The two highest risks were identified to be:

(a) data management in line with the GDPR.

As a result, a data management project was implemented, addressing all aspects of the GDPR, taking pro bono legal advice to ensure the charity is compliant, and this risk is now much lower; and

(b) generating sustainable income in order to deliver services for its beneficiaries.

This item was therefore given higher priority on the next Board agenda, and a fundraising strategy and pipeline of support has been developed and a business consulting fundraising outfit identified to start work for Success in 2022, as well as board agreement to identify in-house resources to deliver on its fundraising strategy in the long-term

Additional information

During 2020 and part of 2021, the charity invested in external consultancy from individuals with widespread charity experience to help them become established as a registered charity. These individuals have now disengaged and the Board agreed to invest in staffing and identify a business consulting firm to help with its fundraising strategy.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

Success is a charitable company limited by guarantee and established under its Memorandum and Articles of Association. In the event of the company being wound up every member of the charity undertakes to contribute such amount as may be required (not exceeding £1).

Trustee selection methods including details of any constitutional provisions:

The Board spent time reviewing the Charity Commission guidance, the Charity Governance Code and other governance reference material. Trustee role descriptions and a Code of Conduct were produced and implemented.

Recruitment and appointment of directors

Trustee recruitment, selection and succession planning will be agreed as part of the ongoing governance of the organisation. This will include consideration of the requirements for a diverse board membership, ensuring that trustees have different backgrounds and experiences to enable better decisions.

A comprehensive programme of governance training was included in board meetings, to ensure that trustees were aware of the responsibilities and expectations of them, and to be able to review their effectiveness. Plans to ensure ongoing board development and training are in progress.

The charity is governed by the Board of Trustees, with advice and support from external freelance consultants, who operate as project managers for some aspects of charitable activity. A series of sub-groups and steering groups support the work of the Board and the operational delivery of charitable aims and objectives. External support is provided on a pro bono basis by a legal firm, as well as several volunteers.

The charity operates within the wider environment of brain tumour charities and services, and has formed links with other charities and NHS services, through informal discussions, with the ultimate aim of enhancing the lives of brain tumour survivors.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2021

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees, who are also the directors of Success for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.


In preparing these financial statements, the trustees are required to:

- select the most suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on a going concern basis unless it is not appropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Management Committee and signed on its behalf by

A handwritten signature in dark ink, appearing to read 'Helen Spoudeas', is written over a light grey rectangular background.

Dr Helen Alexandra Spoudeas (Chair)
Director

16 June 2022

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2021

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	Success Life After Cure Limited
Charity registration number	1188298
Company registration number	11785842
Principal address	100 New Bridge Street London United Kingdom EC4V 6JA

Directors

The directors of the charitable company are its trustees for the purpose of charity law. The trustees and officers serving during the year and since the year end were as follows:

Philip John Austin
Jane Elisabeth Hobson
Richard Michael Crowther
Louisa Jane Wright (resigned 22 June 2021)
Jennifer Alison Limond
Dr Helen Alexandra Spoudeas (Chair)
Marco Previero

Independent examiner	Tom Wilcox Counterculture Partnership LLP Unit 115, Ducie House Ducie Street Manchester M1 2JW
-----------------------------	---

Success Life After Cure Limited
Independent Examiners Report to the Directors
For the year ended 31 December 2021

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2021.

Responsibilities and basis of report

The charity Directors are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').


Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Tom Wilcox
Counterculture Partnership LLP
Unit 115, Ducie House
Ducie Street
Manchester
M1 2JW

16 June 2022

Success Life After Cure Limited
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2021

	Notes	Unrestricted funds £	Restricted funds £	2021 £	2020 £
Income and endowments from:					
Donations and legacies	2	37,365	3,102	40,467	189,177
Charitable activities	3	-	39,092	39,092	14,200
Total		37,365	42,194	79,559	203,377
Expenditure on:					
Raising funds	4	(8,025)	-	(8,025)	(1,711)
Charitable activities	5/6	(35,796)	(34,615)	(70,411)	(72,904)
Total		(43,821)	(34,615)	(78,436)	(74,615)
Transfers between funds		(4,181)	4,181	-	-
Net movement in funds		(10,637)	11,760	1,123	128,762
Reconciliation of funds					
Total funds brought forward		128,762	-	128,762	-
Total funds carried forward		118,125	11,760	129,885	128,762

Success Life After Cure Limited
Statement of Financial Position
As at 31 December 2021


	Notes	2021 £	2020 £
Current assets			
Debtors	13	7,407	41,151
Cash at bank and in hand		128,286	88,948
		135,693	130,099
Creditors: amounts falling due within one year	14	(5,808)	(1,337)
Net current assets		129,885	128,762
Total assets less current liabilities		129,885	128,762
Net assets		129,885	128,762
The funds of the charity			
Restricted income funds	15	11,760	-
Unrestricted income funds	15	118,125	128,762
Total funds		129,885	128,762

For the year ended 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board and signed on its behalf by:



.....
Marco Previero
Director

16 June 2022

Success Life After Cure Limited
Notes to the Financial Statements
For the year ended 31 December 2021

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

Success Life After Cure Limited meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

The financial statements are prepared, on a going concern basis, under the historical cost convention.

Funds

The charity maintains a general unrestricted fund which represents funds which are expendable at the discretion of the trustees in furtherance of the objects of the charity. Such funds may be held in order to finance both working capital and capital investment.

Designated funds comprise of unrestricted funds that have been set aside by the Trustees for particular purposes.

Restricted funds have been provided to the charity for particular purposes, and it is the policy of the board of trustees to carefully monitor the application of those funds in accordance with the restrictions placed upon them.

There is no formal policy of transfer between funds or on the allocation of funds to designated funds, other than that described above

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Donated goods, services and facilities

Donated services and facilities are included in the SOFA when received at the value of the gift to the charity provided the value of the gift can be measured reliably.

Donated services and facilities that are consumed immediately are recognised as income with an equivalent amount recognised as an expense under the appropriate heading in the SOFA.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Taxation

As a registered charity, the company is exempt from income and corporation tax to the extent that its income and gains are applicable to charitable purposes only. Value Added Tax is not recoverable by the company, and is therefore included in the relevant costs in the Statement of Financial Activities.

Debtors

Debtors (including trade debtors and loans receivable) are measured on initial recognition at settlement amount after any trade discounts or amount advanced by the charity. Subsequently, they are measured at the cash or other consideration expected to be received.

Irrecoverable VAT

Irrecoverable VAT is included in the Statement of Financial Activities, and is reported as part of the expenditure to which it relates.

Success Life After Cure Limited
Notes to the Financial Statements Continued
For the year ended 31 December 2021

2. Income from donations and legacies

	Unrestricted funds	Restricted funds	2021	2020
	£	£	£	£
Donations received	32,365	627	32,992	156,182
Grants received	5,000	2,475	7,475	15,000
Donated goods and services	-	-	-	17,995
	37,365	3,102	40,467	189,177

3. Income from charitable activities

	2021	2020
	£	£
Restricted funds		
<i>Reduce social isolation</i>		
Income from charitable activities	39,092	14,200

4. Expenditure on generating donations and legacies

	2021	2020
	£	£
Unrestricted funds		
Donations	8,025	1,711
	8,025	1,711

5. Costs of charitable activities by fund type

	Unrestricted funds	Restricted funds	2021	2020
	£	£	£	£
Amplify voice of survivors	1,574	-	1,574	20,985
Reduce social isolation	7,568	34,615	42,183	30,713
Catalyst for post-cure recovery	4,935	-	4,935	-
Support costs	21,719	-	21,719	21,206
	35,796	34,615	70,411	72,904

Success Life After Cure Limited
Notes to the Financial Statements Continued
For the year ended 31 December 2021

6. Costs of charitable activities by activity type

	Activities undertaken directly	Support costs	2021	2020
	£	£	£	£
Support costs				
Amplify voice of survivors	1,574	4,343	5,917	42,191
Reduce social isolation	42,183	6,516	48,699	30,713
Catalyst for post-cure recovery	4,935	10,860	15,795	-
	48,692	21,719	70,411	72,904

7. Analysis of support costs

	Amplify voice of survivors	Reduce social isolation	Catalyst for post-cure recovery	2021	2020
	£	£	£	£	£
Management	3,822	5,735	9,557	19,114	11,591
General overheads	317	475	793	1,585	2,856
Website development	-	-	-	-	5,605
Governance costs	204	306	510	1,020	1,154
	4,343	6,516	10,860	21,719	21,206

8. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2021	2020
	£	£
Accountancy fees	1,020	500
Staff pension contributions	336	-

9. Staff costs and emoluments

Total staff costs for the year ended 31 December 2021 were:

	2021	2020
	£	£
Salaries and wages	14,852	-
Pension costs	336	-
	15,188	-

Success Life After Cure Limited
Notes to the Financial Statements Continued
For the year ended 31 December 2021

	2021	2020
Staff numbers (FTE equivalent)	1	0
	<u>1</u>	<u>0</u>

12. Comparative for the Statement of Financial Activities

	Unrestricted funds	Restricted funds	2020
	£	£	£
Income and endowments from:			
Donations and legacies	189,177	-	189,177
Charitable activities	-	14,200	14,200
Total	<u>189,177</u>	<u>14,200</u>	<u>203,377</u>
Expenditure on:			
Raising funds	(1,711)	-	(1,711)
Charitable activities	(58,704)	(14,200)	(72,904)
Total	<u>(60,415)</u>	<u>(14,200)</u>	<u>(74,615)</u>
Net income/expenditure	<u>128,762</u>	<u>-</u>	<u>128,762</u>
Total funds carried forward	<u>128,762</u>	<u>-</u>	<u>128,762</u>

13. Debtors

	2021	2020
	£	£
Amounts due within one year:		
Trade debtors	500	6,151
Prepayments and accrued income	6,907	35,000
	<u>7,407</u>	<u>41,151</u>

14. Creditors: amounts falling due within one year

	2021	2020
	£	£
Trade creditors	4,788	837
Accruals and deferred income	1,020	500
	<u>5,808</u>	<u>1,337</u>

Success Life After Cure Limited
Notes to the Financial Statements Continued
For the year ended 31 December 2021

15. Movement in funds

Unrestricted Funds

	Balance at 01/01/2021	Incoming resources	Outgoing resources	Transfers	Balance at 31/12/2021
	£	£	£	£	£
<i>General</i>					
General	128,762	37,365	(43,821)	(4,181)	118,125
	<u>128,762</u>	<u>37,365</u>	<u>(43,821)</u>	<u>(4,181)</u>	<u>118,125</u>

Unrestricted Funds - Previous year

	Balance at 01/01/2020	Incoming resources	Outgoing resources	Transfers	Balance at 31/12/2020
	£	£	£	£	£
<i>General</i>					
General	-	189,177	(60,415)	-	128,762
	<u>-</u>	<u>189,177</u>	<u>(60,415)</u>	<u>-</u>	<u>128,762</u>

Restricted Funds

	Incoming resources	Outgoing resources	Transfers	Balance at 31/12/2021
	£	£	£	£
Conference	39,719	(27,959)	-	11,760
Mentoring	2,475	(6,656)	4,181	-
	<u>42,194</u>	<u>(34,615)</u>	<u>4,181</u>	<u>11,760</u>

Restricted Funds - Previous year

	Incoming resources	Outgoing resources	Transfers	Balance at 31/12/2020
	£	£	£	£
Conference	14,200	(14,200)	-	-
	<u>14,200</u>	<u>(14,200)</u>	<u>-</u>	<u>-</u>

Purpose of restricted funds

Conference

The Charity generated a surplus of £11,760 against the Conference in 2021. Part of those funds are allocated to the conclusion of its monthly workshop series over the course of 2022, and the balance will be re-invested in the Conference planned for October 2022.

Success Life After Cure Limited
Notes to the Financial Statements Continued
For the year ended 31 December 2021

16. Analysis of net assets between funds

	Net current assets / (liabilities) £	Net Assets £
Unrestricted funds		
<i>General</i>		
General	118,125	118,125
Restricted funds		
Conference	11,760	11,760
	129,885	129,885

Previous year

	Net current assets / (liabilities) £	Net Assets £
Unrestricted funds		
<i>General</i>		
General	128,762	128,762
Restricted funds		
	128,762	128,762

17. Company limited by guarantee

Success Life After Cure Limited is a company limited by guarantee and accordingly does not have a share capital.

SUCCESS LIFE AFTER CURE LIMITED

England & Wales - Charity number 1188298

Accounts

Charity number: 1188298
Company number: 11785842
(England and Wales)

Success Life After Cure Limited
Report of the Directors and Unaudited Financial Statements
For the year ended 31 December 2020

Success Life After Cure Limited
Contents Page
For the year ended 31 December 2020

Report of the Directors	1 to 7
Independent Examiner's Report to the Directors	8
Statement of Financial Activities	9
Statement of Financial Position	10
Notes to the Financial Statements	11 to 15
Detailed Statement of Financial Activities	16

Success Life After Cure Limited
Report of the Directors
For the year ended 31 December 2020

The Directors have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2020. The Directors have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Success Charity - Life After Cure exists to enable brighter futures for childhood brain tumour survivors.

To promote and protect the physical and mental health, and relieve the needs of childhood brain tumour survivors ("survivors") treated in the United Kingdom by providing equipment, facilities and services not normally provided by the statutory authorities and in particular:

- (i) providing information, resources, advocacy support and education support to the survivors, their families and their education professionals;
- (ii) providing multi-disciplinary clinician led rehabilitation treatment ancillary to that provided by the statutory authorities;
- (iii) undertaking research into the treatment and outcomes of survivors to identify rehabilitation needs and challenges and publishing the useful results;
- (iv) providing mentoring and network groups for survivors and their families; and
- (v) providing grants to survivors to access medical support.

The directors have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2020

ACHIEVEMENTS AND PERFORMANCE

Significant activities

Prior to registering as a Charity, Success was an allocated charitable fund within University College London Hospitals Charities, created specifically to support a novel, nationally recognised 'beacon' and award-winning service for the increasing survivors of childhood cancer and brain tumours and their families across both Great Ormond Street Hospital and University College London Hospital.

Over a period of some 20 years, since its inception in 2000 by Dr Helen Spoudeas, a paediatric neuro endocrinologist, its aim was to provide age-appropriate, interdisciplinary assessments to a growing group of survivors of childhood cancer and brain tumours. Activities included the provision of neuroendocrine holistic support services with a focus on late treatment consequences, and raising awareness of the effects of cancer treatment on the hormone system.

Since 2017 it has focussed on the more complex and unpredicted consequences of curing brain tumours, especially those in the deep, primitive midbrain, close to vital visual, memory, behaviour and life-sustaining metabolic pathways, by part-funding clinical research, developing graphic educational tools for use in clinics with families and leading on a series of national guidelines for interprofessional management to improve health outcomes for such tumours <https://mediapigeon.io/newsroom/pressat/releases/en/cclg-releases-first-in-a-series-of-guidelines-to-help-with-the-management-of-rare-childhood-tumours-9399> [https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642\(21\)00088-2/fulltext](https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(21)00088-2/fulltext)

It has advocated in Parliament and lobbied professionally for earlier recognition and comprehensive rehabilitation of the brain injury, by location and from diagnosis throughout the growing years. It has accessed the voice of the survivors through three annual conferences 'for survivors by survivors', as a precursor of the November 2020 conference held as a registered charity.

Success became a charity in its own right in early 2020 and in this initial start-up year, the main activity has been the annual Survivors' Conference, which is always well received, this year held virtually for the first time because of the pandemic.

Other activity has included the establishment of an online community forum, for survivors to meet virtually to provide informal peer support and seek answers to questions. The charity has also been planning for other future service developments, alongside undertaking work to ensure the charity meets its statutory governance requirements, as well as essential infrastructure. This has included the development of a new website with improved functionality and accessibility.

Contribution made by volunteers

Most of the activity of the charity is carried out by volunteers. As well as the Board of Trustees, other volunteers have given time and expertise with matters such as website development, organising events, legal advice and producing information resources. There are no paid employees of the charity although the charity has utilised consultants to assist with the operations, fundraising and governance.

A volunteer application process and role descriptions have been developed.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2020

Achievements against objectives

The organisation became a registered charity in March 2020. This coincided with the start of the coronavirus pandemic which has inevitably caused disruption and delay to many planned activities and cancellation of fundraising events.

Nevertheless, the charity has made good steps towards a number of initiatives for beneficiaries.

Primarily, the flagship event is the **Survivors' Conference**. This year was the fourth such event, which had to be held online for the first time due to coronavirus restrictions. This was a significant change, and unfortunately delegates were unable to meet up and network in person as a consequence. However, as a result, more attendees were able to join from a much wider geographical area. Some 280 delegates registered for the event in November 2020, twice as many as the previous physical events held in London, and they were able to join from across the UK and even overseas.

The theme was "bridging the gaps for survivors of childhood brain tumours" which reflects one of the charity's core aims, addressing unmet rehabilitation and support needs.

There were sessions from keynote speakers and experts in their field, as well as a panel discussion chaired by our Patron Dominic Grieve QC, looking at the key drivers to effect change. 43% of delegates suggested the most important factor to promote improvements to services were cognitive and behavioural impairments. This information will be used to shape future developments for the charity.

The most highly rated session was when we heard directly from survivors themselves, bravely sharing their experiences on a wide range of issues affecting them. These stories inspire us as a charity to do better, and we know they also inspire other survivors and parents.

The event was extremely well evaluated, with 100% of attendees rating it as Good, Very Good or Excellent, and all saying they would recommend it to other survivors and families.

This year, due to the changed format, a series of interactive virtual workshops were held in the weeks following the main conference. These enabled survivors and families to meet online and discuss key issues affecting them, on topics such as nutrition and managing weight, online rehabilitation, and making sense of cognitive assessments. These were highly evaluated, with 80% of respondents finding them inspiring and informative.

Success Charity was set up to enhance the life opportunities of children affected by brain tumours. NHS neurorehabilitation is scarce and the recent pandemic withdrew it altogether. We have recently partnered with **ReAbility UK** to train and fund UK therapists on their novel telerehabilitation platform offered 'pro bono' to our beneficiaries in a bursary programme Success continue to evaluate. This will enable brain injured survivors to receive a daily tailored programme of online cognitive and physiotherapeutic activities, assessed and supervised weekly by a registered therapist. A pro bono pilot study with ReAbility between November 2019 and March 2020, before the pandemic showed this digital platform, not yet available in the UK, was feasible to deliver and welcomed by families with home IT equipment. A 3 month programme project is underway for the future roll-out of the platform so that more children can benefit. The advantages of the updated system are that it can be accessed from home using standard IT equipment, and the innovative fun approach encourages participation whilst supervised by a registered therapist giving one to one support on a weekly basis. The programme is set to launch in the Summer of 2021.

Peer Support is a central tenet of the charity's offer for survivors. Other young people who have a shared lived experience of surviving a brain tumour are well placed to provide support for others going through a similar experience. An informal peer support network has been established using a recognised online community forum (Health Unlocked) to enable survivors to meet and chat about their experiences together.

A more formal service, training survivors to gain the skills to become Peer Mentors has been planned during 2020 and is due to start in early 2021. A training provider has been identified to run an accredited course in **Effective Mentoring Skills**, which will enable survivors to achieve a recognised qualification and to gain confidence and valuable life experiences and skills, enhancing their self-esteem and employability.

Once trained, the charity will be able to offer a mentoring service to other survivors using this cohort of peer mentors. Survivors will be able to receive emotional and social support from another young person who has shared a common lived experience of surviving a brain tumour.

In addition, during the year the charity invested in a new **website**, which has improved functionality and accessibility compared to the previous version. It will enable beneficiaries and supporters to access information about the charity and be signposted to appropriate places to find support.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2020

Performance of fundraising activities against objectives set

Several planned fundraising events had to be cancelled due to the pandemic.

However, fundraising performance remained relatively good, thanks to ongoing support by key supporters, particularly from corporate donors. In particular, PZ Cussons who provided £25,000 this year as part of a three year programme to help establish the charity's infrastructure.

We have continued to receive support from Gino Palmeri of GPIM, who had previously sponsored the carol concert in 2019. An online Christmas appeal by GPIM exceeded all expectations by raising over £5,000.

The Conference was supported with educational grants and sponsorship from pharmaceutical companies in line with the regulations governing these.

In addition, other income has come mainly from Trusts and Individual Donors, most notably the Spurway Charitable Trust donating £5,000 (the first of three instalments) and £10,000 from the Gerald and Gail Ronson Foundation.

The charity organised its own online Christmas Appeal raising £400.

During the year, the charity set up its own bank account and accounting system, and the ability to receive donations directly through the website, as well as via an online fundraising platform. Several donations have come in through this route.

We are very grateful to all our supporters and donors for their vital support to help continue our work.

FINANCIAL REVIEW

Significant events

The charity's financial position is in line with expectations. Like many other Charities, the global COVID pandemic has had an impact on Success and its ability to both deliver on its projects and raise funds accordingly. Success will continue to monitor and assess the impact of COVID-19 on its financial position and will continue to adjust its operational expenditure accordingly.

Despite the pandemic, Success has been able to use its funding efficiently and managed costs appropriately, finishing the year with a surplus of just over £128k of unrestricted funds. It has done so in several ways. Firstly, by switching its activities to focus on virtual events and training, for example, and delivering both its annual conference and peer mentoring programme remotely. Secondly, by continuing to monitor expenditure on a quarterly basis and adopting a prudent approach to costs commitments.

Over the last 12 months, Success has committed just over £57k to charitable activities, with the majority of this expenditure going towards the running of our annual conference (our flagship event) and our peer mentoring programme.

Despite early fund-raising success, the Charity is still at very early stages of development, and one of the main financial risks is its lack of recurring income streams in the medium to long-term. Whilst it has sufficient reserves to remain a going concern for the foreseeable future, cost control and a clear fundraising strategy and implementation will need to be a priority for the charity in the next 12 months. The Trustees are fully aware of this financial risk.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2020

Reserves

The Charity continues to monitor and consider appropriate levels of reserves on an ongoing basis at this early stage of its life. The Trustees appreciate the need to balance the maintenance of an adequate level of reserves with the need to allocate sufficient funding to resources required to progress its charitable activities as details in other sections on this report. Given the limited costs at these early stages of development, and the fact that currently, the Charity's total funds carried forward are all unrestricted and stand at £128k as at 31 December 2020, the Trustees do not feel it would be meaningful, at this stage, to set a reserve policy aligned to a given number of months of operational expenditure. The Trustees feel confident that, given the current level of expenditure, total unrestricted funds provide cover for at least six month's worth of operational costs and that this constitutes an adequate level of reserves. The Trustees will continue to monitor reserves on an ongoing basis in the coming year and agree to maintain a minimum cash balance of £50k throughout the year.

The charity's principal sources of funds (including any fundraising)

The charity raises income through a combination of events, individual giving, corporate support and grants. During the year, the charity registered with Easy Fundraising and People's Fundraising and donations have been received through these methods. Credit card and Paypal donations can be made directly through the website.

Risk Policy

The Board of Trustees has conducted a review of the major risks to which the charity is exposed using the Charity Commission framework. A risk register has been established and is reviewed and updated at least annually by the Board. A small working group has been formed to undertake this work, meeting more regularly and reporting directly to the Board for oversight. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces. Internal control risks are minimised by the implementation of procedures for two levels of authorisation of all financial transactions.

The two highest risks were identified to be:

(a) **data management** in line with the GDPR.

As a result, a data management project was implemented, addressing all aspects of the GDPR, taking pro bono legal advice to ensure the charity is compliant, and this risk is now much lower; and:

(b) **generating sustainable income in order to deliver services for its beneficiaries.**

This item was therefore given higher priority on the next Board agenda, and a fundraising strategy and pipeline of support is in development.

Additional information

During the year, the charity invested in external consultancy from individuals with widespread charity experience to help them become established as a registered charity. A number of investments in infrastructure were made, including a new website with enhanced functionality, a donor database, and a thorough governance and compliance review.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

Success is a charitable company limited by guarantee and established under its Memorandum and Articles of Association. In the event of the company being wound up every member of the charity undertakes to contribute such amount as may be required (not exceeding £1).

Trustee selection methods including details of any constitutional provisions:

The Board spent time reviewing the Charity Commission guidance, the Charity Governance Code and other governance reference material. Trustee role descriptions and a Code of Conduct were produced and implemented.

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2020

Recruitment and appointment of directors

Trustee recruitment, selection and succession planning will be agreed as part of the ongoing governance of the organisation. This will include consideration of the requirements for a diverse board membership, ensuring that trustees have different backgrounds and experiences to enable better decisions.

A comprehensive programme of governance training was included in board meetings, to ensure that trustees were aware of the responsibilities and expectations of them, and to be able to review their effectiveness. Plans to ensure ongoing board development and training are in progress.

The charity is governed by the Board of Trustees, with advice and support from external freelance consultants, who operate as project managers for some aspects of charitable activity. A series of sub-groups and steering groups support the work of the Board and the operational delivery of charitable aims and objectives. External support is provided on a pro bono basis by a legal firm, as well as several volunteers.

The charity operates within the wider environment of brain tumour charities and services and has formed links with other charities and NHS services, through informal discussions, with the ultimate aim of enhancing the lives of brain tumour survivors.

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees, who are also the directors of Success for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select the most suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on a going concern basis unless it is not appropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	Success Life After Cure Limited
Charity registration number	1188298
Company registration number	11785842
Principal address	100 New Bridge Street London United Kingdom EC4V 6JA

Success Life After Cure Limited
Report of the Directors Continued
For the year ended 31 December 2020

Directors

The directors of the charitable company are its trustees for the purpose of charity law. The trustees and officers serving during the year and since the year end were as follows:

Philip John Austin
(Appointed: 24 January 2019)
Jane Elisabeth Hobson
(Appointed: 24 January 2019)
Richard Michael Crowther
(Appointed: 24 January 2019)
Louisa Jane Wright
(Appointed: 24 January 2019)
Jennifer Alison Limond
(Appointed: 24 January 2019)
Dr Helen Alexandra Spoudeas (Chair)
(Appointed: 24 January 2019)
Marco Previero (Treasurer)
(Appointed: 24 January 2019)

Independent examiners

Counterculture Partnership LLP
Unit 115
Ducie House
Ducie Street
Manchester
M1 2JW

Approved by the Management Committee and signed on its behalf by

Helen Spoudeas

Dr.Helen.Alexandra.Spoudeas.(Chair).....

Success Life After Cure Limited
Independent Examiners Report to the Directors
For the year ended 31 December 2020

I report on the accounts of the charitable company for the year ended 31 December 2020, which comprise the Statement of Financial Activities, the Statement of Financial Position and the related notes.

Respective responsibilities of trustees and examiner

The Directors are responsible for the preparation of the accounts. The directors consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is required.

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under Section 145 of the 2011 Act;
- to follow the procedures laid down in the General Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the General Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charitable company and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as directors concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the statement below.

Independent examiner's statement


In connection with my examination, no matter has come to my attention:

(1) which gives me reasonable cause to believe that, in any material respect, the requirements:

- to keep accounting records in accordance with 386 and 387 of the Companies Act 2006; and
- to prepare accounts which accord with the accounting records and comply with the accounting requirements of section 394 and 395 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities

have not been met, or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Counterculture Partnership LLP
Unit 115
Ducie House
Ducie Street
Manchester
M1 2JW

Success Life After Cure Limited
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2020

	Notes	Unrestricted funds £	Restricted funds £	2020 £
Income and endowments from:				
Donations and legacies	2	189,177	-	189,177
Charitable activities	3	-	14,200	14,200
Total		189,177	14,200	203,377
Expenditure on:				
Raising funds	4	(1,711)	-	(1,711)
Charitable activities	5/6	(58,704)	(14,200)	(72,904)
Total		(60,415)	(14,200)	(74,615)
Net income/expenditure		128,762	-	128,762
Total funds carried forward		128,762	-	128,762

Success Life After Cure Limited
Statement of Financial Position
As at 31 December 2020

	Notes	2020 £
Current assets		
Debtors	11	41,151
Cash at bank and in hand		88,948
		130,099
Creditors: amounts falling due within one year	12	(1,337)
Net current assets		128,762
Total assets less current liabilities		128,762
Net assets		128,762
The funds of the charity		
Unrestricted income funds	13	128,762
Total funds		128,762

For the year ended 31 December 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the Board and signed on its behalf by:

Helen Spoudeas

.....
Dr Helen Alexandra Spoudeas (Chair)
Director

Success Life After Cure Limited
Notes to the Financial Statements
For the year ended 31 December 2020

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

Success Life After Cure Limited meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Going concern

The financial statements are prepared, on a going concern basis, under the historical cost convention.

Funds

The charity maintains a general unrestricted fund which represents funds which are expendable at the discretion of the trustees in furtherance of the objects of the charity. Such funds may be held in order to finance both working capital and capital investment.

Designated funds comprise of unrestricted funds that have been set aside by the Trustees for particular purposes.

Restricted funds have been provided to the charity for particular purposes, and it is the policy of the board of trustees to carefully monitor the application of those funds in accordance with the restrictions placed upon them.

There is no formal policy of transfer between funds or on the allocation of funds to designated funds, other than that described above

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Donated goods, services and facilities

Donated services and facilities are included in the SOFA when received at the value of the gift to the charity provided the value of the gift can be measured reliably.

Donated services and facilities that are consumed immediately are recognised as income with an equivalent amount recognised as an expense under the appropriate heading in the SOFA.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

Taxation

As a registered charity, the company is exempt from income and corporation tax to the extent that its income and gains are applicable to charitable purposes only. Value Added Tax is not recoverable by the company, and is therefore included in the relevant costs in the Statement of Financial Activities.

Debtors

Debtors (including trade debtors and loans receivable) are measured on initial recognition at settlement amount after any trade discounts or amount advanced by the charity. Subsequently, they are measured at the cash or other consideration expected to be received.

Success Life After Cure Limited
Notes to the Financial Statements Continued
For the year ended 31 December 2020

2. Income from donations and legacies

	2020 £
Unrestricted funds	
Donations received	156,182
Grants received	15,000
Donated goods and services	17,995
	<u>189,177</u>

3. Income from charitable activities

	2020 £
Restricted funds	
<i>Conference</i>	
Income from charitable activities	14,200

4. Expenditure on generating donations and legacies

	2020 £
Unrestricted funds	
Donations	1,711
	<u>1,711</u>

5. Costs of charitable activities by fund type

	Unrestricted funds £	Restricted funds £	2020 £
Provision of Services	20,985	-	20,985
Conference	16,513	14,200	30,713
Support costs	21,206	-	21,206
	<u>58,704</u>	<u>14,200</u>	<u>72,904</u>

Success Life After Cure Limited
Notes to the Financial Statements Continued
For the year ended 31 December 2020

6. Costs of charitable activities by activity type

	Activities undertaken directly	Support costs	2020
	£	£	£
Support costs			
Provision of Services	20,985	21,206	42,191
Conference	30,713	-	30,713
	<u>51,698</u>	<u>21,206</u>	<u>72,904</u>

7. Analysis of support costs

	2020
	£
Provision of Services	
Management	11,591
General overheads	2,856
Website development	5,605
Governance costs	1,154
	<u>21,206</u>

8. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2020
	£
Accountancy fees	500

9. Trustee remuneration and related party transactions

No trustee received any emoluments during the year.

One or more trustees were reimbursed expenses totalling £654 during the current year.

10. Ex-gratia payments

Pro bono support was provided by a legal firm to advise on GDPR compliance and to advise on employment matters. This is estimated to be valued at approx £17,955 representing 30.5 hours over the year.

Success Life After Cure Limited
Notes to the Financial Statements Continued
For the year ended 31 December 2020

11. Debtors

	2020 £
Amounts due within one year:	
Trade debtors	6,151
Prepayments and accrued income	35,000
	<u>41,151</u>

12. Creditors: amounts falling due within one year

	2020 £
Trade creditors	837
Accruals and deferred income	500
	<u>1,337</u>

13. Movement in funds

Unrestricted Funds

	Incoming resources £	Outgoing resources £	Balance at 31/12/2020 £
<i>General</i>			
General	189,177	(60,415)	128,762
	<u>189,177</u>	<u>(60,415)</u>	<u>128,762</u>

Restricted Funds

	Incoming resources £	Outgoing resources £	Balance at 31/12/2020 £
Conference	14,200	(14,200)	-
	<u>14,200</u>	<u>(14,200)</u>	<u>-</u>

Purpose of restricted funds

Conference

The Survivors conference

Success Life After Cure Limited
Notes to the Financial Statements Continued
For the year ended 31 December 2020

14. Analysis of net assets between funds

	Net current assets / (liabilities) £	Net Assets £
Unrestricted funds		
<i>General</i>		
General	128,762	128,762
	128,762	128,762

15. Company limited by guarantee

Success Life After Cure Limited is a company limited by guarantee and accordingly does not have a share capital.

Success Life After Cure Limited
Detailed Statement of Financial Activities
For the year ended 31 December 2020

	2020 £
INCOME AND ENDOWMENT	
Donations and legacies	
Donations	156,182
Grants receivable	15,000
Donated goods and services	17,995
	189,177
Charitable activities	
Income from charitable activities (Conference)	14,200
	14,200
Total incoming resources	203,377
EXPENDITURE	
Raising donations and legacies	
Donations	(1,711)
	(1,711)
Charitable activities	
Cost of direct charitable activity (Provision of Services)	(20,985)
Cost of direct charitable activity (Conference)	(30,713)
	(51,698)
SUPPORT COSTS	
Management	
Management (Provision of Services)	(11,591)
	(11,591)
General overheads	
General overheads (Provision of Services)	(2,856)
	(2,856)
Website development	
Website development (Provision of Services)	(5,605)
	(5,605)
Governance costs	
Governance costs (Provision of Services)	(1,154)
	(1,154)
Total resources expended	(74,615)
Net Income	128,762